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Background: Human immunodeficiency virus (HIV) has been shown to reduce bone 
mineral density (BMD), mineralisation and bone turnover. In the HIV-negative 
population, reduced BMD is associated with delayed bone union and this may also 
be true in HIV infection. Previous clinical and basic science research has suggested an 
association between HIV infection and impaired fracture healing. However, the effect 
of HIV on bone healing is very poorly understood. The aim of this study was to 
establish whether HIV is a risk factor for the development of delayed bone union or 
non-union following a fracture. 
 
Methodology: The project aims were addressed with two related clinical studies 
undertaken at two tertiary referral hospitals in Cape Town, South Africa. 
 
1. HIV in Orthopaedic Skeletal Trauma (HOST) 1 Study: Case-cohort study of 
participants undergoing fracture surgery: All adult participants with fresh tibia 
and femur fractures who underwent IM nailing for fracture fixation were 
eligible for inclusion over a 14-months period. Participants were evaluated at 
six weeks, and three, six, nine and 12 months post-operatively. The primary 
outcome was delayed bone union at six months (Radiological Union Score for 
the Tibia [RUST] score < 9) and the secondary outcome was non-union at 
months 9 (RUST score < 9). 
 
2. HIV in Orthopaedic Skeletal Trauma (HOST) 2 Study: Matched case-control 
study of participants presenting with non-unions (RUST < 9) of fractures: Adult 
participants (cases) with established non-unions of the femur or tibia shaft 
were recruited over a 14-months period and matched for: a) age; b) sex; c) 
fracture site; and d) fracture management type, with ‘control’ participants 






All study participants underwent HIV testing, with measurement of CD4 cell count 
and viral load and a history of anti-retroviral (ART) therapy if appropriate. Bone 
healing was assessed by two blinded independent reviewers, using the RUST scoring 
system. The odds of delayed and non-union by HIV group were estimated and 
compared using univariate and multivariable logistic regression. 
 
Results: 
1. HOST 1 study: A final study population of 358/400 (89.5%) participants, who 
underwent 395/442 (89.4%) IM nailings were recruited over a 14-month 
period. All participants were followed up for a minimum of 12 months. 71 
participants (71/358, 19.8%) were HIV-positive (83 IM nailings [83/395], 
21.0%). HIV was not statistically significantly associated with the development 
of delayed bone healing following an IM nailing of the tibia or femur in this 
study population (univariate OR 0.76, [CI 0.37-1.44], p-value=0.417, 
multivariable OR 1.06 [CI 0.50-2.22], p-value=0.869). However, the HIV-
positive participants had a statistically significant lower risk of non-union 
compared to HIV-negative (univariate OR 0.16 [CI 0.01-0.78], p-value = 0.076, 
multivariable OR 0.17 [CI 0.01-0.92], p-value = 0.100). 
 
2. HOST 2 study: A total of 57 cases were matched with 57 controls, over a 14-
month period. The prevalence of HIV among cases was 7% (4/57) and was 
15.8% (9/57) among controls, with an overall prevalence of 11.4% (13/114) in 
the study population. HIV status was not associated with the development of 
non-union following the management of tibia and femur fractures, on either 
univariate (OR 0.40 [CI 0.10-1.32], p-value = 0.151) or multivariable (OR 0.86 
[CI 0.18-3.73], p-value = 0.831) logistic regression analysis. 
 
Conclusion: The HOST 1 and 2 studies demonstrate that HIV is not associated with 
the development of delayed union following fracture of the tibia or femur. 





developing a non-union. Therefore, fractures sustained in HIV-positive individuals 
can be managed in the same way as those who are HIV-negative, with no increased 
risk of delayed or non-union.  Future areas of research are indicated to assess the 








Background: Human immunodeficiency virus (HIV) has been shown to cause thin and 
brittle bones and reduce new bone being made. In people without HIV, thin and 
brittle bones can cause slow bone healing. Previous laboratory and epidemiology 
research have suggested an association between HIV infection and impaired bone 
healing. The effect of HIV on bone healing is very poorly understood. The aim of this 
study was to establish whether HIV causes slow bone healing or bones not to heal at 
all, following an injury. 
 
Methodology: 
The project aims were addressed with two related studies in two hospitals in Cape 
Town, South Africa. 
1. HIV in Orthopaedic Skeletal Trauma (HOST) 1 Study: All adult participants 
undergoing an operation to fix their broken tibia or femur bone with a type 
of metal nail were eligible for inclusion in the study over a 14-month period. 
Participants were reviewed six weeks, and three, six, nine and 12 months after 
their operation. An assessment of bone healing was made to see if there was 
a difference in the proportion broken bones that were slow to heal or did not 
heal at all was different according to HIV status. 
 
2. HIV in Orthopaedic Skeletal Trauma (HOST) 2 Study: Adults with bones that 
had not healed after sustaining a broken femur or tibia bone were recruited 
over a 14-month period. They were compared to adults whose bones had 
healed to see if there was a difference in the number of participants that had 
HIV. 
All participants underwent HIV testing, with measurement of their treatment for HIV 









1. HOST 1 Study: A final study population of 358 participants, who underwent 
395 operations for a fracture, were recruited over a 14-month period. 71 
participants, 19.8% of the whole study population, had HIV. On analysis, HIV 
was shown not to be a risk factor for the development of slow bone healing. 
Additionally, HIV-positive fracture patients were less likely to experience non-
union. 
 
2. HOST 2 Study: A total of 57 participants whose bones had not healed were 
compared to 57 participants whose bones had healed over a 14-month 
period. There was a similar number of people with HIV whose bones had 
healed compared to those whose had not. Therefore, suggesting HIV did not 
cause a problem with bone healing in the study population. 
 
Conclusion: The HOST 1 and 2 studies demonstrate that HIV does not cause bones to 
heal up more slowly and may even improve bone healing. Therefore, fractures 
sustained in HIV-positive patients can be managed in the same way as those who are 
HIV-negative, with no increased risk of problems with bone healings. Future areas of 
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AIDS   Autoimmune Deficiency Syndrome  
ART   Anti-retroviral therapy 
BMP   Bone morphogenetic protein  
BMI  Body mass index 
CT   Computed tomography  
CI  Confidence interval 
DALY   Daily adjusted life years 
DEXA   Dual energy X-ray absorptiometry 
DKK  Dickkopf-related protein 
DRI  Disability related index 
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IFNg  Interferon gamma 
ISS  Injury severity score 
LEDGF   Lens epithelium-derived growth factor  
LMIC  Low- and middle-income countries 
LRP  Lipoprotein receptor-related protein 
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M-CSF   Macrophage colony- stimulating factor  
MSC  Mesenchymal stem cell 
NHLS   National Health Laboratory Service  
NF  Nando Ferreira 
NY  Nomsa Yekiso 
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NSAIDs Nonsteroidal anti-inflammatory drugs  
PICO  Population, intervention, comparator and outcome  
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PrEP  Pre-Exposure Prophylaxis  
PROM  Patient reported outcome measurements  
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OR  Odds ratio 
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QECH  Queen Elizabeth Central Hospital 
RANKL  Receptor activator of nuclear factor kappa-B ligand 
RNA  Ribonucleic acid  
RR  Relative risk 
RSA  Republic of South Africa 
RTI  Reverse transcriptase inhibitor 
RUST  Radiographic Union Scale for Tibia 
SOCS-1 Suppressor of cytokine signaling- 1 
SSI  Surgical site infection  





TB   Tuberculosis  
TGF-β   Transforming growth factor-beta  
TNF-α  Tumour necrosis factor- α 
TRAF-6  Tumor necrosis factor receptor-associated factor-6 
U.S  United States  
VEGF  Vascular endothelial growth factor  






NNRTI  Non-nucleoside Reverse transcriptase inhibitor 
• DOR  Doravine 
• EFV  Efavirenz 
• ETR  Etravirine 
• RPV  Rilpivirine   
 
NRTI  Nucleoside Reverse transcriptase inhibitor 
• ABC  Abacavir 
• AZT  Azidothymidine 
• FTC  Emtricitabine 
• 3TC  Lamivudine 
• ZDV  Zidovudine 
• d4T   Stavudine  
• TDF  Tenofovir disoproxil fumarate 
• TAF  Tenofovir Alafenamide 
 
PI  Protease inhibitor 
• ATV  Atazanavir 
• APV  Amprenavir  
• DRV  Darunavir 
• IDV   Idiniavir 
• LPV   Lopinavir  
• NVP  Nevirapine 
• FPV  Fosamprenavir 
• RTV  Ritonavir 
• SQV  Saquinavir 
 
FI Fusion Inhibitors 






CCR5 Antagonist C-C chemokine receptor type 5  
  
• MVC Maraviroc 
 
INI  Integrase inhibitors  
• DTG  Dolutegravir  
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CHAPTER 1. INTRODUCTION TO THESIS 
1.1 Background 
Worldwide, approximately 35.3 million people are Human Immunodeficiency Virus 
(HIV) positive, with the highest prevalence seen in sub-Saharan Africa.(1) The 
introduction of anti-retroviral therapy (ART) in 1997 has altered the course and 
nature of patients infected with HIV by increasing the duration of asymptomatic 
infection and, consequently, patients with HIV are attaining close to normal life 
spans.(2), (3) ART consists of a combination of drugs that aim to suppress the HIV 
virus replication and stop the progression of HIV disease. However, despite these 
longer life expectancies, there is little evidence to advise the surgeon and patient 
about the effect of long-term immunosuppression on the fracture repair process in 
orthopaedic surgery.(4) 
 
HIV principally affects a patient’s immunological status by reducing the host CD4 T 
cell count, resulting in an increase in the risk of a patient developing opportunistic 
infections. HIV has also been shown to affect other chemical mediators, including 
interleukins 1 and 6 (IL 1, IL6) and tumour necrosis factor (TNF), which have been 
shown to play a role in the fracture repair process.(5), (6), (7)  
 
HIV and ART have both been shown to reduce bone mineral density (BMD), bone 
mineralisation and bone turnover in clinical studies.(8), (9), (10), (11) In the general 
population, it has been postulated that a reduced BMD is associated with a reduced 
speed of fracture healing. If this relationship were to hold true in the context of HIV, 
then they would not only be at an increased risk of fragility fracture, but also of 
subsequent delayed fracture healing and failure of fracture fixation.  
 
A factor known to affect fracture healing is local blood flow to the site of the injury. 
It is now well established that HIV infection is associated with osteonecrosis, thought 





interruption in blood supply has been shown.(12), (13), (14) ART has also been 
reported to contribute to this pathology.(12) Conditions that jeopardise arterial flow 
to the site of primary bone healing are associated with higher rates of delayed 
fracture healing and non-union.(15), (16), (17) 
 
A small number of studies have investigated the role of HIV in the fracture healing 
process. These have suggested that HIV and/or ART are associated with delayed 
fracture healing and may result in non-union.(18), (19) The molecular and cellular 
mechanisms driving this process remain unclear and the effect of HIV and ART on 
bone healing is very poorly understood. 
 
Our study group has previously demonstrated there may be an association between 
HIV infection and impaired fracture healing. (18), (20) Furthermore, analysis of 
patients presenting to Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi, 
for immediate fracture treatment and non-union surgery, indicates twice the 
frequency of HIV seropositivity in the non-union group (Figure 1-1). (Personal 
communication - Professor WJ Harrison) Other researchers have suggested that HIV 
may impair fracture healing, based on extrapolation from basic science and 
laboratory research. (19) 
 
These observations prompted this study, as the effect of HIV on bone healing is very 
poorly understood and has not previously been thoroughly investigated. 
 
1.2 Primary research question 
Is HIV infection a risk factor for the development of delayed bone union or non-union 






1.3 Aim  
To establish whether HIV is a risk factor for the development of delayed bone union 
or non-union following a fracture.  
The project aims were addressed with two related clinical studies undertaken at two 
tertiary referral hospitals in Cape Town, South Africa  
1. HIV in Orthopaedic Skeletal Trauma (HOST) 1 Study: Case-cohort study of 
participants undergoing intramedullary nailing of the tibia and femur for 
fracture fixation.  
2. HIV in Orthopaedic Skeletal Trauma (HOST) 2 Study: Case-control study to 
investigate risk factors for non-union of fractures of the femur or tibia 
 
1.4 Hypothesis 
HIV is a risk factor for the development of delayed bone union and non-union 
following a fracture. 
 
If this hypothesis were shown to be true, the surgical management of fractures could 
be tailored to optimise bone union during the fracture-healing phase in HIV-positive 
patients, improving outcomes and reducing the substantial physical and social 







Figure 1-1. The HIV status of patients presenting to Queen Elizabeth Central Hospital, 
Blantyre Malawi for intramedullary nailing (IM) with new fractures and non-unions: 








1.5 Background to South Africa, demographics, socioeconomics and health care 
 South Africa  
South Africa, officially named the Republic of South Africa (RSA), is located at the 
southernmost region in Africa. It is bordered to the south by 2,798 kilometres of 
coastline of Southern Africa, extending along the South Atlantic and Indian Oceans 
(Figure 1-2).(21) To the north, it borders Namibia, Botswana and Zimbabwe, and to 
the east of the country, Mozambique and Swaziland. Additionally, it also surrounds 
the country of Lesotho.(21) 
 








South Africa has an estimated population of 56,015,000 (2016), is the largest country 
in Southern Africa and the 25th largest in the world.(21) There are also an estimated 
five million living illegally in South Africa, the majority of which are from 
Zimbabwe.(21) The 2011 census defined five main racial groups living in South 
African. These include Black African at 79.2%; White at 8.9%; Coloured at 8.9%; Asian 
at 2.5%; with other racial groups making up the final 0.5%.(21) There are 11 official 
languages in South Africa. These include: Afrikaans; English, Zulu; Xhosa;; Northern 
Sotho; Tswana; Tsonga; Southern Sotho; Swazi; Venda and Southern Ndebele.(21) 
The three most commonly spoken first languages are Zulu (22.7%), Xhosa (16.0%), 
and Afrikaans (13.5%).(21) This creates an extremely diverse population group of 
people living in the South Africa and is the reason why the country is referred to as 
the ‘Rainbow Nation’.(21) 
 
 Socioeconomics 
According to the World Bank, South Africa is an upper middle-income emerging 
economy and the second largest economy in Africa, after Nigeria.(23) The country 
has an abundant supply of natural resources, well-developed financial, legal, 
communications, energy and transport sectors, and a stock exchange that is Africa’s 
largest (and among the top 20 in the world). It also has a relatively high gross 
domestic product (GDP) per capita compared to other countries in sub-Saharan 
Africa. Despite this, South Africa is still burdened by a relatively high rate of poverty 
and unemployment and is also ranked in the top ten countries in the world 
for income inequality.(23)  
 
Unlike many of the world's low- and middle-income countries, South Africa does not 
have a thriving informal economy, with only 15% of South African jobs in the informal 





as Brazil, where approximately 50% of the jobs are in the informal sector. Official 
unemployment is roughly 27% of the workforce.(3) 
 
More than ten million people live on less than $1 per day,(3) which is the so-called 
food poverty line, below which people are unable to purchase enough food for an 
adequate diet. Additionally, a further 45% of the population in South Africa live on 
approximately $2 per day (the upper limit for the definition of poverty).(3) This is in 
contrast to the top 10% of South Africans who earn 58% of the total annual national 
income, whereas the bottom 70% combined earn a only 17%,(3) creating one of the 
widest economic disparities in the world and one of the unique characteristics of 
South Africa’s current socio-economic climate.  
 
 Health care 
The health system comprises the public government sector and the private sector. 
The public health services are divided into primary, secondary and tertiary through 
health facilities that are located in, and managed by, the provincial departments of 
health. The provincial departments are thus the direct employers of the health 
workforce, while the National Ministry of Health is responsible for policy 
development and coordination.(24) 
 
South Africa’s Constitution guarantees every citizen access to health services (section 
27 of the Bill of Rights).(24) However, everyone can access both public and private 
health services, with access to private health services depending on an individual’s 
ability to pay.(24) The private health sector provides health services through 
individual practitioners, who run private surgeries, or through private hospitals, 
which tend to be located in urban areas. The health care system consumed about 






The private sector serves 16% of the population while the public sector serves 84%, 
reflecting the void between rich and poor seen in the country.(26) The country’s 
population distribution indicates that about 64.7% inhabit the provinces that are 
largely rural in nature.(26) Some of these provinces contain large cities, though the 
bulk of the population lives in rural communities. 
 
The national annual per capita expenditure on health ranges from $1,400 in the 
private sector to approximately $140 in the public sector, and disparities in the 
provision of health care continue to widen every year.(3) The national public health 
sector, staffed by some 30% of the doctors in the country, remains the sole provider 
of health care for more than 40 million people who are uninsured and who constitute 
approximately 84% of the national population. Approximately 16% of South Africans 
(eight million people) have private health insurance that provides access to health 
care from the remaining 70% of doctors who work full-time in the private sector. Up 
to 25% of uninsured people pay out of pocket for private sector care. In recent years, 
permission for senior full-time staff in the public sector to spend a limited proportion 
of their time working in the private sector has diluted their public-service activities.(3) 
 
The management of trauma and injuries in South Africa, such as tibia and femur 
fractures, are predominantly managed by orthopaedic surgeons. However, this 
service is significantly limited in the public sector and in many rural areas.(27) There 
are currently 0.36 orthopaedic surgeons per 100,000 uninsured population 
compared with 8.3 orthopaedic surgeons per insured population.(27) As stated 
earlier, private hospitals only cater to 16% of the population; however, between 80 







CHAPTER 2. HUMAN IMMUNODEFICENCY VIRUS AND ITS TREATMENT 
2.1 Aim of this chapter 
In this chapter the pathogenesis of HIV, virus staging, a summary of antiretroviral 
therapy (ART) treatment and the current picture of how HIV has affected South Africa 
will be discussed. 
 
2.2 Overview 
In order to have an understanding of the effect of HIV on fracture healing, it is 
essential to have a full appreciation of the pathogenesis of the virus and how it affects 
the human body. Additionally, having a good understanding of the different forms of 
ART therapy is vital, since they may not all impact fracture healing and bone 
metabolism to the same degree.  
 
2.3 Human Immunodeficiency Virus 
It has been shown that the HIV epidemic started after zoonotic infection with simian 
immunodeficiency viruses from African primates. It is likely that bushmeat hunters 
were probably the first group to be infected with HIV.(28) There are two main 
different types of HIV virus, HIV-1 and HIV-2. HIV-1 was transmitted from apes and 
HIV-2 from sooty mangabey monkeys.(28) Four groups of HIV-1 exist and represent 
three separate transmission events from chimpanzees (M, N, and O) and one from 
gorillas (P). Groups N, O, and P are mainly restricted to the western regional of Africa. 
The global HIV pandemic was caused by Group M, which started about 100 years ago 
and consists of nine subtypes: A–D, F–H, J and K. Subtype C predominates in Africa 
and India, and accounted for 48% of cases of HIV-1 in 2007 worldwide.(29) Whereas 
in western Europe, Americas and Australia subtype B predominates.(29) Additionally, 
over the last ten years circulating recombinant subtypes are becoming more common 





The reason for the predominant global infection being the HIV-1 subtype is due to 
the high mutation rate of this form of the virus. HIV-2 causes a similar illness to HIV-
1, but immunodeficiency progresses more slowly and HIV-2 is less transmissible.(28) 
In this thesis the focus will be on the HIV-1 which makes up the majority of the 
infections in South Africa. 
 
Globally an estimated 36.9 million people were living with HIV in 2017.(30) (Figure 
2-1) Sub-Saharan Africa, particularly southern Africa, has the highest global burden 
of HIV, with 70·8% of HIV infected people on the planet living in this region.(30) Since 
the introduction of ART and the expanding access to this therapy, the global 
epidemiology of HIV infection has changed significantly. The global prevalence of HIV 
has increased from 31·0 million in 2002, to 35·3 million in 2012. This is due to the fact 
that people on ART are living longer, whereas estimated global incidence of Acquired 
immunodeficiency Syndrome (AIDS) has decreased sustainably from approximately 
3·3 million new infections in 2002, to 2·3 million in 2012. (30) 
 
HIV is a major contributor to the global burden of disease worldwide and in 2010, HIV 
was the leading cause of disability-adjusted life years for people aged 30–44 years, 







Figure 2-1. The estimated number of people living with HIV around the word in 2018 
– World Health Organisation. (30) 
 
 
2.4 Pathogenesis of Human Immunodeficiency Virus 
HIV is a retrovirus that specifically targets CD4+ T lymphocyte cells within the immune 
system of an infected individual. The role of the CD4+ T cells is to formulate the 
immune response to infection by identifying foreign antigens and then generating an 
antibody response.(32), (33) HIV-1 thrives by taking advantage of cellular pathways 
while neutralising and hiding from the different components of the immune system 
so the body cannot fight the infection.(33), (34) 
 
The lifecycle of HIV-1 is very complex (Figure 2-2) and its duration and outcome is 
dependent on the cell activation and target cell type.(35) In the early stage of 
infection, HIV-1 gains access to cells in the body without causing immediate lethal 
damage. However, the entry process can stimulate intracellular signal cascades, 
which as a result might facilitate viral replication.(36)  
 
There are two molecules on the HIV-1 envelope, the external glycoprotein (gp120) 
and the transmembrane protein (gp41). These molecules form the spikes on the 





attaches to the cell membrane by first binding to the CD4+ receptor. Subsequent 
interactions between virus and chemokine co-receptors (e.g. CCR5, CXCR4) trigger 
irreversible conformational changes to the cell.(37), (38) The actual fusion event 
takes place within minutes by pore formation,(38), (39) and releases the viral core 
into the cell cytoplasm. After the core disassembles, the viral genome is reverse 
transcribed into DNA by the virus’s own reverse transcriptase enzyme.(33)  
 
At the middle stage of HIV infection, the viral protein integrase, in combination with 
host DNA repair enzymes, inserts the viral genome into gene-rich, transcriptionally 
active domains of the host’s chromosomal DNA.(40), (41),(42) This results in 
irreversibly transforming the cell into a potential virus producer.  
 
In the late stage, viral proteins are transported to, and assemble in proximity to, the 
cell membrane. (33) Virus egress from the cell is not lytic and takes advantage of the 
vesicular sorting pathway, which normally mediates the budding of endosomes into 
multivesicular bodies.(43) HIV-1 uses this protein-sorting pathway, finally producing 










Since cytoplasmic molecules of the producer cell and components from its cell 
surface lipid bilayer are combined into the new viral particle, virions have 
characteristics of the cells in which they were produced. This results in any detection 
by the immune system difficult.(46) These virus particles are released from the 
infected CD4+ T cell and ultimately enter the blood or extracellular fluid and go on to 
infect another CD4+ T cell, spreading the infection throughout the body.(46) 
 
In summary, HIV attaches to receptors on the CD4+ T cell, and once fused, 
incorporates RNA into the host cell’s DNA. The newly-infected CD4+ T cell then 
replicates its DNA to reproduce large numbers of HIV virions within the host, which 
are released into the bloodstream with a cascade effect.(32) The infected CD4+ cells 
rapidly become ineffective and when left untreated an infected individuals immune 
system deteriorates to become dangerously weak. As a result, HIV-positive 
individuals become susceptible to severe opportunistic infections from organisms 






The severity of an individual’s HIV infection can be measured by the ‘viral load’, which 
measures the amount of virus found within the host’s bloodstream.(32) Patients with 
a high viral load have overwhelming HIV infection, which causes rapid CD4+ T cell 
destruction and a low ‘CD4+ count’ (<350 per microliter).(32) HIV can be separated 
into three phases of infection, commonly referred to as the primary infection phase, 
latency phase and the overt AIDS phase.(33) 
 
The primary infection phase occurs when the infected host creates antibodies in 
response to an HIV infection. This normally occurs within the first 45 days of infection. 
During this time, individuals may have mild flu-like symptoms, headache, diarrhoea 
and a fever, or may have no symptoms at all, a process called seroconversion. Viral 
load figures are high in primary infection, sometimes greater than one million 
copies/ml. While CD4 count falls below normal range of 800–1000 cells/μL.(33) 
 
Succeeding seroconversion, patients may live unaware they have HIV for 10 or more 
years, and ultimately have very few symptoms. However, HIV remains active within 
the infected host, replicating and injuring their immune system and an individual can 
pass on the virus spreading the infection. During HIV latency, the viral load will remain 
high, and CD4 cell counts fall to low levels of around 200 cells/μL or less.(33) 
 
If HIV is left untreated, opportunistic infections and/or malignancy will develop, and 
those who have a CD4 count of less than 200 cells/μL with a AIDs defining illness are 
said to have developed AIDS.(33) This is commonly referred to as advanced or late-
stage HIV. Without treatment, patients with AIDS will likely die within two years as a 
result of persistent and recurrent infection, such as tuberculosis (TB), pneumonia and 






2.5 Antiretroviral therapy 
In the late 1990s, combination ART drug regimens that were able to suppress viral 
replication were developed and made available for the treatment of HIV. This 
completely revolutionised HIV from a progressive illness with definite fatal outcomes 
into a chronic manageable disease.(34) There are currently more than 25 licensed 
ART drugs available, in seven different categories. They block HIV replication at many 
different steps in the virus lifecycle. (Figure 2-2) The overall aim of ART is to reduce 
the host’s viral load to undetectable levels (<40 copies per microlitre) to inhibit HIV 
replication and limit immune system injury to avoid the disease progression. 
 
The introduction and widespread use of ART have significantly altered the natural 
history of HIV infection. However, taking ART can lead to serious medication-related 
adverse effects. These include an increased risk of developing cardiovascular disease, 
lipodystrophy, diabetes, insulin resistance and hyperlactatemia/lactic acidosis.(48) 
Additionally, a number of ARTs drugs have been implicated in the emerging evidence 
that the therapy plays a role in HIV-associated bone disease. 
 
Current recommended combination ART regimens are less toxic, are more effective, 
have a lower pill burden, and are dosed less frequently than those first introduced 








South Africa has the largest HIV treatment programme in the world, accounting for 
20% of people on ART therapy globally. In 2018, UNAIDS reported that 4.4 million 
people were receiving treatment in South Africa. This equates to 61% of the people 
living with HIV in the country.(53) The country also has one of the largest domestically 
funded programmes in the world, with about 80% of the AIDS response funded by 
the government.  
 
In 2003, the government introduced  this treatment programme to provide ART to all 
patients with HIV infection.(54) Spending on HIV increased at an average annual rate 
of 48.2% between 1999 and 2005.(54) The level of growth was consistently higher 
than that in other areas of national health expenditure and has continued at an 
annual rate of approximately 25%, with dedicated HIV funding estimated at $400 
million (in U.S. dollars) per annum.(54) 
 
The success of this ART programme is evident in the increases in national life 
expectancy in South Africa, rising from 61.2 years in 2010 to 67.7 years in 2015.(55) 
Today, HIV-positive individuals in South Africa have a near-normal life expectancy, 
provided they are started on ART before their CD4 count drops below 200 cells per 
cubic millimetre.(3) 
 
Despite the steps made to treat HIV, its prevalence remains high (18.9%) among the 
South African general population, although it varies markedly between regions.(56) 
For example, despite a national prevalence of 18.9%, there is a rate of 6.8 and 5.6% 
in Northern Cape and Western Cape, respectively.(57), (58) 
 
As mentioned earlier, throughout South Africa, including the Western Cape, the WHO 
guidelines for the treatment of HIV are followed, using TDF + 3TC (or FTC) + EFV) as 






CHAPTER 3. FRACTURE HEALING 
3.1 Aims of this chapter 
In this chapter a discussion of the pathogenesis of fracture healing, epidemiology and 
factors that influence bone healing will be presented. 
 
3.2 Overview 
Fracture healing is a multifactorial process affected by a number of biological factors, 
injury characteristics, management strategies and the mechanics of the fracture 
fixation.(59) The multifaceted system of bone healing can be simplified into several 
stages of healing, beginning with hematoma formation, followed by inflammatory 
response, cell proliferation and differentiation, and finally ossification with 
subsequent remodeling of the new bone. 
 
3.3 Epidemiology of fractures 
Traumatic injury is a major cause of global mortality and disability. Worldwide, 
trauma-related deaths exceed those from HIV/AIDS, malaria and tuberculosis 
combined.(60) Additionally, these injuries occur at disproportionately higher rates in 
low-income and middle-income countries (LMIC), with 83% of the 4.6 million global 
deaths from injury occurring in LMICs.(60), (61), (62) For every trauma-related death, 
many more nonfatal injuries occur, including fractures.(63) It is estimated that for 
every injury-related death, 10 to 50 people sustain temporary or permanent 
disabilities. Furthermore, traumatic injuries result in more than 220 million disability 
adjusted life years (DALYs) lost each year in LMICs.(60)  
 
The resulting disability can be especially crippling for the poorest patients, who 
experience a vicious cycle of poverty from health-care costs and decreased 





incidence of musculoskeletal injury is increasing in LMICs.(65), (66), (67), (68) Added 
to this, delayed treatment worsens the burden of trauma-related disability in poor 
resource settings.(69), (70) 
 
Globally, despite injury-related fractures constituting a major drain on health-care 
resources (71), (72), national epidemiological data for fracture incidence rates are 
lacking. Countries without such data, including South Africa, have to infer statistics 
based on results from other regions, in a high-income setting, which is highly 
problematic because of substantial variations in incidence rates. 
 
A increasingly common cause of injury and death in South Africa is interpersonal 
violence with guns, with growing numbers of fractures as a result of gunshot wound 
(GSW) injuries.(73) The number of gun and firearm-related crimes, injuries and 
deaths continues to increase worldwide, with a reported rise in firearm offences of 
23% in the United Kingdom (UK)(74) and 9% in the United States of America (USA)(75) 
between 2015 to 2016. In total, gun-related violence kills over an estimated 250,000 
people each year and injures millions of others worldwide everyday.(76) 
 
While the mortality rate attributable to firearms in SA is high (31.1 per 100,000 
national and 41 per 100,000 in Cape Town (73), the burden of non-fatal firearm-
related injuries is significantly worse. The SA government has not released 
disaggregated statistics on violent crime involving firearms or gun-related injuries in 
over a decade. Allard et al suggested that 127,000 non-fatal GSWs occurred per 
annum across the country in 2005.(77) In a study in Cape Town, from one of the 
recruiting hospitals for the patients in this study, Martin et al reported that treating 
an orthopaedic GSW patient costs USD 2,940 per injury, uses 194 minutes of theatre 
time, and the patient occupies a hospital bed for an average 9.75 days.(73) As a result, 
injuries as a result of GSW cost the SA public health sector over 13 times the national 






With increasing burden of trauma and interpersonal violence and the fact that the 
highest rate of injury occurs in the working age population, this results in a substantial 
loss of earnings for households, societies and countries as a whole. An estimated 
US$180 billion is likely to be lost annually due to injury in LMICs.(60) This is occurring 
in populations with an expanding number of people living longer with HIV and having 
a higher risk of injury during their lifetime. Therefore, a better understanding of 
fracture healing in patients with HIV is important. 
 
3.4 The biology of fracture healing 
The biology of fracture healing is a complex biological process. Four main bone 
components contribute to the healing process: the injury site, including the cortex, 
the periosteum, the bone marrow and the external soft tissues. Following the initial 
trauma, bone heals by either direct/primary osteoneal or indirect/secondary fracture 
healing, which consists of both intramembranous and endochondral bone formation. 
Secondary bone healing is the most common pathway, since primary bone healing 
requires an anatomical reduction and rigidly stable conditions, commonly only 
obtained by open reduction and internal fixation. In all other non-stable conditions, 
bone heals via secondary healing. 
 
 Primary fracture healing 
Primary bone healing, also referred to as direct bone healing, only occurs when there 
has been anatomical reduction and interfragmentary compression of a fracture, 
leading to no motion between the fracture surfaces under functional load (absolute 
stability). When the correct requirements are achieved, primary bone healing can 
occur by direct remodelling of lamellar bone, the Haversian canals and blood 
vessels.(78) Primary healing of fractures can either occur through contact healing or 
gap healing. Both processes involve an attempt to re-establish an anatomically 





3.4.1.1 Contact healing 
When a fracture gap between bone ends is less than 0.01 mm and interfragmentary 
strain is less than 2%, a fracture heals by  contact healing.(79) Under these conditions, 
cutting cones are formed at the ends of the osteons closest to the fracture site.(78) 
The tips of the cutting cones consist of osteoclasts, which cross the fracture line. 
These cavities are then filled by bone produced by osteoblasts residing at the end of 
the cutting cone. Consequently, this results in the simultaneous generation of a bony 
union and the restoration of Haversian systems formed in an axial direction.(78) The 
bridging osteons later mature by direct remodelling into lamellar bone resulting in 
fracture healing without the formation of periosteal callus. 
 
3.4.1.2 Gap healing 
Gap healing differs from contact healing in that bony union and Haversian 
remodelling do not occur at the same time. It occurs if stable conditions and an 
anatomical reduction are achieved, but the gap between the bones is less than 800 
μm.(78) In this process the fracture site is primarily filled by lamellar bone oriented 
perpendicular to the long axis, requiring a secondary osteonal reconstruction, unlike 
the process of contact healing. The primary bone structure is then gradually replaced 
by longitudinal revascularised osteons carrying osteoprogenitor cells, which 
differentiate into osteoblasts and produce lamellar bone on each surface of the 
gap.(78) This lamellar bone, however, is laid down perpendicular to the long axis and 
is mechanically weak. This initial process takes approximately three and eight weeks, 
after which a secondary remodelling resembling the contact healing cascade with 






 Secondary fracture healing 
Secondary fracture healing, also referred to as indirect hone healing, consists of callus 
formation by both endochondral and intramembranous bone healing with 
subsequent callus formation.(80) It commonly occurs in non-operative fracture 
treatment and in certain operative fracture fixation methods in which some motion 
occurs at the fracture site, including intramedullary nailing, external fixation, or 
‘biological’ internal fixation of complicated comminuted fracture.(81), (82) 
 
3.4.2.1 Intramembranous ossification  
Intramembranous ossification involves the formation of bone directly, without first 
forming cartilage, from committed osteoprogenitor and undifferentiated 
mesenchymal cells that reside in the periosteum, farther from the fracture site.(83) 
It results in callus formation, described histologically as ‘hard callus’.(83) In this type 
of healing, the bone marrow’s contribution to the formation of bone is during the 
early phase of healing, when endothelial cells transform into polymorphic cells, which 
subsequently express an osteoblastic phenotype.(83) 
 
3.4.2.2 Endochondral ossification 
Endochondral ossification involves the recruitment, proliferation and differentiation 
of undifferentiated mesenchymal cells into cartilage, which becomes calcified and 
eventually replaced by bone. Its chronological characteristics include a number of 
identifiable stages, including an initial stage of haematoma formation and 
inflammation, subsequent angiogenesis and formation of cartilage, cartilage 
calcification, cartilage removal, bone formation, and, ultimately, bone remodelling. 
This type of fracture healing is contributed from the adjacent to the fracture 
periosteum and the external soft tissues, such as the muscle, providing an early 






3.4.2.2.1 Haematoma and inflammation 
Following an injury, a haematoma is immediately generated, which consists of cells 
from both peripheral and intramedullary blood, as well as bone marrow cells. The 
response causes the haematoma to coagulate in between and around the fracture 
ends, and within the medulla, forming a template for callus formation.(80) The injury 
initiates an inflammatory response, which is necessary for the healing to progress. 
There is an expression of proinflammatory cytokines, signalling molecules and growth 
factors critical for tissue regeneration. The acute inflammatory response peaks within 
the first 24h and is complete after seven days.  
 
The initial proinflammatory response involves secretion of tumour necrosis factor-α 
(TNF-α), interleukin-1 (IL-1), IL-6, IL-11 and IL-18.(80) These factors recruit 
inflammatory cells and promote angiogenesis.(78) The TNF-α concentration has been 
shown to peak at 24h and to return to baseline within 72h post trauma.(80) During 
this timeframe TNF-α is expressed by macrophages and other inflammatory cells, and 
it is believed to mediate an effect by inducing secondary inflammatory signals, and 
act as a chemotactic agent to recruit necessary cells. TNF-α has also been shown in 
vitro to induce osteogenic differentiation of mesenchymal stem cells (MSCs).(84),(85) 
 
IL-1 and IL-6 are believed to be most important ILs for fracture healing. (85), (86), (87) 
IL-1 expression overlaps with that of TNF-α with a biphasic mode. It is produced by 
macrophages in the acute phase of inflammation and induces production of IL-6 in 
osteoblasts, promotes the production of the primary cartilaginous callus, and also 
promotes angiogenesis at the injured site.(85), (86), (87) IL-6, on the other hand, is 
only produced during the acute phase and stimulates angiogenesis, vascular 







3.4.2.2.2 Cartilaginous and periosteal bony callus  
Following the formation of the primary haematoma, a fibrin-rich granulation tissue 
forms.(78) Within this tissue, endochondral formation occurs in between the fracture 
ends, and external to periosteal sites. These regions are also mechanically less stable 
and the cartilaginous tissue forms a soft callus, which gives the fracture a stable 
structure.(89) In animal models (rat, rabbit, mouse) the peak of soft callus formation 
occurs seven to nine days post trauma, with a peak in both type II procollagen and 
proteoglycan core protein extracellular markers.(83) At the same time, an 
intramembranous ossification response occurs subperiostally directly adjacent to the 
distal and proximal ends of the fracture, generating a hard callus. It is the final 
bridging of this central hard callus that ultimately provides the fracture with a rigid 
structure, which allows weight bearing.(80) 
 
3.4.2.2.3 Mineralisation and resorption of the cartilaginous callus  
In order for bone regeneration to progress, the primary soft cartilaginous callus needs 
to be resorbed and replaced by a hard-bony callus. As fracture callus chondrocytes 
proliferate, they become hypertrophic and the extracellular matrix becomes 
calcified. A cascade orchestrated primarily by macrophage colony-stimulating factor 
(M-CSF), receptor activator of nuclear factor kappa B ligand (RANKL), osteoprotegerin 
(OPG) and TNF-α initiates the resorption of this mineralised cartilage.(90) During this 
process, M-CSF, RANKL and OPG are also thought to help recruit bone cells and 
osteoclasts to form woven bone. TNF-α further promotes the recruitment MSC with 
osteogenic potential, but its most important role may be to initiate chondrocyte 
apoptosis.(90) The calcification mechanism involves the role of mitochondria, which 
accumulate calcium containing granules created in the hypoxic fracture environment. 
 
After expansion into the cytoplasm of fracture callus chondrocytes, calcium granules 
are transported into the extracellular matrix, where they precipitate with phosphate 
and form initial mineral deposits. These deposits of calcium and phosphate become 





peak of the hard callus formation is usually reached by day 14 in animal models.(83) 
As the hard callus formation progresses and the calcified cartilage is replaced with 
woven bone, the callus becomes more solid and mechanically rigid.(80) 
 
3.4.2.2.4 Bone Remodelling  
Finally, the fracture healing cascade initiates a second resorptive phase, this time to 
remodel the hard callus into a lamellar bone structure. This final bone remodelling 
phase is biochemically coordinated by IL-1 and TNF-α.(91), (92) Furthermore, some 
bone morphogenic proteins (BMPs), such as BMP2, have been postulated to also be 
involved in this phase.  
 
The remodelling process is carried out by an equilibrium of hard callus resorption by 
osteoclasts, and lamellar bone deposition by osteoblasts. Although the process is 
initiated as early as three to four weeks in animal and human models, the remodelling 
may take years to be completed to achieve a fully regenerated bone structure 







3.5 Non-union and delayed union 
There is a lack of agreement amongst orthopaedic surgeons regarding the 
assessment of fracture healing and definitions of delayed union and non-union. Due 
to the varying definitions, this influences the decision to intervene in an effort to 
promote fracture healing, a factor particularly important in a resource limited setting. 
It also creates challenges in assessing outcomes across studies reporting fracture 
healing data.  
 
A survey of 444 orthopaedic surgeons, response rate 77%, demonstrated definitions 
of delayed union ranging from one to eight months, whereas definitions of non-union 
ranged from two to twelve months.(94) There was considerable disagreement about 
both clinical and radiographic criteria to define fracture union as well as the average 
time required for diagnosis of delayed or non-union. The same results were reported 
by a systematic review of 123 studies. (95) Researchers concluded that there is a lack 
of consensus with regard to the definition of fracture-healing in the current 
orthopaedic literature.(95) 
 
While no standardised definition of non-union exists among orthopaedic surgeons, 
the Food and Drug Administration (FDA) defines non-union as a fracture that persists 
for a minimum of nine months without signs of healing for at least three months.(96) 
This definition was not intended for clinical use, but was specifically devised for the 
testing and comparison of medical devices. It does, however, remain the most widely 
used definition of non-union in clinical practice. 
 
Megas et al (97) defined non-union as a cessation of all reparative processes of 
healing without bone union, while Marsh et al (98) specifically emphasised the 
cessation of both the periosteal and endosteal healing responses without bony 
bridging. Many authors have suggested more pragmatic working definitions. 





potential to heal without intervention.(99) Jones et al (100) and Brinker et al (101) 
defined non-union as the point normal biological healing ceases and will not continue 
without surgical intervention. While Wiss et al (102) suggested that the designation 
of a non-union be made once the surgeon believes the fracture has little or no 
potential to heal. Although these definitions are not limited by temporal restrictions 
and are more directed toward clinical use, they are, however, dependent on surgeon 
experience to predict fracture healing. 
 
The Judet and Judet classification, modified by Weber and Cech in 1976, classified 
non-unions according to the vascularity of the bone ends.(103) The vascularity was 
determined based on strontium-85 uptake at the fracture site to delineate the 
viability of the bone ends.(103) Bone scintigraphy examinations are not widely used 
to diagnose non-unions today and are especially difficult to perform in resource-
limited settings. The amount of fracture callus visible on normal radiographs is 
therefore currently used as a surrogate marker for fracture site vascularity. (97). 
(104) Subsequently, non-unions are divided into two main categories of hypertrophic 
non-union and atrophic non-union.(105), (106)  
 
In hypervascular non-union, also known as hypertrophic non-union, fracture ends are 
vascular and are capable of biological activity. There is evidence of callus formation 
around the fracture site on radiographs and it is thought to be in response to 
excessive micromotion at the fracture site.(107) Avascular non-union, also known as 
atrophic non-union, is caused by avascularity or poor blood supply of the fracture 
ends.(108), (109) There is no or little callus formation on x-ray and fracture line 
remains visible. This type of non-union requires biological enhancement in addition 
to adequate immobilisation to heal.(105) Oligotrophic non-unions are thought to 
have a similar blood supply to hypertrophic non-unions and have the potential to heal 
(110), but possess an inadequate healing response characterised by little or no callus 





atrophic and oligotrophic non-unions often have the same radiographic 
appearance.(111) 
 
Delayed bone healing is as difficult to define as non-union. Delayed healing 
corresponds to a fracture that shows slower progression to healing than anticipated, 
but does not necessary progress to non-union.(112), (113) However, this will vary 
depending on the site of the fracture; with reports of average union times of 
approximately 16 weeks for the tibia and 12 weeks for the femur being reported, 
although a number of ranges have been suggested.(112), (113), (114), (115) 
However, this depends on a number of parameters, as discussed in this chapter. 
 
Commonly suggested ranges for an overall risk of non-union have been suggested 
and the commonly quoted rates of 5-10% does not arise from any clear data or 
previous study, despite being highlighted in many scientific papers.(116) Varying non-
union rates are found in different types of fractures, ranging from up to 3-22% in the 
tibia diaphysis (117), (118) to 2-10% in the femoral shaft after reamed nailing.(119)  
 
3.6 Classification of fracture healing 
Determining a fracture has healed requires radiologic and clinical assessment. 
However, as discussed there is no uniform definition of fracture union.(94) A 
systematic review by Corrales et al (95) reported eleven different criteria utilised to 
define union. Similarly, clinical trials indicate a lack of objective tools to assess 
fracture healing radiographically or clinically, making union as a nebulous primary 
outcome.(120) 
 
Historically, radiographs have been a poor parameter and unreliable when used to 
define fracture healing. They have not been shown to be reliable or accurate when 






apply to the callus, and therefore, a callus which has a fracture line is scored as 2, 
while a callus which is bridged (i.e. no fracture line) is scored as 3. (124) 
 
Computed tomography (CT) has been shown to be superior to plain radiography in 
assessment of union and visualisation of fracture lines.(130) However, this 
investigation is expensive and not easily available in the research setting. Using CT to 
assess union and non-union was not undertaken as standard management in the 
study sites of the research in this thesis. 
 
Despite the advances in imaging, biomechanics and serology, physical exam remains 
one of the primary methods of determining fracture union in clinical practice, 
particularly in resource-limited settings, where radiographs or any other 
investigations may not be available. The lack of full weight-bearing is a very useful 
clinical diagnostic tool to assess fracture healing and is referred to as functional 
union.(131), (132) 
 
There has been an increase in the use of patient reported outcome measurements 
(PROMs) in assessing fracture healing and as primary outcome measures in research 
studies, suggesting a shift towards patient-centric orthopaedic care.(120), (133), 
(134) PROMs assessments generally either measure general physical and 
psychological health, such as the EQ5D ((135), (136), or are disease-specific, such as 
the disability related index (DRI)(Appendix 13-1). (137), (138)  
 
Eighty patients were studied using a generic quality of life PROM to evaluate changes 
in baseline score after treatment of long bone non-union fractures. (139) All patients 
with healed non-union demonstrated improved scores and decreased pain levels. 
This was seen to a greater degree in patients who achieved union by final follow up. 
These results suggest that it may be possible to track fracture healing via PROMs and 






3.7 Factors influencing bone healing 
 Age 
In skeletally mature adults it has been suggested that advancing age has a significant 
impact on skeletal repair. (140) Studies of fracture healing in rats have shown that 
the formation of cartilage and bone, and cartilage resorption, were delayed in elderly 
animals.(141) Furthermore, there was evidence that accretion of mineral into the 
callus was reduced in elderly animals.(142), (143) In contrast, evidence from clinical 
research is conflicting and no valid conclusions can be drawn to date.(144), (145) 
 
Clinical data is currently conflicting. Mills et al demonstrated, in a prospective cross-
sectional study over a five-year period and involving just under 5,000 non-unions, 
that although the number of fractures increased with age, the number of non-unions 
did not. The non-union rate per fracture was highest in the 30 to 44-year age group, 
20 times greater than that in the 0 to 14-year-olds and 2.5 times higher than in those 
aged over 75.(116) 
 
 Sex 
Female patients over 55 years of age have demonstrated comparatively poor healing 
outcomes compared to the general population and a potential increase in non-union 
rate when compared to males.(59) After the menopause, women have a lower rate 
of oestrogen, which plays an important role in promoting bone formation, 
stimulating anabolic and reducing catabolic processes. Calori et al (59) suggest that 
these decreased oestrogen levels and generally diminished biologic activity may be 
responsible for the observed trends.(59) There is little evidence of any clinical 
difference in fracture healing in young (<55 years) adult male and females. However, 





potentially increasing their risk of issues with union but this is speculative and 
requires further research.(116) 
 
 Diet 
During the process of fracture healing, there is an increase in metabolism 
requirements in the body. For this reason, the importance of a diet rich in protein, 
calcium and phosphorus, and vitamin D has been assessed in a number of clinical 
trials.(146) Nutritional deficiencies seem to have the maximum influence on the later 
phases of bone callus formation.(146)  
 
In an animal study, vitamin B6-deficiency caused a significant delay in the maturation 
of callus in rats.(147) Vitamin C has also been shown to be essential for the 
maintenance of differentiated functions of osteoblasts, including fracture repair, 
(148) and other investigators have shown that supplementary vitamin C in an animal 
model accelerates fracture healing.(149) Additionally, vitamin C content in the diet 
improved mechanical and histological parameters of fracture repair in a rat 
model.(149) Other researchers have shown the importance of dietary protein and 
calcium, phosphorous and vitamin D in fracture healing, again in an rat animal 
model.(146) 
 
Despite increasing evidence in animal models, the lack of clear clinical research 
makes it difficult to draw conclusions regarding the exact effect of diet and nutrition 
on fracture healing in clinical practice. 
 
There are also conflicting reports regarding high body mass index (BMI) on fracture 
healing. Some researchers suggest high BMI is a risk factor for non-union following 





union and high BMI (152), or an increase in surgical complications in obesity but not 
an increase in the rates of delayed or non-union.(153) 
 
 Vitamin D 
At a cellular level, vitamin D is involved in every stage of the complex process of 
fracture healing through its effects on inflammatory cells, cytokines, growth factors, 
osteoblasts, osteoclasts and through its effect on the process of mineralisation. The 
role of vitamin D in fracture healing poorly understood. There are a limited number 
of conflicting experimental studies reporting either a negative (146), (154),  (155) or 
no effect of vitamin D deficiency on fracture callus formation and mechanical callus 
quality. It is also debated whether vitamin D supplementation supports the fracture-
healing process,(146), (156), (157), (158) although 70% of fracture patients display 
vitamin D deficiency.(159)  
 
In rat models, vitamin D has been shown to be associated with impaired fracture 
healing compared to normal fracture healing in a vitamin D-sufficient control group. 
(160) Furthermore, animal models have demonstrated less resistance to torsional 
stress, (146) increased bone fragility, delayed union, smaller amount of callus and 
undermineralised bone. (146), (160) Fischer et al (158) demonstrated that fracture 
healing was only marginally disturbed in calcium and vitamin D-deficient mice. 
However, deficient mice displayed significantly increased serum parathyroid 
hormone levels and osteoclast activity, as well as reduced bone mass in the intact 
skeleton post-fracture, suggesting considerably enhanced calcium mobilisation from 
the intact skeleton during bone regeneration. Calcium and vitamin D 
supplementation initiated post-fracture prevented post-traumatic bone loss by 
reducing bone resorption and furthermore improved bone repair. These results 
suggest that adequate calcium and vitamin D supply post-fracture is essential to 





bone loss and to reduce the risk of secondary fractures in osteopenic patients with 
calcium/vitamin D deficiency.(158) 
 
Regarding vitamin D’s effect on BMD, a meta-analysis concluded there was very little 
evidence of an overall benefit of vitamin D supplementation on BMD.(161) Although 
small increases in bone density at some skeletal sites in some studies were reported, 
when these increases are offset against the individual findings of deleterious effects, 




There is evidence reporting increase risk of delayed or non-union in people who 
smoke.(162) Nicotine prevents cellular proliferation during the fracture healing 
process, altering the maturing of macrophages and fibroblasts and acting directly on 
osteoblasts.(163) It is also a vasoconstrictor agent, causing an alteration of the tissue 
perfusion with consequent hypoxia and ischemia. A deficit in the formation of the 
haematomas at the fracture site and an alteration of biomechanical properties in the 
newly-formed bone has been assessed in patients who smoke more than 10 
cigarettes per day.(163) Decreased vascularisation of a fracture site has also been 
reported to cause delayed bone healing leading to non-union.(164)  
 
 Alcohol 
Alcohol has been shown to plays a role in inhibiting fracture healing, especially when 
it is taken in excessive doses in the post-trauma period.(165) Alcohol abuse in 
patients with fractures inhibits new bone formation and is considered to be 





bone is lacking mineralisation and consequently has decreased mechanical stability 
at the fracture site due to low rigidity of the newly-formed bone.(165) 
 
 Medical comorbidities 
3.7.7.1 Diabetes 
Both animal and clinical studies have demonstrated a significantly higher incidence 
of delayed union, non-union, and an increase in fracture healing time in diabetic 
compared with non-diabetic patients.(166), (167), (168), (169) There are several 
implicated factors – mainly vascular and neuropathy problems. A reduction in the 
formation of collagen in the bone callus and a marked reduction of cells involved in 
the repair process have been noted in diabetic patients.(170)  
 
Aderinto et al (171) reviewed 27 diabetic patients who sustained a tibial fracture 
treated with a reamed intramedullary nail and compared them with a control group 
who did not have diabetes. When reviewing the union rate, the diabetic patients had 
a non-union rate of 9%, compared to 0% in the control group. 
 
3.7.7.2 Osteoporosis 
Patients with osteoporosis experience a progressive loss of bone mass and an 
increase in the risk of fractures. Osteoporotic bone is bone that has an altered 
structure due to the reduced presence of trabecular components, which causes the 
loss of mechanical resistance. There is a reduction of osteoblasts and, thus, to callus 
production.(172)  
 
The mechanical and biological factors that are involved in the healing process of bone 
are certainly affected by age and osteoporosis. Alterations in bone metabolism, like 





healing. However, the mechanics of this influence of osteoporosis on fracture healing 
have not yet been clarified and clinical evidence is still lacking.(173) 
 
3.7.7.3 Anaemia 
Studies in iron-deficient anaemic rats have demonstrated significant deficiencies in 
bone healing, with a decrease in the rate of union and loss of strength. These changes 
have been attributed to a decrease in oxygen tension and a deficiency of iron, which 
is required for function of the electron transport system within the cell and for 
hydroxylation of proline in collagen formation.(174), (175) 
 
Further work in a rabbit model showed an inhibition of fracture healing in 
hypovolaemia, which was attributed to impaired delivery of oxygen to the fracture 
site. These investigators found that a decrease in blood volume associated with 
anaemia delayed healing, but normovolaemic anaemia had no adverse effect, 
suggesting that attention to fluid rehydration following trauma was sufficient and 
that blood transfusion was not required to maintain normal fracture healing.(176), 
(177) Therefore, it appears that fluid resuscitation is important in the acute phase to 
allow fracture repair to progress normally, while attention to correction of chronic 
iron deficiency is necessary to decrease the rate of non-union: an important point to 
consider when managing polytrauma patients. 
 
3.7.7.4 Peripheral vascular disease 
Peripheral vascular disease adversely affects the blood flow to the tissues, including 
the bone and the surrounding soft tissue envelope. This will impair delivery of 
oxygen, inflammatory cells and nutrients to the fracture site. There will be an 
accumulation of carbon dioxide (CO2) and other metabolites rendering the local 
environment acidic. This combination of factors is considered to be detrimental to 





non-union has not been directly addressed, investigation of tibial fractures has shown 
that those with an associated injury to the posterior tibial artery have a significantly 
higher rate of non-union and take longer to achieve union than fractures without this 
vascular injury.(178), (179) 
 
3.7.7.5 Hypothyroidism 
The effect of thyroxine deficiency has been examined in a rat model of fracture 
healing in which methimazole was used to obliterate thyroid function.(180) This 
demonstrated that hypothyroidism inhibited endochondral ossification, resulting in 
an impairment of repair. Treatment with L-thyroxine returned the repair process to 
normal, suggesting that hypothyroidism will inhibit secondary bone healing, although 
primary bone healing appears to be unaffected. Again, it is not known if this effect 
translates to clinical practice. 
 
3.7.7.6 Renal disease 
Animal models have shown that progressive deterioration in kidney function leads to 
lower bone regeneration capacity following a fracture.(181) In addition, kidney 
disease results in the development of osteoporosis and an increase in fracture 
risk.(182) Therefore, due to these changes it is suggested that there is an increased 
risk in delayed and non-union in patients with chronic kidney disorders. But this is yet 
to be proven in clinical practice. 
 
 Nonsteroidal anti-inflammatory drugs 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly avoided by 
orthopaedic surgeons because of their possible influence on bone healing. This view 
originates from multiple studies, in particular animal studies, that show delayed bone 





to play a role in the reduction of osteoblastic activity and inhibit synthesis of 
prostaglandins, which in turn causes a delay in the formation of bone callus.(184) 
However, the true effect of NSAIDs on bone is still not known and the literature still 
does not offer a clear consensus with regard to the safety or harm of NSAID utilisation 
following orthopaedic procedures in clinical practice. The great variability in the 
interpretation of the available evidence appears to suggest that NSAIDs may affect 
bone healing, but that this effect depends on the type, dose, timing and length of 
exposure.(183), (185) 
 
 Injury, location of fracture and classification 
There are number of factors to consider related to the injury and mechanism of injury 
that are likely to contribute to issues with the fracture healing process. The 
mechanical environment surrounding the fracture can affect the healing process. This 
is highly dependent on the fracture characteristics and the fixation technique utilised. 
Perren’s theory of interfragmentary strain postulates that reparative tissue will 
develop at a fracture site in accordance to the strain tolerance of the tissue and the 
local strain environment between fracture fragments.(186) According to this theory, 
a simple fracture line that is not compressed and neutralised will have a higher 
likelihood for non-union relative to a fracture site exposed to a low strain 
environment. Some technical surgical factors can also affect union, for example, 
reamed femoral nailing reports a higher union rate than unreamed femoral 
nailing.(187) Furthermore, presence of a fracture gap has been indicated to increase 
the non-union risk; however, this variable must be taken in context with the fracture 
type (simple versus comminuted) and fixation strategy (compression plating or nail, 








 Mechanism  
3.7.10.1 Low energy 
Low energy injuries generally cause less significant damage to the soft tissues, and to 
the bone. The relatively minimal fracture site haematoma, the more stable fracture 
configuration and the minimal damage to the soft tissues and the periosteum rarely 
leads to healing delays and complications.(59) However, if a fracture is sustained with 
a low energy injury, it is more likely to be a fragility fracture and, as discussed earlier, 
there has been a suggestion that osteoporotic fracture may be associated with 
delayed bone healing.(173) 
 
3.7.10.2 High energy 
High energy injuries cause more complex, more comminuted and displaced fractures, 
often with considerable tissue loss, serious damage to the soft tissues and to the 
vascular system, compared to closed injuries. Therefore, these factors may lead to a 
reduction of blood flow to the fracture site and decrease the physiological inversion 
of the endosteal flow.(78)  
 
Experimental studies have shown an up to 50% reduction of the cortical blood flow 
immediately after trauma due to vasoconstriction in the marrow and periosteum 
vessels.(189) In cases where the bony fragments are devascularised, or where 
periosteal stripping and destruction produces necrotic bony fragments and large 
defects, the risk of an atrophic non-vital non-union is high. It has been shown that 
serious damage to one or more important veins in the lower limb increases the 
incidence of non-union by about threefold.(190) Finally, fractures caused by high 
energy trauma are more difficult to reduce and stabilise compared to lower energy 







 Topography of fracture 
Fractures of the metaphysis area of a bone have a lower incidence of union defects 
and shorter healing times compared to fractures of the diaphysis.(59) The repair 
mechanism of metaphyseal fractures starts from cancellous bone that regenerates 
more rapidly and also has greater vascularisation. Healing processes in the 
metaphyseal area are therefore faster and less susceptible to obstructive factors than 
those encountered by diaphyseal fractures. (59)  
 
Bone ossification can occur even when there is considerable damage to the 
periosteum and to the vascularity of the fracture fragments.(191) The anatomical site 
of the fracture compared to the location of the vessels that supply the bone is also 
important. Fractures that are distal to the nutritional centre have a greater risk of 







 Classification of fracture  
There are a number of ways to classify fractures. The most generic common 
classification is the AO classification by Muller.(193) Muller identified four different 
groups of fractures: simple, unstable, potentially unstable and highly unstable. The 
full classification system can be seen in Table 3-2. 
 
Table 3-2. AO classification of fractures (189) 
 
 
3.7.12.1 Simple - stable 
Simple fractures, types A2 (oblique), A3 (transverse) and B2 (with an angulated 
wedge) have a single site or a wedge, potentially stable, that has a sufficient support 






3.7.12.2 Complex - unstable 
Complex fractures, types A1 (spiral), B1 (spiral wedge) and B3 (multi-fragmentary 
wedge) are potentially unstable, as they do not have a sufficient support area to 
guarantee fixation by simple inter-fragmentary compression.(194) 
 
3.7.12.3 Comminuted - highly unstable 
In comminuted fractures types C1 (spiral complex) and C3 (multiple fragments) the 
multiple fragments and comminution represent a high risk of devascularisation and 
necrosis of the fragments, with a consequent loss of substance and the need to 
provide a biological stimulus, in addition to mechanical stimulus, to obtain a good 
level of healing. Comminuted fractures can result in challenges with regards to 
stabilisation of a fracture, since it is not always possible to obtain a stable fixation 
that will facilitate callus formation and maturation.(195) 
 
3.7.12.4 Segmental - potentially unstable 
Only type C2 (two segments) belong to this group, which have a two fracture sites on 
the same bone segment. This again results in challenges related to fixation. On 
occasions, it is possible to obtain good level of healing of one of the two fracture sites, 
while the other one evolves towards non-union.(193) This group will evolve towards 
a type of non-union that differs depending on the type that each fracture site in the 
segment involved belongs to. It is type C fractures that have the greatest tendency to 
evolve into non-union: literature shows about 40% of type C fractures of the diaphysis 
of the femur evolve towards non-union, while types B and A have much lower 






 Open fractures 
Certain characteristics of fractures can influence the progression of fracture healing. 
Disruption of the soft tissue envelope through either an open fracture (197) or open 
reduction during intramedullary nailing (198) has been shown to increase the risk of 
non-union. The degree of fracture comminution has also been shown to increase the 
risk of non-union in open fractures, likely due to substantial damage of the 
periosteum and soft tissue at the fracture site.(196) 
 
The Gustilo-Anderson (GA) classification (Table 3-3), devised in 1976, divides exposed 
fractures into three groups that do not have a direct correlation with the evolution 
into non-union. (199) Group three were usually high-energy open fractures and were 
further subclassified by Gustilo et al into A, B, and C according to the severity of the 











A commonly neglected factor which worsens the prognosis of a fracture is the 
coexistence of multiple trauma.(202) The most frequently used evaluation system for 
a multi-trauma patient is the Injury Severity Score (ISS).(203) The multiple trauma is 
generally considered as a systemic illness with various levels of involvement of both 
the musculoskeletal system and the internal organs. On the basis of damage to 
bones, which may or may not be associated with injuries to other organs, its 
considered that a multiple trauma patient are those with an ISS≥ 16.(203) However, 
patients with an ISS ≤ 16 but with more than one fracture could be considered as 
multiple fracture patients.  
 
The incidence of non-union is significantly higher in polytrauma patients with 
multiple injuries (not just fractures) than in patients with isolated injuries.(204) 
Impaired bone regeneration in multi-trauma patients may be caused by several local 
changes that occur after high-energy impact, such as open fractures, poor condition 
of the surrounding soft tissue, and large-bone defects.(204) 
 
Animal studies have suggested that systemic changes after multi-trauma could 
disturb fracture healing.(205), (206), (207) A animal study demonstrated that blunt 
chest injury altered the cellular composition of the fracture haematoma in rats and 
negatively affected the outcome of bone repair by inducing hypertrophic callus 
formation.(208) Also, intraperitoneal injection of lipopolysaccharides, a frequently 
used model that mimics trauma-induced systemic immune responses, disturbed 






In a clinical study, Bastian investigated the relationship between the systemic 
immune response to severe injury and outcome of bone regeneration. They 
demonstrated that peripheral blood-leukocyte kinetics differed significantly between 
multi-trauma patients with normal and impaired fracture healing of the tibia during 
the first two weeks after injury. They hypothesised that systemic inflammatory 
changes after major trauma contribute to this high incidence of impaired bone 
healing in severely injured individuals.(209)  
 
 Infection  
In a high proportion of non-unions, up to 40%, have undiagnosed underlying 
infection. (210) However, an infection does not necessarily result in non-union. It may 
contribute to the creation of conditions such as sequestrum (necrotic cortical bone), 
infected tissue, interposition of necrotic soft tissue between the fracture fragments 
and to hardware loosening and fixation failure.(211) Additionally, infections are more 
common following open fractures and are thought to contribute to a worse prognosis 











CHAPTER 4. HUMAN IMMUNODEFICENCY VIRUS AND BONE 
4.1 Aim of this chapter 
In this chapter theories and mechanisms through which HIV has an influence on bone 
metabolism, BMD and blood supply to bone will be explored. Furthermore, the 




The key aspects involved in the relationship between fracture healing and HIV 
infection relate; 
(a) to the effects of the virus and ART on bone metabolism, and  
(b) to the effects of both the virus and ART on the immune system.  
 
Altered rates of bone formation and resorption, in a disrupted metabolic and 
cytokine environment, not only have implications for the BMD and fracture risk, but 
also for remodelling in secondary bone healing.(19) A major factor known to affect 
fracture healing is local blood flow to the site of the injury. It is now well established 
that any stage of HIV infection is associated with osteonecrosis, due to interruption 
in osseous blood supply, although the mechanism for this has not been elucidated. 
(12),(14) ART has also been reported to contribute to this effect on the blood supply 
to bone.(19) Conditions that jeopardise arterial flow to the site of primary bone 
healing are associated with higher rates of delayed fracture healing and non-
union.(89) Furthermore, a small number of clinical studies have investigated the role 
of HIV in the fracture healing process. (12),(14) These have suggested that HIV and/or 
ART are associated with delayed fracture healing and may result in non-union.(18), 
(213) Overall, the molecular and cellular mechanisms driving this remain unclear and 
the true effect of HIV and ART on bone healing is very poorly understood. Here a 
discussion of the suggested potential basic science mechanism by which HIV may 






In order to understand the potential mechanisms through which HIV and ART affect 
bone metabolism, bone formation and BMD, it is essential to have an awareness of 
the cells, factors and proteins involved in homeostatic bone remodeling. Osteoclasts 
form from precursors that derive from the monocytic lineage and express the surface 
molecule, receptor activator of NFk B (RANK). Under the influence of the key 
osteoclastogenic cytokine RANK Ligand (RANKL) these cells differentiate into bone 
resorbing osteoclasts.(214) The osteoclastogenic and pro-resorptive activity of 
RANKL is moderated by its physiological decoy receptor osteoprotegerin (OPG). In 
both humans and animals, the ratio of RANKL to OPG is considered to be the final 
arbiter of the rate of osteoclastic bone resorption, and an inappropriate balance 




 TNF-α, RANKL and OPG 
TNF-α plays a critical role in HIV pathogenesis and HIV utilises the TNF-alpha signalling 
pathway for spreading the infection.(215) TNF-α has been observed at high levels in 
HIV patients, (215) and high HIV ribonucleic acid (RNA) viral load and T-cell activation 
have been associated with elevated levels of RANKL, which may therefore lead to 
osteoclast formation and increased bone turnover.(216), (217), (218) Interferon 
gamma (IFNg), a physiological inhibitor of RANKL signalling, is considerably 
downregulated in advanced HIV infection.(214) Therefore, a limited capacity to 
suppress RANKL during HIV infection may also lead to increased osteoclast activation 
and bone resorption. TNF-α has also been shown to mediate apoptosis of human 
osteoblasts.(219) Additionally, Vikulina et al has shown that bone loss in HIV 
transgenic rats was associated with an increase in RANKL and a parallel decline in 





 Wnt signalling pathway 
The lipoprotein receptor-related protein (LRP5) gene role is to provide instructions 
for making a protein that is embedded in the outer membrane of many types of cells 
in the human body. It is known as a co-receptor because it works with another 
receptor protein, frizzled-4 (produced from the FZD4 gene) to transmit chemical 
signals from outside the cell to the cell's nucleus. FDZ4 and the LRP5 protein 
participate in the Wnt signalling pathway, a series of steps that affect the way cells 
and tissues develop. Wnt signalling is important for cell division, attachment of cells 
to one another, cell movement and many other cellular activities.(221) 
 
The LRP5 gene plays a role in the development and maintenance of bone, helping to 
regulate BMD.(221) The circulating factor Wnt binds to LRP5 on osteoblast surface 
membranes to initiate intra-cellular signalling. This drives production of osteogenic 
molecules including bone morphogenetic protein (BMP) and OPG, culminating in 
bone formation. It has recently been demonstrated that Dkk-1 (Dickkopf-related 
protein), a molecule which inhibits this pathway, and therefore bone formation, is 
induced by TNF-α and up-regulated in HIV-positive patients.(222) 
 
 Osteocalcin 
Levels of osteocalcin are linked to the modulation of bone growth, bone 
mineralisation and have been used to show bone formation.(223) Osteocalcin has 
been shown to be reduced in the serum of HIV-positive individuals, and this has been 
reported to be a result of the down-regulation of calcitropic hormones parathyroid 
hormone (PTH) and 1,25 dihydroxychole-calciferal. Circulating osteocalcin has been 
shown to correlate positively with the CD4 count, and negatively with both TNF-α 






 Inflammatory cytokines 
The initiation of fracture healing is stimulated by local release of pro-inflammatory 
cytokines such as TNF-α, interleukin-1 (IL-1) and IL-6 activates cytokine cascades 
which starts the recruitment and differentiation of cells involved in the formation of 
fracture callus and bone healing. Inhibition of an inflammatory response by cyclo-
oxygenase inhibitors is known to adversely affect the process of fracture 
healing.(225) Although HIV infection is immunosuppressive, as mentioned earlier, 
cross-sectional studies showing that serum TNF-α is often raised in HIV-positive 
subjects in comparison with healthy control groups indicate that the production of 
inflammatory cytokines is possible in the context of HIV.(224), (226) ,(227), (228), 
(229) The effects of chronically raised levels of TNF-α on fracture healing are 
speculative. Ongoing inflammation could prime the body for an inflammatory 
response to a fracture, resulting in a highly efficient up regulation of cytokines. 
Alternatively, an increased baseline level of TNF-α could theoretically lead to 
desensitisation, preventing or decelerating the healing process to the detriment of 
the patient.(19)  
 
 IGF-1 
A study of perinatally HIV infected children has found an association between low 
concentrations of insulin-like growth factor-1 (IGF-1) and reduced bone ultrasound 
attenuation,(230) a correlate of BMD. An inverse correlation between IGF-1 and IL-6 
was observed. In addition, IGFs have an anabolic function on the skeleton and IGF-1 
is known to be the major effector of bone growth.(231) Both IGF-1 and IL-6 are 
involved in fracture healing, however their effect on fracture healing in advanced HIV 








 Immuno-skeletal interface 
The immune and skeletal systems are closely interlinked and changes in the immune 
system influence skeletal metabolism. Osteoclast precursors are derived from 
monocytic cells and activated lymphocytes secrete osteoclastogenic cytokines 
including RANKL and TNF-α (232), and cytokines that drive up osteoclastic bone 
resorption in inflammatory conditions including rheumatoid arthritis (233), 
periodontitis (234), (235) and during oestrogen deficiency.(236) Additionally, in 
contrast, under basal physiological conditions, both human (237) and mouse (238) B 
cells are a source of OPG. B cell OPG production is further sustained by interactions 
with T cells, in part though CD40 ligand (CD40L) co-stimulation. (237), (238) Animal 
models of B-cell deficiency, T-cell deficiency and CD40 and CD40L deficiency all 
display severe bone loss and significantly diminished total OPG production.(238) 
 
Interestingly, in HIV-transgenic rats there is a switch from the production of bone-
sparing OPG by B cells to production of bone-destroying RANKL.(220) Furthermore, 
treatment of peripheral blood CD4 T cells in vitro with the HIV-1 coat protein gp120 
caused a decline in T-cell OPG production. However, such actions have yet to be 
demonstrated in HIV-1-infected patients. 
 
Another central cytokine involved in the immuno-skeletal interface is interferon 
gamma (IFNg). Under inflammatory conditions, IFNg has been found to promote 
bone loss by up-regulating the activity of antigen-presenting cells and leading to T-
cell activation and osteoclastogenic cytokine production.(239) However, IFNg has 
also been shown to be a potent direct inhibitor of osteoclast formation by 
antagonising the downstream signal transduction from the RANKL receptor, 
RANK.(239), (240) Specifically, IFNg induces degradation of tumor necrosis factor 
receptor-associated factor-6 (TRAF-6) (240), a critical adapter protein that links RANK 
to downstream osteoclastogenic transcription factors including NF-k B and c-Jun N-





recently reported that the suppressor of cytokine signalling-1 (SOCS-1), a potent 
inhibitor of IFNg signal transduction, is significantly elevated in cells derived from 
individuals with progressive HIV infection, as well as in HIV-1 transgenic rats. (240) It 
is speculated that up-regulated SOCS-1 may contribute to elevated 
osteoclastogenesis by removing the dampening effect of IFNg on the differentiation 
of osteoclast precursors in the context of HIV. (240) 
 
The overall effect of T cells on bone, depends on their activation state. Activated CD4 
T cells promote bone loss in inflammatory diseases such as rheumatoid arthritis(233) 
and periodontitis.(242) T cell–deficient mice have significantly increased bone 
resorption and reduced bone density, as compared to controls.(243) Conversely, 
resting CD4+ T cells may contribute to dampening of bone resorption in vivo.(238) 
HIV is an inflammatory disease and therefore CD4 T cells could behave in a similar 
way as in a rheumatoid arthritis, resulting bone loss. Depending on the stage of the 
HIV infection and if an individual is on ART, this could influence activation of the CD4 
T-cells and ultimately fracture healing. 
 
Bone formation is inhibited by CD8 T cells and this has been demonstrated in a 
number of in vivo studies. (244), (245) In a mouse model, Reinke et al, established 
that depletion of CD8 T cells improved fracture callus formation and bone mineral 
density. Additionally, increasing the CD8 T cell population resulted in delayed fracture 
callus formation and decreased bone mineral density. (245) By affecting the function 
of CD4 T-cells and antigen presenting cells that are required for correct CD8 T-cell 
maturation, HIV is able to decrease the circulating pool of effector and memory CD8 
T-cells that are able to combat viral infection. (244) The end result is a loss of CD8 T-
cell function. This downregulation in CD8 T cells in HIV-positive individuals could 
theoretically result in a subsequent improvement in fracture healing, not seen in HIV-
negative individuals with still normal levels of CD8 T cells. However, the overall action 
of T-cells and immune system on the fracture repair process in HIV-positive 





4.4 Human Immunodeficiency Virus and bone mineral density 
Osteoporosis is a significant global health problem that causes deterioration in the 
microstructure of the bone, leading to a compromised bone strength, which 
predisposes the individual to an increased risk of fractures of the hip, spine, forearm, 
and other skeletal sites. (173) 
 
The diagnosis of osteoporosis is usually considered in the presence of a low-energy 
traumatic fracture and considered to be present when the bone density 
measurement (BMD) is found to be below a certain value. Dual energy X-ray 
absorptiometry (DEXA) is the gold standard of BMD and is measured at the lumbar 
spine and hip. Osteoporosis is defined as BMD measurement at the hip or spine ≤ 2.5 
standard deviations below the mean BMD for a healthy, young, sex-matched 
population (T-score). Osteopenia is defined as a T-score between −1.0 and −2.5. 
Normal BMD is any T-score higher than -1.0.(246) A Z-score compares an individual’s 
bone density to the average BMD of the population average of people with the same 
race, age and gender. 
 
BMD can also be measured with peripheral imaging devices. These include the DXL 
Calscan (Demetch AB), a dual energy X-ray absorptiometry device for determining 
heel BMD. The system is based on the standard technique of dual energy X-ray 
absorptiometry, using a fan beam configuration, but introduces an additional laser 
measurement of heel thickness intended to improve accuracy. In a number of large 
population-based studies, when measuring calcaneal BMD with DXL, it has been 
confirmed that calcaneal BMD measurements appear to have predictive ability for 
osteoporosis-related fractures that does not substantially differ from that of gold 
standard measurements of lumbar spine and hip BMD using a standard DEXA 
machine. This has been shown in both male and females, old and young.(247), (248), 





threshold of -2.5 for classification of osteoporosis is in concordance with the WHO 
definition of osteoporosis. (250)  
 
Measurement of BMD using a peripheral imaging device has a number of advantages 
over traditional BMD measurement with a standard DEXA machine. Practically it is 
simple to use, mobile and it is significantly quicker and cheaper to perform an 
assessment with compared to standard DEXA. For this reason, such imaging is now 
widely used in the NHS for screening of fragility fracture patients, instead of 
traditional measurements.  
 
A reduction in BMD is a common complication of HIV and its treatment. This has been 
documented by a number of cross-sectional studies (8), (9), (10), (11), (252), (253), 
(254), with low BMD, osteopenia and osteoporosis being found in both male and 
female HIV-infected patients (255), (256) compared to non-infected individuals.(257) 
Furthermore, ART, independently has been shown to decrease BMD and this will be 
discussed in more depth in later chapter.(253)  
 
A reduction in BMD is a well-recognised cause of fragility fractures (173) and, as such, 
HIV-related decrease of overall bone stock could potentially increase the risk of 
fracture and its related morbidities. With increasing survival attributable to better 
ART, an HIV-related reduction in BMD could compound age-related causes of altered 
bone density, such as the menopause, with clinical implications of an increase in 
fragility fractures worldwide in HIV-positive patients.(253) Furthermore, in the 
general population, it has been postulated that a reduced BMD is associated with a 







4.5 Human Immunodeficiency Virus and osteonecrosis 
One of the factors known to affect fracture healing is local blood flow to the site of 
the injury. (89) In experimental models, de-vascularised fracture sites have impaired 
healing.(15), (17) A further concern about the implications of HIV infection on 
fracture healing arises from the fact it is now established that HIV and its treatment 
can cause osteonecrosis, predominantly of the femoral head.(12), (254), (258), (259), 
(260) 
 
Osteonecrosis is a condition in which there is cell death of various bone components 
including haematopoietic fat marrow and mineralised tissue due to reduced 
arteriolar blood supply.(12) The estimated incidence of osteonecrosis in the general 
population is 0.135%.(259) Risk factors for osteonecrosis, in the absence of HIV, can 
be subdivided into traumatic and non-traumatic. Traumatic causes include fractures 
and dislocations. Non-traumatic causes include alcohol abuse, collagen vascular 
disease, deep sea diving, systemic steroids, hyperlipidemia, hypercoagulability, sickle 
cell disease, smoking, Gaucher’s disease, pregnancy, pancreatitis and irradiation.(12) 
However, in approximately in 8-20% of osteonecrosis cases, no association with the 
known risk factors has been noted.(261) The reported estimated incidence of 
osteonecrosis in HIV patients ranges from 0.45 to 1.33%, which is significantly greater 
than in the general population.(262), (263) 
 
The reason for such a high incidence of osteonecrosis in HIV-positive individuals is 
not known. Some authors have attributed the increasing incidence to 
hypertriglyceridaemia, which is frequently seen in HIV-positive individuals. 
Hypertriglyceridaemia secondary to the use of protease inhibitors has also been 
reported.(261), (263), (13) Additionally, there have been associations reported 
between retrovirus infection and the presence of both raised anti-phospholipid 
antibodies (264) and protein-S deficiency.(265), (266), (267) This suggests the 





compromise. It remains unclear whether osteonecrosis is an HIV-related 
complication, an adverse effect of ART or is caused by another HIV-associated 
condition, as is the mechanism through which this occurs. However, conditions which 
may jeopardise arterial flow to the site of primary bone healing are associated with 
higher rates of delayed and non-union of fractures.(16) The suggestion that HIV 
infection may have adverse effects on blood flow, as evidenced by its reported 




4.6 Human Immunodeficiency Virus and fracture risk 
There appears to be a concurrent increased fracture risk among HIV-positive 
individuals compared with HIV-negative populations. The National Osteoporosis 
Foundation has recently included HIV infection and ART as risk factors for 
osteoporosis and fragility fractures.(268) In a large population-based study of 8,525 
HIV-infected and 2.2 million non-HIV-infected individuals, total fracture incidence 
was 2.87 (95% CI, 2.52–3.23) in HIV-positive individuals, compared with 1.77 (95% CI, 
1.75–1.79) in the uninfected group (P<0.0001).(269) A nearly three-fold increase in 
incident fracture rates was identified among participants in the HIV Outpatient Study 
as compared to the National Hospital Ambulatory Medical Care Survey, a 
representative sample of the U.S. general population.(270) 
 
A questionnaire-based evaluation of low-trauma fractures among Canadian women 
found that HIV-positive women were more likely to have a history of fragility fracture 
compared with women without HIV (OR, 1.7; 95% CI, 1.1-2.6) despite similar BMDs 
in both groups.(271) 
 
More recently, a Spanish population-based cohort study including over 1.1 million 





between HIV infection and hip fracture incidence, with an almost five-fold increased 
risk in the HIV-infected individuals, independent of sex, age, smoking, alcohol 
drinking and comorbidities. Similarly, a 75% higher risk of all clinical fractures and a 
60% increase in risk of non-hip clinical fractures among patients with a diagnosis of 
HIV infection was found.(272) Finally, another nationwide case-control study in a 
Northern European population found that HIV infection is associated with an almost 
three-fold increase in overall fracture risk. In HIV patients with an almost nine-fold 
higher risk of hip fracture.(273) 
 
 
4.7 Human Immunodeficiency Virus and vitamin D 
The prevalence of vitamin D deficiency (defined as <35 nmol/L April through 
September or <25 nmol/L October through March) was reported as 29% among HIV-
positive individuals in the Netherlands, Northern Europe.(274) Interestingly, vitamin 
D levels varied with ART medications, with lower levels occurring in NNRTI-treated 
compared with PI-treated individuals.(274) Tenofovir in particularly has been 
highlighted as the main ART contributing to vitamin D deficiency in HIV positive 
individuals.(275), (276) 
 
In a study of HIV-positive individuals living in Boston, USA, the prevalence of vitamin 
D deficiency (defined as ≤20 ng/mL and >10 ng/mL) was similar to that listed in the 
study from the Netherlands, with 36.8% falling into vitamin deficiency group.(195) 
Approximately 10% of the study population in the Boston study were defined as 
having severe vitamin D deficiency (≤10 ng/mL).(195) A high proportion of low 
vitamin D stores (25[OH]vitamin D) in HIV-positive individuals as been reported.(277)  
 
In summary, HIV-positive individuals are at risk of vitamin D deficiency and ART 
contributes to this. As discussed in Chapter 3, although vitamin D has been shown to 





scarce to confirm if this deficiency correlates with impaired fracture healing in the 
human patient population. 
 
Note that throughout this thesis when referring to the measurement or value of 






CHAPTER 5. ANTI-RETROVIRAL THERAPY AND BONE: A Review of the 
Literature 
5.1 Aim of the chapter 
In this chapter the effect that ART drugs and combination therapies have on bone 
metabolism, BMD, fracture risk and fracture healing will be discussed. A summary of 
abbreviations for various ART drugs and drug combinations can be found in Table 5-1. 
 
Table 5-1. Anti-retroviral therapies and abbreviations 
NRTI Nucleoside reverse-transcriptase inhibitors  
ABC   Abacavir 
AZT   Azidothymidine 
FTC   Emtricitabine 
3TC Lamivudine 
d4T     Stavudine 
TDF   Tenofovir disoproxil fumarate 
TAF   Tenofovir Alafenamide 




Non-nucleoside reverse-transcriptase inhibitors  
DOR   Doravine 
EFV Efavirenz 
ETR     Etravirine 






APV    Amprenavir 
ATV   Atazanavir 
DRV Darunavir 
FPV   Fosamprenavir 
IDV    Idiniavir 






RTV (referred to as r when in 
combination Lopinavir e.g. LPV/r 
Ritonavir 
























As mortality in patients with HIV began declining in 1996 following the introduction 
of combination ART treatment programs, there has been a shift in treatment goals 
from preventing death to prolonging life and improving health in individuals with 
HIV.(278) As discussed in Chapter 2, there are six classes of ART drugs. At the time 
the study was undertaken, the WHO recommends a combination of two NRTIs, with 
the NNTRI (TDF + 3TC (or FTC) + EFV) for the management of HIV.(50) This is the 
approach and regimen that is currently used in South Africa and is the therapy 
combination that the vast majority of patients currently under treatment for HIV in 
the Western Cape are taking. These guidelines are continuous evolving and being 
updated on an annual basis by the WHO. Patients are only given different treatment 
regimens in South Africa if they experience side effects to first-line therapy, are 
pregnant or an adolescent/child.  
 
A number of ART drugs have been implicated in the emerging evidence that the 
therapy plays a role in HIV-associated bone disease. However, first-line therapies and 
regimens have evolved with development of newer medications, many with 
improved tolerance and dosing requirements. Accordingly, evaluating the direct 
effect of medications on bone has been difficult to assess long term.(278) Moreover, 
determining the direct effects of specific ART agents on bone health independent of 
their effects in suppressing HIV replication and associated inflammation has proven 
difficult. Finally, since they are taken in combination therapy regimens, determining 







5.3 The effect of anti-retroviral therapy on bone and bone mineral density 
In a meta-analysis comparing HIV-positive patients treated with ART to those who 
were ART-naïve, ART-treated individuals were more likely to have osteoporosis.(279) 
Across 11 studies of 884 HIV-positive patients, 67% had reduced BMD, of whom 15% 
had a osteoporosis, compared with HIV-negative controls. Compared with ART-naive 
patients (n = 202, 10 studies), ART-treated individuals (n = 824) had 2.5-fold increased 
odds of presenting with reduced BMD. However, it is important to note there was no 
adjustment for potential confounding factors in this study’s statistical analysis. In 
other studies, ART duration has been associated with lower BMD in some 
groups.(280), (281), (282) 
 
The Strategies for Management of Antiretroviral Therapy (SMART) study was 
undertaken to assess continuous ART treatment against intermittent ART to 
maximise ART benefits while minimising toxicities related to duration of ART 
treatment. However, the study was ended early due to an increased risk of death, 
AIDS-defining illness and other serious, end-organ disease in the treatment 
interruption group. Nonetheless, in individuals receiving continuous ART, loss of BMD 
was greater compared with patients taking intermittent ART.(283) In an additional 
analysis of the same study group, markers of bone turnover and inflammation were 
increased in patients on continuous ART, while intermittent ART was associated with 
an initial decrease in bone turnover followed by stabilisation.(284)  
 
A number of studies have demonstrated that BMD may initially fall following ART 
initiation but recover after prolonged use.(285), (286) The majority of bone loss 
appears to occur in the first 12 months of starting ART. However, in a recent study of 
patients treated with ART for an average of five to eight years, there was significant 
continued bone loss on DEXA findings at the spine and hip. This loss was greatest 
among those individuals treated with TDF.(287) When trying to identify individual 





higher when initiating TDF (NRTI) and/or PI regimens, in comparison with NNRTIs. 
(288), (289), (290) 
 
The AIDS Clinical Trials Group showed that the loss of BMD with ART initiation is 
greatest for those individuals with low CD4 cell counts, particularly those with a CD4 
count < 50 cells/mm3.(291) Additional factors that were independently associated 
with BMD loss included older age, female sex, lower BMI, higher HIV-1 plasma viral 
loads, initiation of PI and initiation of TDF.(291) 
 
 
5.4 Nucleoside reverse transcriptase inhibitors – mechanism of action on bone 
NRTIs inhibit the enzyme DNA polymerase-γ leading to loss of structure and function 
of mitochondrial DNA.(290) This, in turn, leads to alternative energy production, 
increasing lactate production from pyruvate, with resultant hyperlactataemia and 
even lactic acidosis in a smaller subset of patients.(290) In NRTI-treated patients, 
hyperlactataemia occurs in 15% to 20% of individuals, and lactic acidosis occurs in 
less than 0.4% patients.[10] It has been suggested that chronic acidosis induces 
calcium mobilisation from bones in an attempt to restore electrolyte 
homeostasis.(292), predominantly in trabecular bones, such as the vertebral bodies. 
In addition to metabolic changes, it is likely that NRTIs may have direct effects on 
osteoclasts. For example, ZDV has been shown to potentiate RANKL–mediated 
osteoclastogenesis.(293) 
 
Starting TDF has been associated with increases in parathyroid hormone (PTH) levels, 
(294) which has been shown to enhance normal fracture healing in animal models, 
although this effect has not been shown to translate to the clinical setting.(295) 
Exposure of TDF to mouse osteoblasts in vitro demonstrated altered gene expression 
involved in cell signaling, cell cycle control and amino acid metabolism, implicating 





dysfunction, resulting in chronic phosphaturia, which may cause low total body 
phosphate despite normal serum phosphate, possibly leading to osteomalacia.(297), 
(298) Conversely, some studies do not corroborate the association between TDF and 
nephrotoxicity. In patients on TDF with a normal baseline renal function, no 
statistically significant hypophosphatemia was shown.(299) Furthermore, several 
additional studies have shown that the incidence of hypophosphatemia is the same 
between TDF-treated and untreated study groups.(300), (301) Overall, baseline renal 
function may be more important as a determinant of bone loss than the effects of 
TDF itself. 
 
Inhibition of mitochondrial DNA replication occurs with some NRTIs, leading to 
osteoblast dysfunction.(302) Paradoxically, switching to TDF may improve 
mitochondrial function, suggesting that different ART drugs have varying effects on 
bone metabolism.(303) A further suggestion is that initiating ART causes a rapid 
recovery of T cells, peaking around 12 weeks. During immune reconstitution there 
are changes in circulating cytokine levels, including RANKL, potentially influencing 
bone loss.(284) 
 
There are a number of different mechanisms through which it has been suggested 
the NRTIs may influence bone metabolism and BMD. A definitive mechanism has not 
been determined and the pathogenesis is poorly understood. It is likely that 
individual drugs influence bone metabolism through several pathways at once and to 
different overall extents.  
 
This thesis will now go onto discuss studies investigating the individual NTRIs 






5.4.1.1 Tenofovir disoproxil fumarate and bone mineral density 
One of first ART studies to assess BMD investigated 600 ART-naïve patients 
randomised to receive either TDF or d4T, in combination with 3TC and EFV.(304) This 
demonstrated significant BMD reduction at 144 weeks with TDF compared to d4T 
treated groups at the lumbar spine (-2.2% vs. -1%, p=0.001) and hip (-2.8% vs. -2.4%, 
p=0.060). The majority of loss in the lumbar spine occurred within 24 weeks and 
stabilised after this point, with loss at the hip occurring within the first 48 weeks and 
then stabilizing thereafter. No further progression was noted at extended follow-up 
at 288 weeks.(305) Similar bone loss has been shown consistently in a number of 
trials of TDF.(306), (307), (308), (309) 
 
In 220 Botswanans taking pre-exposure prophylaxis (PrEP) of TDF/FTC or placebo, use 
of TDF/FTC was associated with significantly less gain in BMD when compared with 
placebo at week 30 at the forearm (+0.97% vs. +1.83%, p=0.010), hip (-1.03% vs. 
+0.52%, p=0.003) and also the lumbar spine (-0.09% vs. +1.55%, p=0.001).(310) 
Significantly more participants had low BMD at baseline compared with that 
expected from study cohorts based high-income countries (6.8% vs. 2.3%, p<0.001). 
There were increases in BMD throughout the study in the placebo group, meaning 
that patients who were supposed to be healthy were, in fact, undergoing a period of 
normalisation of their BMD. However, consistently similar results have also been 
seen in a variety of populations, reinforcing the negative effect of TDF on HIV-
negative individuals BMD.(311), (312) 
 
BMD may also improve if TDF is switched to another NRTI therapy.(313) Finally, only 
one paper to date appears to show favorable effects of TDF on BMD.(314) Therefore, 
TDF does appear to cause an overall decrease in BMD, which may be time dependent 







 Other reverse transcriptase inhibitors and bone mineral density 
Evidence of other NRTIs affecting bone metabolism and BMD is less clear and many 
trials use TDF as a comparison. Therefore, concluding that the medication is only less 
detrimental comparatively to TDF.  
 
A randomised trial of 41 patients randomised to either continue LPV/r + 2NRTIs or 
switch to LPV/r + 3TC saw increases in total BMD in the switch group (+1.04%, 95% 
CI 0.06 to 2.01%).(315)  No significant differences were seen in the continuation 
group and a larger increases in BMD were seen with discontinuation of TDF. Similar 
favourable effects of 3TC have been seen when switching from NRTIs to TDF/FTC or 
ABC/3TC and with switch from ABC/3TC to TDF/FTC.(316), (317), (318), (319) 
 
A study of 24 patients randomized 3:2 to either halve their treatment dose of d4T or 
continue unchanged showed that  at 48 weeks, half-dose treatment group stopped 
the progression of BMD loss (0.0% vs. -1.7%, p=0.003).(320) The authors suggested 
that the lower dose might be less tolerant to breaches in adherence, but full dose 
appeared more detrimental to bone. 
 
In a trial of 50 men, BMD loss was greater in participants initiated on ZDV/3TC 
compared with NVP at the femoral neck (-6.3 vs. -2.3%, p=0.0006) and lumbar spine 
(-5.1 vs. -2.6%, p=0.07).(321) BMD changes with NVP stabilised after 12 months, 
whereas in the ZDV/3TC group, continued to deteriorate at the femoral neck for up 
to 24 months. ZDV/3TC has demonstrated similar effect on bone to TDF/FTC 
previously.(322) However, no studies to date has investigated the effect of TDF or 






5.5 Protease inhibitors – mechanism of action on bone 
PIs stop viral replication by selectively binding to viral proteases and then blocking 
proteolytic cleavage of protein precursors that are required for the production of 
infectious viral particles. 
 
As discussed in Chapter 2, the Wnt/β-catenin pathway is involved in osteoblast 
differentiation and drives forward the production of osteogenic molecules including 
bone morphogenetic protein (BMP) and OPG, ending in subsequent bone formation. 
The PI RTV has been shown to increase the production of proteins that block the 
canonical Wnt β-catenin signalling. (323) RTV has also been shown to inhibit the 
pathway, potentially resulting in a decrease in osteoblast differentiation. Therefore, 
contributing to the pathogenesis of decreased BMD seen in patients on RTV.(324) 
 
RTV has been shown in vitro to inhibit osteoclast differentiation directly in a dose-
dependent manner. The effects were reversible within three days of removing RTV 
from in vitro cultures, with maintenance of normal osteoclast differentiation.(325) 
Confirming these in vitro findings, the ANRS 121 Hippocampe study group, 
demonstrated that reduction in lumbar spine BMD was significantly worse in the PI/r 
(boosted PI with RTV) and NNRTI arm (-4.4%±3.4%) and the PI/r and NRTI arm (-5.8% 
+/- 4.5%), compared with the NNRTI and NRTI arms without PIs (-1.5%±2.9%).(326) 
 
RTV, but not IDV or NFV, has been shown to block interferon-γ-mediated TRAF6 
degradation. TRAF6 has an important role in osteoclastogenesis, by acting as the 
intermediate between RANK activation and NF-κB and MAP kinases activation. This 
effect of RTVs on bone, appears to be reversible by interferon-γ administration. (323) 
Other in vitro studies have confirmed these initial findings that RTV has a role in 
inhibiting osteoclast cell differentiation.(325), (327) Further in vitro studies have 
demonstrated that osteoclast activity increases in the presence of NFV, IDV, RTV and 





significantly increased OPG and decreased RANKL in vivo, but other PIs, including 
ATV, SQV, and IDV, did not.(328) 
 
An in vitro study demonstrated that the PIs RTV, IDV and NFV decreased cytochrome 
p450 activity, in particular 25-hydroxylase and macrophage 1α-hydroxylase, resulting 
in decreased vitamin D.(329) However, clinical data linking PI with impairment of 
vitamin D are limited and overall inconsistent. Some studies have reported an 
association between RTV exposure and lower odds of vitamin D insufficiency or 
deficiency(330) and others have found higher levels of vitamin D in HIV-positive 
individuals taking PIs therapy compared with those taking NNRTI or naïve 
patients.(274) 
 
Overall, there is a variation in the mechanism and extent to which different PIs 
influence bone metabolism, and these are still poorly understood. 
 
 Protease inhibitors and bone mineral density 
A cross-sectional study of HIV-positive men taking PIs compared to HIV-negative 
individuals showed higher incidence of low BMD (relative risk (RR) 2.19 [95% CI 1.13 
- 4.23] p-value = 0.02) in those taking PIs.(331) These results have been confirmed by 
additional research (256), (279), (332), and one research group demonstrated 
recovery of BMD after stopping PI therapy.(333) 
 
When compared to other ART groups, conflicting results have been shown regarding 
the degree of BMD loss with different PIs. Patients initiated on PIs had significantly 
lower BMD at 48 weeks compared with NNRTIs and NRTIs (-4.4% vs. -1.5%, p=0.07 
and -5.8% vs. -1.5%, p=0.001).(326) Conflicting reports comparing EFV (NNTRI) or 
LPV/r (combination PIs) with ZDV/3TC (NRTI) in 106 ART-naïve patients over 96 weeks 





differences between groups were not significant (-2.3 vs. -2.5%, p=0.86). Another 
study compared three treatment regimens, LPV/r, EFV and 2NRTI, in paired 
combinations and reported similar results.(335) A similar trend has been shown by 
further studies comparing different treatment ART regimens with PIs. (331), (336), 
(337)  
 
Interestingly, in a comparison of continuing TDF/FTC/EFV (NTRI and NNTRI 
combination) or switching to DRV/r (PI monotherapy), BMD at the femur increased 
with DRV/r (+2.9% vs. -0.003%, p<0.05) and also the lumbar spine (+2.6% vs. +0.008%, 
p<0.05).(338) This suggest that TDFs effect on BMD is greater than PI combination 
therapy. However, available results are conflicting, and this is likely due to the 
inherent nature of the effect of varying combinations of ART on bone, making it 
difficult to draw valid conclusions about individual ART drugs. 
 
The data concerning PIs effect on BMD might also be explained by the increase in 
visceral fat.(339) It has been shown that there is a substantial gain in fat mass 
correlating with a sharp drop in BMD observed in individuals taking PI therapy.(340) 
Simulated increases in body fat have demonstrated reduction in the mean DEXA 
measurement of spine BMD, although not in the hip.(341) However, like with NRTI, 
no studies have investigated the effect of PIs on fracture healing to date. 
 
 
5.6 Other anti-retroviral therapy and bone mineral density 
Additional classes of ART, other than NRTIs, NNRTIs and PIs, have been shown to have 
an effect on bone and BMD. At the time this study was undertaken, these classes 
were not first line therapy in South Africa and few, if any, of the patients in this study 
cohort were taking any other classes of ART, other than NRTIs, NNRTIs and PIs. 






INIs block the action of integrase, a viral enzyme that inserts the viral genome into 
the DNA of the host cell. Because integration is a vital step in retroviral replication, 
blocking it ultimately stops further spread of the virus. Starting HIV treatment with 
RAL (INIs) + DRV/r (PIs combination) caused less BMD loss compared with TDF/FTC 
(NRTI combination) + DRV/r over 48 weeks (+9.2 vs. -7.0 g/cm2, p=0.002).[72] This 
again suggests BMD loss is greater with TDF combinations. Unfortunately, virological 
efficacy was inferior with RAL, but its beneficial effect on bone when compared with 
NRTIs and PIs has been demonstrated in a number of other studies.(337), (342), 
(343), (344), (345), (346), (347) 
 
In a cohort of 262 patients, those taking CCRT antagonist maraviroc had significantly 
higher BMD compared to those on TDF (-1.51% vs. -2.40%, p<0.001).(348) These 
results were echoed by the GUSTA trial, which compared switching to MVC+DRV/r 
against the continuation of stable ART.(349) 
 
 
5.7 Emerging anti-retro viral therapy: Tenofovir Alafenamide 
TAF is a pro-drug of TDF that has recently been licensed and may cause fewer side 
effects than TDF. A pro-drug is a biologically inactive compound that can be 
metabolized in the body to produce a drug. Regarding TAF, this is hydrolysed to TDF 
intra-cellularly by cathepsin A, resulting in higher intracellular tenofovir diphosphate 
with lower dosing.(350) 
 
An in vivo study in dogs demonstrated preferential distribution of TDF to lymphatics 
with TAF compared with TDF.(351) The plasma levels of TDF were 10% less than those 
with TDF administration, which may reduce bone and other side effects of TDF. (351) 
 
A number of clinical trials have compared the treatment of TAF with TDF using BMD 





(353), (354), (355) Two phase 3 clinical trials comparing EVG/COBI/FTC and TAF with 
EVG/COBI/FTC and TDF in 1733 patients over 48 weeks showed patients on TAF 
combination therapy had a reduction in changes in BMD at the hip and spine. They 
also experienced fewer side effects, with the exception of increases in total 
cholesterol, LDL and HDL cholesterol with TAF.(353) Similar results were found at 96-
week follow-up, with BMD not changing.(354) 
 
Recently, the reported beneficial effects of TAF compared to TDF have been 
questioned. A meta-analysis reported, from nine clinical trials, that TDF in 
combination with RTV or COBI was associated with higher risks of bone and renal 
adverse events, and lower HIV suppression rates, when compared with TAF. By 
contrast, when RTV and COBI were not used, there were no efficacy differences 
between TAF and TDF, and little differences in safety. The authors concluded that 
health economic value of TAF compared to the relatively low-cost generic TDF may 
be limited when these drugs are used without COBI AND RTV.(356) 
 
 
5.8 Anti-retroviral therapy and fracture risk 
As discussed, it has been well established that certain ARTs, particularly TDF and PIs, 
cause a decrease in BMD, although this varies between therapies. However, it is 
important to determine if this decrease in BMD translates to an increase in the risk 
of fragility fracture. In a recent publication from the Veterans Health Administrative 
Data Clinical Case Registry (VHA CCR), researchers characterised the risk of 
osteoporotic wrist, vertebral or hip fractures among a cohort of 56,600 HIV-positive 
individuals.(288) [32] Cumulative exposure to the ARTs TDF and LPV/r were both 
independently associated with fracture.  
 
A large retrospective observational study of 56,660 patients determined that TDF had 





0.001).(288) Whereas, cumulative exposure to the antiretrovirals TDF and LPV/r were 
both independently associated with fracture. 
 
Another recent publication evaluated fracture risk after ART initiation among 4640 
HIV-infected individuals. (357) They identified 135 persons who experienced 151 
incident fractures occurring a median 2.3 years after ART initiation. Fracture rates 
were significantly higher in the first two years after ART was started, when compared 
to subsequent time periods. The type of ART an individual was taking was not 
associated with fracture incidence. The authors speculate that BMD decline with ART 
initiation is linked with change in bone mass and quality, leading to increased fracture 
risk. Additionally, in theory, as patient health improves over time with ART, the risk 
of falls and subsequent fractures may decrease with overall health improvement, 
suggesting there may be a catabolic window after ART initiation that leaves 
individuals susceptible to a fragility fracture. 
 
The most recent of studies investigating at fracture risk and ART found no evidence 
of any increase in risk of a fracture after exposure to TDF or to PIs. Among 861 
reviewed cases, 261 fractures were osteoporotic and 254 of cases were matched to 
at least one control (376 controls). 49% of patients had been taking TDF and 82% had 
been on PIs. After taking into account a number of confounding factors, including the 
AIDS status, geographic location of an individual’s home, body mass index, smoking 
status, alcohol consumption, exposure to steroids and the time point an individual 
was enrolled, there was no association between the risk of fracture and exposure to 
TDF (OR 1.04 [CI 0.86-1.27]), to NRTIs, or to PIs (OR 1.02 [0.92-1.12]).(339) 
 
ARTs, particularly TDF and PIs, may increase the risk of an individual with HIV 
sustaining a fracture due to decrease in BMD; however, results are conflicting with 
the most recent evidence showing no excess risk of fracture after exposure to TDF or 
to PIs. As already highlighted, there is currently no literature available reporting the 





of ARTs on the fracture repair process. Therefore, no conclusion can be drawn to 
address the question of whether ART impairs fracture healing. The cohort reported 
in this thesis is the largest to date and will hopefully shed some light on this issue. 
 
5.9 Summary 
The treatment of HIV has evolved significantly since the approval of ZDV in 1987 for 
the treatment of HIV. The initial aim of ART was to slow a pandemic of HIV. 
Development of new ART drugs and administration of them in combination, with the 
aim of reducing resistance and improving efficacy, has resulted in the life expectancy 
of an appropriately treated HIV-positive individual may approach that of an HIV-
negative member of the population.(358)  
 
Combination therapy and the inability to compare HIV-infected patients with 
untreated controls makes it difficult to draw clear conclusions regarding the definite 
effect of different ART on bone BMD, bone metabolism, fracture risk and fracture 
healing. Evidence to date appears to implicate TDF as having the clearest detrimental 
effect on BMD, closely followed by various PIs. Other drugs in the NRTI class may have 
similar, but less severe effects. The effect of ART on fracture healing has not been 
previously investigated in laboratory or clinical studies. 
 
It is unethical to use HIV-infected patients as non-treated controls, making it 
challenging to determine the exact degree of bone loss that is caused by ART on top 
of that caused by the HIV infection itself. In addition, it is difficult to draw conclusions 
from studies treating uninfected patients with ART as pre-exposure prophylaxis, as 
the demographics of such high-risk groups have not historically matched the general 
HIV-infected population. Comparison must be made between drug combinations, 






Changing to ART with a favourable bone profile may lead to recovery in BMD, 
although this needs to be balanced with maintaining the virological efficacy of the 
alternative ART therapy, which is essentailly the primary reason for the treatment 
itself. Additionally, in the majority of studies, follow-up seldom exceeds 96 weeks in 
prospective trials and so it is currently unknown how patients’ BMD is affected 10 or 
even 20 years later, or if fracture risk can be reduced in particularly at-risk patients 
by switching their ART when their BMD reaches a specific point. However, minimising 
BMD loss in this group of patients is particularly beneficial, as HIV itself may also 
reduce BMD, and patients with HIV may have other comorbidities that compound 
this effect (increased rate of smoking, poor nutrition). Nevertheless, the significance 
of a slight decrease in BMD that does not continue to decline remains to be proven, 
especially if an alternative ART may lead to relapse of the viral disease. Therefore, it 
is important that further research is undertaken taking into account these factors, to 
get a better understanding of the effect of ARTs and combinations on BMD, bone 






CHAPTER 6. FRACTURES IN HIV-POSITIVE INDIVIDUALS: A Systematic 
Review of the Literature 
6.1 Aims of chapter 
This chapter aims to report the findings from a systematic review of the outcomes of 
operative treatment of fractures in HIV-positive individuals. A formal meta-analysis 
could not be carried out due to the variability in the methodology and outcome 
measures in each study.  
 
This systematic review has been published under the title ‘Fracture management in 
HIV-positive individuals: a systematic review’ in the journal ‘International 
Orthopaedics’.(213) This chapter uses much of the information from this systematic 
review and the contribution by all the authors is acknowledged. For this publication, 
the author of this thesis (Simon Graham) devised the concept of the paper, undertook 
the literature search, lead the write up, edits and final submission of the paper. 
  
6.2 Overview 
A small number of clinical studies have investigated the role of HIV in the fracture 
healing process. These studies have suggested that HIV and/or ART may be 
associated with impaired fracture healing. (18), (19) The molecular and cellular 
mechanisms driving this remain have been discussed in previous chapters but main 
unclear and the effect of HIV and ART on bone healing is very poorly understood. This 
chapter assesses the current available clinical literature to date on the management 







 Selection criteria 
The eligibility criteria are listed in Table 6-2 
 
Using the studies identified, backward referencing of eligible studies and existing 
reviews was undertaken to increase the number of relevant studies. The abstracts of 
relevant orthopaedic and HIV/AIDS conferences were included to expand the number 
of studies included. 
 
The systematic review was carried out according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidance.(362) The process of the 







Figure 6-1 Flow diagram of literature search (213) 
 
 Literature search 
The final search identified a total of 26 studies, which were included in this systematic 







 Early Infection 
6.4.1.1 Closed fractures 
There were seven studies that investigated early wound infection and/or early 
implant sepsis in closed fractures managed with open reduction and internal fixation 
following a fracture (Table 6-3). The time period used to determine infection type 
varied between all of the studies. In this systematic review, early wound infection 
was defined as an ASEPSIS (363) score >10, as this would suggest a disturbance of 
wound healing.(363) This same definition of an ASEPSIS score of greater than 10 was 
used by the Malawi research group.(363) However, the definition used in the other 
studies was not consistent.(18), (364-369)  
 
In a retrospective study, Paiement et al (364) (San Francisco, USA) reported a zero 
wound infection rate for closed fractures for HIV-positive patients (n=14), compared 
to a rate of 4% in the HIV-negative control group (n=446). As ART status was not 
included in the paper, and as this study was undertaken prior to the introduction of 
ART, it is assumed that none of the study participants were taking ART. 
 
Harrison et al (18) (Malawi), reported similar findings in a prospective single blind 
study. They reported the results of 28 HIV-positive individuals that were not taking 
ART and a control HIV-negative group of 108. Wound infection rates were 4% and 6% 
respectively and this differences in the proportion of infections was not statistically 
significant. 
 
Bahebeck et al (366) (Cameroon) demonstrated an infection rate of 5% (n=74) in HIV-
positive participants compared to 1% (n=572) in the HIV-negative. This study 
prospectively analysed a cohort of patients with closed fractures that underwent 





osteoarthritis. Prior to surgery, 5% of participants were taking ART, which increased 
to 59% (n=74) at follow-up. Forty-four patients had a CD4 count <500 cells/mm3. 
 
In the largest prospective single blind study, researchers from Malawi reported the 
outcome of 118 HIV-positive cases and 418 HIV-negative controls undergoing 
fracture fixation surgery.(368) They reported wound infection rates of 4% in HIV-
positive participants and 6% in the HIV-negative group, which was not statistically 
significant. Only 5% of the 118 HIV-positive patients were initially on ART, which later 
increased to 16% on follow-up. 
 
Similar overall rates were reported by Nawale et al (365)(India) in a retrospective 
analysis of 35 ART-naïve HIV-positive participant’s and 35 HIV-negative controls 
control. The wound infection rates were 6% (n=35) and 4% (n=35) respectively. 
 
The most recent study carried out by Hao et al (369) (Denver, USA) did not use the 
ASEPSIS score to define infection. Instead, the surgical site infection (SSI) was used 
(Centre for Disease Control/National Healthcare Safety Network). In 24 patients with 
HIV, with 92% (22/24) taking ART at the time of injury, one participant developed an 
SSI, therefore a 4% rate of early wound infection was reported. 
 
Not all researchers have found low rates of infection. Abalo et al (367) (Togo) 
reviewed HIV-positive patients with 28 closed fractures that underwent open 
reduction and internal fixation. They reported an infection rate of 29% in this study 
population and before surgery, 35% of the participants were on ART. There was no 
control group included in the study. 
 
Overall, other than in one study (367), the evidence suggests that HIV is not a risk 
factor for early implant sepsis following fracture surgery


6.4.1.2 Open fractures 
6.4.1.2.1 Wound infection 
Fourteen studies examined wound infection in HIV-positive individuals managed 
operatively following an open fracture (Table 6-4). The study design was extremely 
heterogeneous these studies. A number of different definitions of wound infection 
were used and in some not stated at all. Varying fixation methods and injuries were 
included and commonly the grade of open injury was not always defined. When 
external fixators were used to manage injuries, it was not always possible to 
determine if authors were reporting wound infection rates regarding pin track 
infections or infection of the fracture. Furthermore, the majority of studies were 
retrospective, and study participants were followed up for different lengths of time.  
 
Howard et al (370) (South Africa) studied open tibial fractures and showed an early 
wound infection rate of 11% (n=28) in their HIV-positive study population, compared 
to 20% (n=57) in the HIV-negative controls. In the HIV-positive participants, the mean 
CD4 count was 432 and 11% (n=28) were on ART. In a prospective analysis by Aird et 
al (371) (South Africa), 35 ART-naïve participants underwent various methods of 
internal and external fixation following an open fracture. The proportion of early 
wound infections in HIV-positive group was 15% (n=33), whereas the HIV-negative 
participants had a 22% (n=86) infection rate (risk ratio (RR) 0.69 (95% CI 0.3 to 1.7). 
It is important to note that Aird et al’s results showed variation infection rates among 
the Gustilo-Anderson grades, with higher rates of infection in grade-I and -II, 
compared to III. Similar wound infection rates of 5% (n=39) were reported by Nawale 
et al (365) and other smaller studies have found similar findingss.(372, 373)  
 
Conversely, Bates et al (368) (Malawi) reported the outcomes of 21 HIV-positive 
individuals in a prospective single blind cohort study who underwent a number of 
different forms of fracture fixation, including K-wire, screws, plates and IM nails. The 





had an infection rate of 15% (n=81). Only 5% (n=21) of this study population were on 
ART preoperatively, which increased to 16% postoperatively. 
 
The majority of the smaller studies (< 20 patients) reported high rates of infection in 
HIV-positive individuals managed operatively following open an fracture.(18, 364, 
365, 367, 374, 375) However, due to the small number of participants included in 
these studies, caution needs to be used when interpreting their results. 
 
It is challenging to accurately draw valid conclusions from the studies discussed due 
to the deficiencies in study design, patient numbers and the reporting of outcomes. 
However, there is an apparent trend towards higher rates of infection in open 










6.4.1.2.2 Pin track infection 
Four studies focused on analysing the proportion of pin track infections in HIV-
positive patients managed with external fixators following open fractures (Table 6-4). 
All of the studies classified pin track infections using the Checketts (379) scoring 
system. Howard et al (370) (South Africa) reported outcomes of 17 HIV-positive 
participants and showed severe (grade-V or -VI) pin track infection rates of 18%, 
whereas the infection rate for the HIV-negative control group 13% (n=40). In the 
retrospective study by Ferreira et al (380) (South Africa) pin track infections of a 
Checketts score ≥II were reported. The proportion of pin track infections in HIV-
positive participants was 20% (n=40), 63% of which were commenced on ART 
postoperatively. A similar pin track infection rate of 21% (n=168) was reported in  the 
HIV-negative study cohort. Ferreira et al (380), included a third group of participants 
of unknown HIV status and they had pin track infection rate of 24%. There was no 
statistically significant difference for incidence or severity between the three groups 
reported. (380) 
 
Norrish et al (377) (Malawi) reported results from 15 HIV-positive participants 
stabilised with an external fixation, who were not taking ART. This study population 
had a pin track infection rate (Checketts score>II) of 60% compared to 20% in the HIV-
negative participants (n=35). Only one study participant required surgical 
intervention for their infection. Harrison et al (20) (Malawi) demonstrated a 75% 
rates of pin track infection in seven cases, while 21 controls in their study had 
infection rates of 19%. 
 
Mixed rates for pin site infection have been shown in HIV-positive individuals 
undergoing external fixation for fracture fixation, with all but one research group 
demonstrating higher rates of infection in HIV-positive patients. Limitation again 
include the study designs and number of participants included in the studies. 
Additionally, the care of pin tracks has been changed in many centres worldwide in 





literature does not include these newer treatment regimens. In conclusion, from the 
evidence available, the proportion of pin site infections appears to be higher in HIV-
positive patients, but more research is required.  
 
 Long-term outcomes 
6.4.2.1 Late implant infection 
There were five studies that investigated late implant infection in closed and open 
fractures (Table 6-5). Late implant infection was defined as deep infection, which 
became evident six or more months after fracture surgery. 
 
In prospective studies, Harrison et al (382) (Malawi) (n=26) and Graham et al(383) 
(Malawi) (n=103) reported that there were no late implant infections in HIV-positive 
trauma patients who sustained closed fractures that underwent fracture fixation 
surgery. The mean follow-up in these two studies was 12 and 27 months respectively. 
None of the study population were taking ART in the Harrison study pre-operatively 
but 8% had started ART post-operatively. In the study population in the study 
reported by Graham et al(383)(Malawi) 27% of postoperative HIV-positive 
participants were taking ART at follow-up. 
 
In a prospective study undertaken by Keetse et al (384) (South Africa), 12-month late 
implant infection rates were 3% for both HIV-negative (n=120) and HIV-positive 
(n=40) study groups. Brijlall (385) (South Africa) reported 18 of 21 late implant 
infections were seropositive in HIV-positive individuals and patients presented a 
mean of 24 months (no range given) after fracture surgery. Neither of the studies 
reported the definition of late implant infection, which is likely to have had a major 






In terms of late infection following an open fractures, Graham et al (383) (Malawi) 
did not find any cases in twelve study participants. Phaff et al (386) (South Africa) 
deonstrated a late implant infection rate of 8% in both the HIV-positive study 
population, and the HIV-negative cohort. 
  
In summary, HIV does not appear to be a risk factor for late implant infection 
following fracture fixation for closed injuries. Two small study reported similar results 
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6.4.2.2 Non-union 
In all of the non-union studies, a clear definition of the method for determining 
fracture union, either radiologically or clinically, was not reported, making accurate 
interpretation of the results challenging. There were sustainial difference in duration 
of follow-up, showing the lack of consistency of these studies. For this review, a 
delayed union was defined as a fracture that was not healed at six months and a non-
union was defined as a fracture that had not healed at 9 months. Clinically, union was 
considered to be present if there was return of function and weight bearing and a 
pain-free range of motion, whereas for radiographic union three out of the four 
cortices on anterior-posterior and lateral X-rays had to be bridged.(123) 
 
6.4.2.2.1 Non-union in closed fractures 
Eight authors reported non-union in closed fractures, with a mix of prospective(382, 
384, 389) and retrospective studies. (367, 390) (Table 6-6) 
 
Harrison et al (Malawi) showed a 0% non-union rate in 26 HIV-positive ART-naïve 
participant that were clinically and radiologically assessed.(382) Gardner et al 
(Malawi) reported a 5% non-union rate in 95 HIV-positive individuals in a similar 
setting (389), 6% of whom were taking ART.  
 
Keetse et al (384) (South Africa) investigated 40 closed femoral fractures in HIV-
positive patients that had undergone IM nailing for fracture fixation. However, the 
method of evaluation of non-union was not reported. One participant in the HIV-
positive participants was on ART at the time of follow-up. None of the 40 study 
participants developed non-union, whereas the HIV-negative control group (n=120) 






Abalo et al (367) (Togo) did not describe how they defined non-union, and showed 
rates of 11% (n=4) non-union in their HIV-positive group of 36 participants. Cummins 
et al (390) (Republic of Ireland), in a retrospective study, also failed to give a definition 
of non-union, and reported three of the four HIV-positive patients developed a non-
union. Hao et al (369) (USA) reported outcomes from a cohort of 24 HIV-positive 
patients, 92% of which were taking ART, with closed fractures, none of whom 
developed non-union. 
 
Babruam (374) (South Africa) followed up 11 closed fractures in their study 
population of ART-naïve participants that underwent IM nailing fixation and showed 
that all had united within four months of surgery. Brijlall (385) (South Africa) 
examined an ART-naïve HIV-positive cohort of 18 participants with infected implants 
postoperatively and reported a rate of non-union of 11%. Neither Babruam (374) nor 
Brijlall (385) presented the method of evaluation of non-union. 
 
All the eight studies reviewed were poorly designed, with no consistent definition of 
union and none used a validated radiological scoring system, making it difficult to 
draw any valid conclusion from the current clinical literature available. 
 
6.4.2.2.2 Non-union in open fractures 
Six study groups investigated non-union in open fractures. Aird et al (391) (South 
Africa) reported rates of non-union of 15% (n=33) in HIV-positive patients and 4% 
(n=100) in the HIV-negative controls. However, the method of evaluation, length of 
follow-up, grade of open fracture and energy of the initial injury were not recorded.  
 
In a prospective analysis of 13 HIV-positive individuals, Phaff et al (386) (South Africa) 
reported a rate of non-union of 8% (n=1). There was one patient who was on ART at 
the time of study follow-up, who did not develop a non-union. The proportion of non-





clinically and radiographically in this study. However, due to the low numbers, it is 
difficult to draw valid conclusions from this study. 
 
A retrospective study by Nawale (392) (India) of 39 patients, not on taking ART, 
demonstrated rates of non-union of 10%. In five study participants Gardner et al 
(389) (Malawi) described a non-union rate of 20%. These two authors assessed 
patients for non-union on radiological imaging. 
 
Prospective studies undertaken by Harrison et al (20) (Malawi) and Babruam (374) 
(South Africa) followed patients up for less than 9 months, therefore not fulfilling this 
thesis’s criterion of non-union. Harrison et al (20) followed their study population up 
for six months using clinical evaluations and radiographs. They reported a 43% (n=3) 
rate of delayed union in seven patients. Babruam (374) followed three patients who 
were HIV-positive for four months and reported that one patient (33%) did not show 
fracture union at the end of follow-up, whereas the two HIV-negative patients had 
full fracture union. These two studies were the only ones to report any outcomes in 
related to delayed fracture union. However, due to the low number of study 
participants included, no conclusions can be draw from this data. 
 
Similar deficiencies identified when reporting infection outcomes in HIV positive 
individuals are evident in studies undertaken investigating delayed and non-union in 
closed fractures. Studies include small patient numbers, there is a lack of a clear 
statistical plan and a prospective power calculation and poor overall study design. 
However, for open injuries, despite these deficiencies, evidence suggests that HIV-
positive patients who have an open fracture may be at higher risk of developing 
delayed and/or non-union compared to HIV-negative patients. However, again more 






There have been a number of studies with appropriate length of follow-up and 
number of patients that have investigated early infection in closed fractures, 
demonstrating no increased risk of infection in HIV-positive patients. (365), (366), 
(368) 
 
In the studies reporting pin track infections, there were varied rates of infection using 
a consistent scoring method, in the Checketts scoring system. All but one research 
group reported higher proportions of infection in HIV-positive individuals. A number 
of limitations surround the study designs and patient numbers included. However, 
from the evidence available, the rate of pin site infection seems to be higher in HIV-
positive patients. 
 
Mixed results have been demonstrated for early wound infection rates in HIV 
patients with open fractures. Aird et al documented the largest study with lower rates 
of wound infection in the HIV-positive patients compared to HIV-negative controls 
but had significant variations among the Gustilo-Anderson grades of open fractures. 
Participants with a grade-I Gustilo-Anderson had a delay in their time to debridement 
in this study, which could potentially explain the higher than expected rates of 
infection observed in the grade-I open fractures. Excluding Howard’s study, all the 
other studies reported an increased risk of infection in the HIV-positive patients 
following an open fracture. The differences in the quality of these studies reported 
so far makes it difficult to draw clear conclusions, and more well-designed and 
standardised studies including Gustilo-Anderson grading and other key paramters 
already discussed are needed.  
 
Low rates of late implant infection in the HIV-positive patients with closed fractures 
have been demonstrated in studies so far. In open fractures, there is minimal data 






In all of the studies evaluated in this systematic review, there was a lack of a clear 
definition of delayed and non-union to allow consistent evaluation between the 
studies. Fracture union is dependent on a huge number of different variables, many 
of which have been discussed in previous chapters.(395, 396) All the studies included 
were poorly designed, including no definition of union and none used a validated 
radiological scoring system for bone union, such as the RUST Score.(123, 124) There 
was also a lack of controls to compare fracture healing outcomes, small patient 
numbers were reported, and no study demonstrated a clear prospective power 
calculation or statistical plan to definitively give an answer to the question of whether 
HIV increases your risk of delayed or non-union following a fracture. Therefore, it is 
difficult to draw any valid conclusions from the studies reviewed in this systematic 
review. As discussed in the previous chapter, pre-clinical science research has 
suggested that HIV infection may be associated with delayed and non-union of 
fractures.(19) However, the lack of robust clinical evidence highlights the importance 
of determining the effect of HIV on fracture healing. 
 
No study included enough participants taking ART to draw meaningful conclusions 
about the effect of ART on the fracture repair process. There has been a potential 
association between issues of impaired fracture healing and the use of ARTs.(19) 
However, the multiple sources of heterogeneity such as duration of treatment, 
different drug regimens and differing degrees of immunosuppression make it difficult 
to assess the any effect. ART might also be expected to improve wound infection 
rates after open fractures and to reduce late implant infection in HIV-positive 






 Systematic review limitations 
The systemic review inclusion criteria ensured that all available literature was 
analysed, including abstracts that were not published as full papers, resulting in some 
loss of detail relating to study design and definitions. Other limitations were that any 
articles that were not in the English language were excluded. However, the majority 
of researchers publish in English and this is unlikely to have missed any major papers. 
 
 Conclusions of systematic review 
Historically, there have been suggestions that fracture surgery on HIV-positive 
individuals should be avoided and, if undertaken at all, removing the implants 
following fracture union should be considered to reduce the risk of infection.(397) 
This systematic review confirms that from current available clinical data, the surgical 
management of fractures in the HIV-positive groups is not contra-indicated. 
 
The outlook in the closed fractures is very encouraging, as it appears comparable to 
infection rates obtained in HIV-negative patients with equivalent injuries. The effect 
of ART on bone healing is uncertain and has not been sufficiently investigated. 
 
There are a number of areas where more research is necessary; in particular, the 
effect of HIV and ART on wound infection rate after open fractures, as well as the 
impact of HIV and ART on fracture healing. The focus of this thesis will aim to give a 
clearer answer to the latter problem, if HIV and its treatment are a risk factors for the 












CHAPTER 7. GENERAL METHODOLOGY 
7.1 Aims of this chapter 
This chapter discusses methodological aspects that are common to the HOST 1 and 
HOST 2 studies, including study sites, laboratory procedures, data management and 
ethical considerations. Methods pertaining to each study – namely study design, 
population, clinical definitions, procedures, sample size, statistical analysis and 
timescale, will be discussed under the individual chapters. 
 
7.2 Study sites 
 Groote Schuur Hospital 
Groote Schuur Hospital (GSH) is the main teaching hospital of the University of Cape 
Town's Medical School (Figure 7.1). The name Groote Schuur is Dutch for 'Great Barn' 
and the hospital was named after the original Groote Schuur estate built in the 17th 
century by Dutch settlers when the city of Cape Town was founded. The original 
hospital building was built with the aid of public subscription and government 
funding. In 1932, building started and the hospital was completed and opened in 
1937. Constructing the new hospital commenced in 1983 and it opened in 1989. GSH 
is world famous for being the institution where the first ever human-to-human heart 
transplant took place, performed by the surgeon Christiaan Barnard. 
 
 
The orthopaedic trauma department is a Level 3 trauma unit and has a total of 92 
acute orthopaedic admission beds, providing a predominantly adult-orientated 
service. There are eight full-time orthopaedic consultants and 24 registrars working 
within the department. In 2017, there were approximately 1850 orthopaedic 
admissions and 1704 orthopaedic trauma surgeries performed. (Personal 






GSH and TBH provide a split tertiary service to the Western Cape, covering a 
population of approximately six million people. However, the Northern and Eastern 
Cape do not have a functional tertiary hospital, therefore this creates a combined 
estimate of an extra 14.2 million people who would see GSH or TBH as their nearest 
tertiary referral trauma hospital.(Figure 7-1) 
 
Figure 7-1. Groote Schuur Hospital – the new hospital in the left front foreground and 
the old hospital in the back right. 
 
 
 Tygerberg Hospital 
Tygerberg Hospital (TBH) is a tertiary hospital located in Belville, Cape Town, South 
Africa, 20 km from GSH (Figure 7-2, Figure 7-3). The hospital was officially opened in 
1976 and is the largest hospital in the Western Cape, with over 1900 hospital beds, 
making it the second-largest hospital in South Africa. It acts as a teaching hospital in 
conjunction with Stellenbosch University. 
 
The Division of Orthopaedic Surgery of Tygerberg Academic Hospital is also a Level 3 
trauma unit and has a total of 160 acute admission beds for trauma and emergencies, 





consultant surgeons, 18 junior registrars and approximately 600 orthopaedic trauma 
admissions per month. 
 
Figure 7-2. Tygerberg Hospital – the university is the building at the front and the 
hospital is located at the back. 
.  
Figure 7-3. Locations of Cape Town city centre (red), Groote Schuur (yellow) and 









 The Cape Flats 
The Cape Flats is the name given to an area of land situated to the southeast of the 
central city region of Cape Town.(Figure 7-4) From the 1950s onwards, the area 
became home to people that the South African apartheid government designated as 
non-white. The government forced non-white people out of more central urban 
areas designated for white people and into government-built townships in and 
around the Cape Flats. The Cape Flats is now home to much of the population of 
Greater Cape Town. (398) It is also where the poorest communities are located and 
many of the houses are non-permanent settlements, where crime, violence and 
unemployment are high. Furthermore, it’s in these areas where HIV is most 
prevalent.(398) It is also the main drainage area for both of the study site hospitals. 
 









The following staff were employed to conduct the study: 
• Two research nurse coordinators (Nomsa Yekiso and Nosipho Mncwabe): 
responsible for consent and enrolment of participants during recruitment period; 
taking the majority of clinical specimens; coordinating participant follow-up and 
field worker visit schedule; undertaking telephone follow-up of study 
participants: HIV and ART counselling and HIV clinic referral and follow-up. 
• One database designer: responsible for the design of the Redcap database and 
initial database testing. 
• One database manager: responsible for maintenance of the database and raising 
any queries related to data collection. 
In addition to screening and enrolment of study participants, study staff also 
contributed to routine clinical activities at both GSH and TBH. 
 
7.4 Laboratory procedures 
 Sample registration and storage  
All clinical specimens collected from study participants were processed at the GSH or 
TBH on-site laboratories. Both laboratories participate in the UK National External 
Quality Assessment Scheme (NEQAS).  
 
Each study specimen was labelled with a pre-printed hospital identification number 
and person details, with a corresponding laboratory specimen submission form that 
contained the same details, in addition to the participant’s name and date of birth. 
This allowed treating clinicians to access to the results from the National Health 
Laboratory Service (NHLS) in a timely fashion. Laboratory test results were 







 HIV test, CD4 count and viral load measurement 
The HIV status of study participants was determined using rapid HIV tests as per 
WHO-recommended algorithm and national guidelines (Figure 7-5) (50)); Alere 
DetermineTM HIV-1/2 assay (Alere Medical Co. Ltd., Chiba, Japan) was used as the 
initial screening test, and Uni-GoldTM Recombigen HIV test (Trinity BioTech, 
Wicklow, Ireland) as the confirmatory test. 
CD4+ T-cell counts were performed on a FACScountä flow cytometer (Becton 
Dickinson, BD Biosciences, San Jose, USA). The viral load measurement was 






Figure 7-5. Algorithm for use of the rapid HIV test  (50) 
 
 
7.5 Data management  
Standard operating procedures for data management without breach of 
confidentiality were followed. The HOST study utilised two custom-made ‘REDCap’ 
databases hosted at the University of Cape Town, South Africa. REDCap (Research 
Electronic Data Capture, Vanderbilt University, Tennessee, USA) is a secure, web-
based application designed to support data capture for research studies. The system 
provides audit trails for tracking data manipulation. Each study subject was allocated 
a unique identifier. Data on subject demographics, baseline history of injury, 
treatment and surgery were recorded, as well as risk factors for delayed bone healing 
and/or non-union. This information was recorded manually by the HOST study team, 
onto specially designed, paper-based data collection forms. Data from the paper 





Nosipho Mncwabe (NM) (study research nurse, Figure 7-6). Once the data was 
entered, a series of steps was taken to check for transcription errors, including the 
nurses checking the data of each other’s entry for all patients. Data entry for each 
data form was checked by me and finally by the Clinical Research Centre database 
management team at the University of Cape Town, with 100% quality assurance on 
critical variables. 
 
Figure 7-6. Research nurses Nomsa Yekiso (left) and Nosipho Mncwabe (right).  
 
Once the dataset for a particular analysis was complete, a manual (visual) and 
automated (the R for Statistical Computing) checking of critical variables was 
performed. Outliers thus identified (defined as a value that is more than three 
standard deviations from the mean) were then checked manually against original 
data forms. A number of minor errors were found and corrected before analysis.  
 
Laboratory results were received in a web-based format via the NHLS Prelink National 
Laboratory Information Management System. The research nurses entered these 
results into the study database and subsequently went through the same checks 





protected against data loss. Data was extracted from the database for analysis into 
either Microsoft Excel (Microsoft, Seattle, Washington USA) or the R Project for 
Statistical Computing version 3.6.1 (The R Foundation for Statistical Computing, 
Vienna, Austria). 
 
Patients’ BMD was measured using a DEXA Heel Scanner, Calscan DXL (Rothband 
Medical Imaging Supplier). This information was stored on a Calscan DXL Application, 
located on an assigned password-protected study laptop computer. These results 
were then entered onto the database using the methods described above. 
 
7.6 Statistical analysis 
Statistical analysis plans are described in the Methods section of the individual 
studies. All analyses were undertaken using ‘R’ for Mac OS statistical computing 
software (R 3.6.1 GUI 1.70 El Capitan build [7684]). Missing observations were 
included in the analysis of each study by creating missing value categories.  
 
7.7 Ethical approval 
The HOST 1 and 2 study received local and the University of Cape Town and University 
of Stellenbosch Faculty of Health Science Human Ethics Committee approval in July 
2017 – reference number 590/2016 and N17/05/052. Furthermore, approval from 
Liverpool School of Tropical Medicine Research Ethics Committee (protocol number: 
17.013) was gained. 
 
The principal investigator and collaborators declared that this submission was in 
accordance with the principles laid down by the Responsible Research Publication 
Position Statements as developed at the Second World Conference on Research 






There were several subsequent amendments to address minor study modifications. 
See Appendices (Appendix 13-2, Appendix 13-3) for details of the consent forms and 
patient information sheets in English (Xhosa, Afrikaans and Zulu translations were 
also used but are not included in this thesis). Written informed consent was obtained 
from all subjects and the say consent and patient information was used for both 
studies. 
 
HIV testing was offered to all patients of our study units, based on the 
recommendations of the Department of Health HIV Counselling and Testing Policy 
Guidelines. Since a substantial proportion of participants were HIV-positive, every 
effort was made to safeguard patient confidentiality. 
 
All study team members underwent Good Clinical Practice training prior to 
commencement of the study. Informed consent was obtained from all study 
participants, either written or witnessed verbal consent, with thumbprint if the 








CHAPTER 8. HIV IN ORTHOPAEDIC SKELETAL TRAUMA STUDY 1: Aims, 
Design, Methodology and a Descriptive Analysis of the Study Cohort 
8.1 Aims of this chapter 
In this chapter a description of the study aims, methods and a descriptive analysis of 
the HIV in Orthopaedic Skeletal Trauma (HOST) 1 study cohort will be presented.  
 
8.2 Introduction 
There have been no previous large, appropriately powered, prospective studies 
undertaken investigating the effect of HIV on fracture healing. As already discussed, 
there have been studies undertaken in the past, but most have been retrospective. 
In all of the studies evaluated to date, there was a lack of a clear definition of delayed 
or non-union to allow consistent evaluation between the studies. None of the studies 
used a validated radiological scoring system for bone union, such as the RUST score. 
The largest study by Gardner et al (389) investigated bone union in an extremely 
heterogenous cohort of HIV-positive participants, who had numerous types of 
fractures and had undergone several different forms of fracture fixation. The primary 
author of this thesis was also involved in the follow-up of this cohort of participants, 
assessing the incidence of late infection, and published these results.(388) The above 
findings and my previous research in Malawi (388), (399), (400) enabled a gap to be 
identified in the current literature and prompted this research. 
 
The main hypothesis underlying this research is that HIV infection causes delayed 
bone union and is a risk factor for the development of non-union following a fracture. 
If this hypothesis were shown to be true, the  surgical management of fractures could 
be tailored to optimise bone union during the fracture-healing phase in HIV-positive 
participants, improving outcomes and reducing the substantial physical and social 
burden that occurs in these participants as a result of traumatic injuries.(18) 





to minimise this risk, since the burden of trauma is an increasing problem in low and 
middle-income countries where people with HIV infection are living longer.(213) 
 
8.3 Aims and objectives 
The aim of the HOST 1 study was to establish whether HIV infection was a risk factor 
for the development of delayed bone union or non-union following a fracture.  
The main objectives of the HOST 1 study were to: 
1. Establish whether HIV infection is a risk factor for the development of delayed 
bone union or non-union following a fracture. 
2. Assess other risk factors associated with delayed bone union or non-union in 
HIV-positive and -negative adults. 
3. Determine the incidence of superficial, deep and late wound infections in HIV-
positive and -negative participants following fracture surgery. 
 
8.4 Methodology 
 Study design 
A multi-centre prospective case-cohort study of participants undergoing fracture 
surgery within the Orthopaedic and Trauma Department at GSH and TBH, Cape Town, 
South Africa was undertaken.  The study was undertaken over a 14-month period, 
between September 2017 until December 2018. Participants who underwent surgery 
had a HIV test and were subsequently followed up over a 12-month period to 
determine the proportion of participants whose fracture healed and those that 
developed delayed union and non-union. 
 
The protocol for this study was published in the South African Orthopaedic Journal, 
2018 and is available as an open access article, downloadable directly from the 
journal website on the following link  - 





publication, the author of this thesis (Simon Graham) established the concept, lead 
the write up, edits and final submission of the paper. 
 Study site 
Participants were enrolled from the orthopaedic department of two tertiary referral 
trauma hospitals, GSH and TBH, in Cape Town, South Africa.  
 Study population 
All participants older than 18 years of age with fresh (within two weeks of injury), 
closed and open, tibia and femur fractures who underwent intra medullary (IM) 
nailing for fracture fixation were potentially eligible for inclusion in the study. The 
following eligibility criteria were applied: 
 
Inclusion criteria - Participants were eligible for this study if they: 
• were 18 years or older at assessment 
• had surgery undertaken at GSH or TBH 
• underwent surgery within two weeks of injury 
• were assessed for inclusion by the study team within two weeks surgery 
• sustained a closed or open fracture of the tibia or femur 
• underwent IM nailing for fracture fixation 
 
Exclusion criteria - Participants were excluded from participation in this study if they 
had: 
• pathological fracture 
o Fractures which occur from low energy injuries which occur through an 
area of bone weakness with a pre-existing abnormality 
• intertrochanteric femur fractures  
• paraplegia 





• open injury for >48 hours before the first debridement 
• severe burns 
• evidence that the participant would be unable to adhere to study procedures, 
complete questionnaires or attend follow-up major head injury 
 
Those who sustained multiple injuries had their injuries documented and were 
included in the enrolment process.  
 Study procedures 
8.4.4.1 Enrolment 
Participants who had undergone IM nailing for fracture fixation were approached 
post-operatively for consideration for inclusion in the study as stipulated by the 
ethics committee. Persons that met the eligibility criteria who were willing to 
consider participation in the study received a participant information document 
(translated into Xhosa, Zulu, Afrikaans or English). Written informed consent was 
obtained from the participant. 
 
Study participants underwent a baseline questionnaire, and established risk factors 
for delayed bone healing and non-union were recorded. 
 
The participants’ full blood count, renal function, vitamin D level and albumin were 
assessed (Table 8-1). Due to the fact that participants were recruited following their 
operative procedure, the pre-operative haemoglobin was extracted from the 
laboratory records prior to surgery. All participants underwent HIV testing and a 
measurement of the participants’ CD4 count and viral load if positive. If the 
participant was already known to be HIV-positive (previous laboratory confirmation 
required) and taking ART, their ART regimen was recorded, if appropriate. If a 
participant was found to have a new diagnosis of HIV, standard local hospital protocol 






debridement. On all occasions the surgeon who undertook the first debridement for 
an open fracture was consulted before a score was assigned. 
 
A picture of the proforma including the participant’s name and base ward was 
uploaded to an encrypted smartphone application (WhatsApp) that all those involved 
in the study had access to. This proforma was then placed in the assigned area in the 
operating theatre for collection by the research nurses. (Figure 8-1) The research 
nurses subsequently collected the proforma and then reviewed the participants on 
the ward post-operatively to screen for enrolment. Furthermore, all participants 
waiting for and who had undergone IM nailing were added to a list during the 
morning trauma meeting and cross-referenced with the proformas collected to 
ensure no participants were missed. The research nurses also undertook daily 
screenings of inpatient admissions and discharges at both hospitals to ensure all 
possible candidates were screened for inclusion. 
 
Figure 8-1. Assigned area in the operating theatre for placement of the completing 
surgical proformas for collection by the research nurses 
 
To identify any participants missed using the above process, all trauma clinic 
attenders were screened on a daily basis by the study team to identify participants 





participants in the study were reviewed as outpatients on one set day at both GSH 
(Wednesday) and TBH (Thursday). It was department policy for all participants who 
underwent IM nailing of the femur or tibia to be followed up in these two trauma 
clinics, irrespective of study enrolment. If any patient who had undergone IM nailing 
presented to the trauma clinic on any other day, the surgeon reviewing them 
organised a review by the research team that day to screen the participant for 
enrolment. This rarely happened, since the vast majority of participants were 
screened in hospital. 
 
Following screening by the research nurses the participants were either enrolled or 
excluded from the study. If there were any concerns regarding eligibility for the study, 
the principal investigator (Simon Graham) personally reviewed the participant with 
the research nurses. Furthermore, if a participant declined enrolment, the research 
team reviewed them again during their admission to see if they had reconsidered. 
 
If a participant did not attend follow-up clinic, the research nurses called the 
participant to re-organise their clinic appointment. If the participant was not 
contactable, their next of kin was contacted. Following this, a letter was sent to the 
participant’s address. If the participant still did not attend clinic, the study team tried 
a number of methods to ensure the participant attended follow-up, including visiting 
the participant’s home or place of work, using contacts in the community, visiting 
known places where the study participants socialised or went to church (Figure 8-2). 
If the participant was still not contactable or traceable following the above steps, they 







Figure 8-2. Nosipho, research nurse, on a field trip to find of one of the HOST 1 Study 
participants who had missed his follow-up appointment. He was homeless and his 
address was ‘under the N1 motorway bridge, Woodstock, Cape Town’. The 
participant was located with his partner and subsequently came to all the rest of his 
clinic appointments until fracture union. Written consent was provided by the 




The full visit assessment schedule for the study is provided in Table 8-2. Participants 
were followed up for 12 months from recruitment in total. X-rays were performed 
post-operatively to determine the fracture classification and at six weeks, three, six 
and nine months to assess union, and additionally out with this schedule if clinically 
indicated. Once union was confirmed by RUST score, no further x-rays were 
performed. All participants were seen in clinic at six months post-surgery. If a 
participant’s fracture was confirmed to have united on RUST score at six months or 
sooner, they were followed up via telephone consultation at nine and 12 months. If 
they had not healed at six months, participants continued to have face-to-face follow-
up in clinic at nine months. If they had healed, they were followed up at 12 months 





according to our outcome definitions, the participants were either offered surgery 
for revision of their non-union or, if there was still potential for bone healing without 
intervention in the view of the responsible orthopaedic consultant surgeon and 
myself, they were reviewed in clinic at 12 months with an x-ray. If at any time the 
responsible consultant surgeon felt that there was a need for further surgery to 
achieve union before nine months, surgery was offered, following a joint discussion 
with two consultant orthopaedic surgeons. (Figure 8-3) 
 
Figure 8-3. Nosipho, research nurse, reviewing a participant in follow-up clinic and 








Participants recruited and followed up at GSH had their BMD measured using a DEXA 
Heel Scanner, Calscan DXL (Figure 8-4). No Calscan DXL was available at TBH and 
although the scanner is portable, it did not leave GSH hospital for security reasons. 
 
Figure 8-4. Participant undergoing measurement of their BMD with the Calscan DXL. 
Written consent was provided by the patient to use image. 
 
 
Participants were reimbursed for their attendance at the follow-up clinic. This was in 
order for the participant to pay for their transport to clinic. The reason for this is due 
to the fact that the vast majority of participants enrolled were from low income 
households, lived far away from the hospitals and attending clinic commonly took the 
whole day, resulting in them missing a day’s work. Furthermore, the research team’s 
experience suggested that the likelihood of a participant attending clinic without this 
reimbursement was likely to be very low. At GSH and TSH the usual follow-up in 
trauma clinic is less than 40% following an orthopaedic operation (personal 
communication – Sithombo Maqungo and Nando Ferreira). Once the participant’s 
fracture had healed there was no clinical reason for the participant to re-attend 






8.4.5.1 Outcome definitions 
The following are how the main outcomes of the study were defined. 
 
Union: 
• Radiological union on RUST score (score of three on at least three cortices in AP, 
lateral, medial or posterior cortex – a total of nine or more) within six months of 
surgery.(125), (126), (127), (128) 
 
Delayed bone union: 




One or both of the following: 
• Impaired bone healing at nine months on RUST score (RUST score < 9). (125), 
(126), (127), (128) 
• Need for further surgery to achieve union (RUST<9) before nine months: decision 
made by two orthopaedic surgeons. Note that this definition was set at the 
beginning of the study and included in the study published protocol. However, no 
participant had confirmed non-union by this method. (125), (126), (127), (128) 
 
Superficial wound infection 
• Superficial surgical site infection (SSI) 
The Center for Disease Control and Prevention definition of a ‘superficial surgical site 
infection’ is a wound infection involving the skin and subcutaneous tissue that occurs 








Deep wound infection  
The Center for Disease Control and Prevention definition of a ‘deep surgical site 
infection’ is a wound infection involving the tissues deep to the skin that occurs 
within 30 days of injury (closed reduction of fracture) or 90 days (open reduction of 
fracture).(363) (Appendix 13-5) 
 
Late implant infection 
This describes any late wound breakdown (>30 days for closed reduction of fractures 
or >90 days for openly reduced fractures) or sinus formation, or unexplained late pain 
with associated radiological changes consistent with peri-implant infection.(388) This 
was determined on clinic follow-up for those still under review. Those participants 
who were under telephone review were called and assessed over the phone to report 
on their wound, using the described criteria. (Appendix 13-6) 
 
Bone mineral density 
• Normal – T score of <1 standard deviation (T score <−1) below the peak bone 
mass of a healthy young adult. European reference values were used since no 
comparison values for South Africa were available. 
• Osteopaenia – T score of between 1 to 2.5 standard deviations (T score −1 to −2.5) 
below the peak bone mass of a healthy young adult. 
• Osteoporosis – T score of >2.5 standard deviations (T score <−2.5) below the peak 
bone mass of a healthy young adult. 
 
Injury Severity Score 
• No polytrauma - Injury severity score of 15 or less on electronic Trauma Health 
Record 







Patient reported outcome measured (PROMS) Disability Rating Index (DRI) – 
Appendix 13-1 
The DRI is a self-administered, 12-item Visual Analogue Scale questionnaire assessing 
the participants’ own rating of their disability.(403) This measure was chosen as it 
addresses ‘gross body movements’ rather than specific joints or body segments. 
Therefore, it would facilitate the assessment of participants with different fractures 
and injuries of the lower limbs. 
 
8.4.5.2 Determining the study outcome measures 
Union 
Bone healing was assessed using a validated X-ray scoring system – the radiological 
union scoring system for the tibia (RUST scoring system). (125), (126), (127), (128) 
Two independent reviewers (Maritz Laubscher and Pravesh Panchoo, both 
orthopaedic surgeons), blinded to HIV status, assessed radiological fracture union on 
radiographs at time points shown in Table 8-2. All patient identifiable information 
was removed from the x-rays prior to viewing them by the reviewers and no 
laboratory results were made available for them to assess HIV status. If there was a 
disagreement between the two reviewers regarding the outcome using the RUST 
score, a third reviewer (Professor Michael Held (MH), orthopaedic surgeon) 
independently reviewed the x-ray and assessed fracture union using the RUST score. 
Whichever RUST score outcome the third reviewer made (union or non-union), 
resulted in the final outcome decision for the participant. 
 
The RUST score applies a score from 1-3 to the medial, lateral, anterior and posterior 
cortex of the bone (total 12). (123), (124) One indicates a fracture line with no 
bridging callus. Two indicates a fracture line with bridging callus and three suggests 
no fracture line plus bridging callus (see Chapter 3). If three cortices, out of four 
(medial, lateral, anterior and posterior), have a score of three (RUST = 9) then this 





of three (RUST ≤ 9) then this fracture was classified as delayed union (6 months) or a 
non-union (9 months) depending on the follow-up time point.  
 
The zone of comminution was measured by a single orthopaedic surgeon (Maritz 
Laubscher) on the first post-operative x-ray using the graphics option of the computer 
x-ray software and a previously published technique.(404) The zone of comminution 
was measured from the most proximal part the fracture exited the bone, to the most 
distal point the fracture exited the bone. This method was used in a previous study 
undertaken in the same research department on similar study participant.(404) The 
reviewer was blinded to the HIV status of the patient. It is acknowledged that ideally, 
two reviewers who were blinded to the HIV status should have measured the fracture 
comminution and appropriate statistical analysis undertaken to determine inter-
observer reliability should have been undertaken. However, due to time and resource 
restrictions this was not done. Therefore, due to potential inaccuracies and biases in 
the measurements of zone of comminution it was not included in the final analysis, 
but the results can be seen in Appendix 13-7. 
 
Infection 
When a participant was diagnosed with an SSI or DSI by the Principal investigator 
(Simon Graham), the participants had an assessment of their wounds in person by a 
single orthopaedic surgeon blinded to the HIV status (Martiz Laubscher – GSH, Nando 
Ferreira - TBH) and a photographs were taken.  
 
Injury Severity Score 
The injury severity score (ISS) was prospectively calculated by an electronic Trauma 
Health Record on admission hospital by the Trauma Care Team at both sites. (405) 
On the occasions that this was not completed prospectively on admission, one 
orthopaedic surgeon (Martiz Laubscher), who was blinded to the participants HIV 
status, completed the electronic Trauma Health Record for the participant 






Fracture classification was determined by a single orthopaedic surgeon (Martiz 
Laubscher), blinded to HIV status, on post-operative x-ray. The AO classification 
system was used for the tibia and femur and the Winquist and Hansen classification 
system were used for the femur. Appendix 13-8, Appendix 13-9. 
 
 Completion of the study 
The maximum length of time a participant was followed up for the study was 12 
months. Participants who still needed follow-up assessments as part of the clinical 
management continued to be treated by the Trauma and Orthopaedic Surgery Unit, 
until their condition has stabilised to a point where no further medical intervention 
was required, and they were discharged. 
 
 Withdrawals 
Participants who were recruited but declined to continue to take part in the study at 
any time were withdrawn without prejudice. A decision to decline consent or 
withdraw did not affect the standard of care the participant received and they 
continued standard hospital follow-up care. 
 
Participants had two options for withdrawal: 
 
1) Participants withdrew from completing any further questionnaires but allowed the 
study team to still view and retain, anonymously, any relevant hospital data that was 
recorded as part of normal standard of care, e.g. X-rays and further surgery 
information. 
 





of withdrawal was included in the final analysis of the study, thereafter no further 
data was collected for that censored participant. 
 
 Adverse events  
Serious adverse events (SAE) were defined as any serious untoward medical 
occurrence in a clinical study subject and which do not necessarily have a causal 
relationship with the treatment. These included any untoward and unexpected 
medical occurrence that: ‘results in death’, ‘is life-threatening’, ‘requires 
hospitalisation or prolongation of existing in-patients’ hospitalisation’, ‘results in 
persistent or significant disability or incapacity’, ‘is a congenital anomaly or birth 
defect’ or ‘any other important medical condition which, although not included in the 
above, may require medical or surgical intervention to prevent one of the outcomes 
listed’. These were recorded in on the electronic ‘Redcap’ database. 
 
 Sample size calculation 
A previously established orthopaedic surgical register suggested that 400 participants 
were likely to undergo IM nailing of the tibia and femur at the two centres over the 
14-month study period and would be eligible for inclusion: 80% (n=320) were 
assumed to be able to complete follow-up, giving an estimated overall loss to follow-
up rate of 20%. 
 
On the basis of previous research(114), (124), (126), (406), (407), it was estimated 
that 85% (n=272) of the 320 participants would have fracture union at six months 






Assuming that 20% of the controls would be HIV-positive (388), (368), the sample size 
would have 82.8% power to detect at least two-times difference in HIV prevalence in 
the cases compared to controls (from 20% to 40% at the 5% significance level). 
 
For participants with more than one lower limb injury that met the inclusion criteria, 
each injury was included as an individual case and entered separately into the study. 
However, for the sample size calculation the participant was only counted as one 
participant, even if they had multiple IM nails. For example, if a participant had three 
lower limb IM nails, they were entered into the database as three different IM nails, 
with three different study numbers. However, they were classified as one individual 






Figure 8-5 Study sample size calculation  
 
 
 Statistical analysis 
Distributions of baseline characteristics were summarised using means, medians, 
proportions and distributional measures (standard deviations and interquartile 
ranges) and tabulated and plotted and compared between exposure groups (HIV-
positive vs. HIV-negative). 
Analysis method and how the treatment effects were presented: 
1. For the primary outcome (delayed union), a multivariable logistic regression 
model was constructed to estimate the odds ratio and 95% confidence 
interval for delayed union comparing between HIV-positive and HIV-negative 
participants and adjusting for important confounders identified apriori 
through construction of putative causal diagrams. A separate model was 
constructed for HIV-positive participants only to estimate the associations 
between HIV-associated predictors (e.g. CD4 cell count, viral load, ART use) 





2. For the secondary outcome non-union, DSI similarly multivariable logistic 
regression model was constructed to estimate the odds ratio and 95% 
confidence interval for non-union comparing between HIV-positive and HIV-
negative participants and adjusting for important confounders. Models were 
not constructed for secondary outcomes of SSI and late implant infection due 
to the low number of participants who experienced these outcomes. 
 
When constructing the univariate and multivariable logistic regression models, 
confounding factors were identified from known factors that have been shown to 
clinically influence the outcome. For example, smoking is a well-established risk 
factor for delayed union and was therefore included in the delayed union 
multivariable logistic regression model. (163)  
 
Confounders that had been identified to show little if any statistical significance in 
the study analysis or on testing the models with the parameter added, were not 
included in the modelling. 
 
An example of how the models were constructed is summarised below. The models 
were initially built with established known confounding factors, plus HIV status. For 
delayed union the following confounding factors were added; 
a) HIV Status 
b) Gender 
c) Age  
d) Smoking 
e) Open fracture 
f) Fracture site 
g) DSI 
The models were then constructed, and addition factors were added to the models 
to assess if they made the model more accurate (e.g. post-operative haemoglobin). 





test, then the factor was added to the model. If it did not, then it was excluded from 
the models.  
 
Some of the enrolled participants had more than one tibia or femur fracture. 
Therefore, in the analysis, confidence intervals were adjusted for clustering. 
 
Analysis of difference between continuous and categorical data not using logistic 
regression analysis, was assessed using t-test or chi-squared test respectively. 
 
All statistical analysis was undertaken using ‘R’ statistical computing software. 
 
 Study timescale  
The study schedule for the duration of recruitment and follow-up up was as follows: 
• September 2017 December 2018 – subject recruitment (baseline) took place 
at GSH and TBH (14 months) 
• October 2017- November 2019 – subject follow-up (up to 12 months) took 









8.5 Results: Descriptive analysis of HOST 1 study cohort 
8.5.1.1 Recruitment 
From September 2017 until December 2018, 638 participants underwent 683 IM 
nailings of the femur and tibia across the two study sites. All participants were 
screened and considered for inclusion in the study. 238 participants (241 IM nailings) 
did not meet the study inclusion criteria and were not enrolled (Figure 8-6). The 
predominant reason for participants not being enrolled was that the injuries were 
intertrochanteric femur fractures (88/241, 36.5%) and participant refusal to 
participate in the study (51/241, 21%). The full breakdown of the exclusion criteria 
and the number of participants excluded from enrolment can be found in Table 8-4. 
 








8.5.1.2 Baseline characteristics 
The main study cohort of 400 participants - who underwent 442 IM nailings - were 
enrolled in the study over a 14-month period from September 2017 until December 
2018. Participants with 215 tibia and 227 femoral nails (right side: 242 and left side: 
200) were enrolled. 361 participants had a single IM nail and 39 participants had 
more than one IM nail, all as part a single visit to the operating theatre on the same 
day (Table 8-5). The median age of the participants was 32.4 years (Interquartile 
range [IQR] 18-71 years) (Figure 8-7) and the majority of the participants were male, 
313 (78.3%) vs female: 87 (21.7%). 
 
Participants’ median height was 1.70 meters (IQR: 1.37-1.88m) and median weight 
was 65 kilograms (IQR: 40-126 kg), giving a median body mass index (BMI) of 23.0 
kg/m2 (IQR:15.5 – 51.2) (Figure 8-8). As the age of the participant increased, the BMI 
increased. (Figure 8-9) Furthermore, men and smokers had a lower overall BMI 
(Figure 8-10, Figure 8-11). 
 
There was a higher proportion of smokers compared to non-smokers – 225 (56.3%) 
vs 175 (43.3%). Almost all of the participants (98.22%) who smoked had been 
smoking for more than 12 months prior to enrolment.   
 
The two study sites were tertiary referral trauma hospitals that receive referrals from 
surrounding district level hospitals. 24.5% (98/400) of the participants recruited were 
initially seen at a district level hospital before admission to GSH or TBH. All of the 
participants had their surgery at one of the two study sites. The median time taken 
to arrive at hospital following the injury was nine (4-24) hours. 
 
The basic demographics and characteristics of the study participants are summarised 







Time taken to arrive at 
treating hospital 
(Median:IQR, hours) 
9 (4-24) 10 (4-24) 12 (6-18) 0.840 
 
Patient reported outcome 
measure (PROMs) 
    
DRI pre-op (median: IQR) 0 (0-34.3) 0 (0-28) 0 (0-34.3) 0.090 
 
BMI – body mass index 
DRI- Disability rating index 
CI – Confidence interval 
IM- Intra medullary 
IQR – Inter quartile range 






Figure 8-7. Age range of study participants 
 







Figure 8-9. The relationship between age of participant and BMI 
Line – represents linear regression model and 95% confidence intervals and same 
applies throughout thesis 
 















8.5.1.3 HIV status  
The prevalence of HIV in the study population was 18.8% (75/400 participants). The 
75 HIV-positive participants underwent 87 IM nailings, giving an overall prevalence 
of HIV per IM nail of 19.7% (87/447) (Table 8-4). The HIV-positive participants were 
older than the HIV-negative participants –35 years (IQR 19-58) vs 31 years (IQR 18-
71). (Figure 8-12) HIV-positive and negative participants had a similar BMI and HIV-
positive males had a lower BMI than HIV-positive females (Figure 8-13). HIV 
prevalence was higher amongst smoker (HIV-positive 54% vs HIV-negative 41.2%) 
compared to non-smokers (p-value = 0.05). (Table 8-5). 
 
Over 32% (24/75) of the HIV-positive participants were initially seen at a district level 
hospital prior to admission to one of the two study sites, compared to 22.8% (74/325) 
of HIV-negative participants, but this was not statistically significant (p-value = 0.100). 
However, this may suggest that a higher proportion of HIV-positive participants lived 
in areas away from the two tertiary referral hospitals. The district level hospitals 







Figure 8-12. The median age of HIV-positive participants and HIV-negative at 
enrolment 
 
Figure 8-13. The relationship between BMI and age of participants at enrolment, 







All 400 participants recruited had a HIV test. The majority of HIV-positive participants 
(42/75, 56%) knew their HIV diagnosis prior to enrolment in the study (Table 8-6). 
The rest of the participants had their diagnosis made during their admission (25/75, 
33.3%) or within two weeks of their discharge (8/75, 10.6%). The median length of 
time a participant had a diagnosis of HIV was 1397(686-3565) days/3.8 (1.9-9.8) 
years. 
 
42 out of 75 HIV-positive participants (56.0%) were taking ART on enrolment to the 
study and almost all of these participants were taking the same first line therapy - 
TDF, 3TC + ERV (38/42, 90.5%). As discussed in previous chapters, this is the current 
first line regiment for the treatment of HIV in the Western Cape of South Africa. Those 
participants who were on ART had been taking it for a median of 1732 (IQR 678-3568) 
days/4.7 (1.8-9.8) years. 
 
The CD4 and viral load was measured for 65 out of the 75 HIV-positive participants 
within two weeks of surgery.  The median CD4 count was 393 cell/mm3 (IQR: 63-
1145) and the median viral load was 2.13 log10 copies/ml (IQR: 1.3-4.62).  
 
In the study population with HIV, older age correlated with lower viral loads and 
higher CD4 counts (Figure 8-14, Figure 8-16). This may reflect a compliance issue with 
the medication in the younger participants. This would suggest that compliance with 
medication is better in the older aged participants. This mirrors the literature, that 
has shown that higher proportions of older adults in sub-Saharan Africa are adherent 
to ART medication regimens compared with younger adults.(408)  
 
The participants on ART on enrollment had a slightly lower baseline CD4 count 
(median CD4 344 cell/mm3 [IQR 264-566] vs median CD4 446 cell/mm3 [IQR 284-
670] p-value=0.1) (Figure 8-15). However, those on ART had much lower viral load 






The basic demographics and characteristics of the HIV study participants are 














Viral load (cps/ml) on admission 
 (Log10, median, IQR) 
 
2.13 (1.3-4.62) 
ART – Anti-retroviral therapy 
cps – copies 
HIV – Human immunodeficiency virus 



















Figure 8-15. The relationship between CD4 count at baseline and age of HIV-positive 







Figure 8-16. The relationship between viral load at baseline count and age of HIV-
positive participants  
 








8.5.1.4 Place of residence  
Out of the 400-participants enrolled in the HOST 1 Study, 350 participants provided 
a current fixed address in order to determine where the participants were living at 
the time of their injury. The majority of participants injured (342/350, 97%), lived in 
and around the Cape Town City Metropolitan Municipality (Figure 8-18). A further 
seven participants (Table 8-7) lived in the Western Cape and one participant lived in 
the Northern Cape but travelled back to Cape Town for their follow-up. A full 
breakdown of the location where participants lived, and maps of their Global 
Positioning System (GPS) home address can be seen in Figure 8-19, Figure 8-20, 
Figure 8-21. 
 
Using GPS co-ordinates of participants addresses from enrolment and mapping out 
the approximate position of the Cape Flats, it was possible to determine that the 
highest density of the study population were living in the Cape Flats areas (250/342, 
73.01% (Figure 8-22). The Cape Flats does not have an official designated border and 







Figure 8-19. Map of GPS co-ordinates of study populations throughout South Africa. 
 
 








Figure 8-21. Map of GPS co-ordinates of study populations throughout the Cape 


















8.5.1.5 Medical co-morbidities  
The majority of the study population had no medical problems that increased their 
risk of developing non-union following a fracture. Five participants (1.25%) were 
diabetic. None of these participants were taking insulin, four were on oral tablets and 
one was diet controlled. A full summary of the medical risk factors for non-union can 
be found in Table 8-8.  
 
16 patients (16 IM nails) had previously had a history of being treated for tuberculosis 
disease, with all reporting successful outcomes and were symptom free for at least 
six months before sustaining their injury. None of the patients were taking NSAIDs or 
steroids prior to their injury. A summary of the co-morbidities of the study population 









Figure 8-23. Bone mineral density of study population 
 
Figure 8-24. T-score of study population 
 








Figure 8-26. The relationship between T score and age, stratified by sex 
 







Figure 8-28. The relationship between T-score and age, stratified by HIV status 
 








8.5.1.6  Household and socioeconomic characteristics  
The level of completion of secondary school education in the Western Cape is 65.4% 
(411), compared to 71.5% (286/400) in the study population (Table 8-4). The 
unemployment rate in the Western Cape is reported to be 29.1%. (412) However, 
between the age of 15-24 years it is 55.2% and decreasing to 32.4% in ages 25-34 
years.(412) In the study population the unemployment rate was much higher than 
the regional average, at 52.5 % (210/400) with a median age of 32.36 years (18-71 
years). 
 
The percentage of households connected to an electricity supply from the mains in 
the Western Cape has increased from 76.7% in 2002 to 84.4% in 2017.(413) The 
percentage of households that used electricity for cooking increased from 57.5% in 
2002 to 75.9% in 2017.(413) Whereas, over 97.65% (391/400) of participants had 
access to mains electricity and 94.8% (379/400) used electricity as the primary 
method of cooking in the study population. Only 74% (296/400) of the study 
population had access to piped water to their home, compared to 88.6% of South 
Africans.(414)  
 
Currently, just over four-fifths (80.1%) of South African households lived in formal 
dwellings, followed by 13.6% in informal dwellings, and 5.5% in traditional 
dwellings.(413) The majority of study participants lived in structured formal housing 
(373/400, 93.3%), as measured by the material made up of the floor to their homes. 
Although higher levels of formal housing and access to electricity are higher than the 
regional average. The fact access to piped water are lower and the level of education 
and employment is much lower, the socioeconomic level of the study cohort as a 
whole appears lower than the regional average.  
 
The HIV-positive cohort had a higher crowding index (1.5 [IQR: 0.25-4] vs 1.33 





rooms, compared to the HIV-negative participants, although not statistically 
significant (p-value= 0.72). Higher crowding index has been shown to correlate with 
socioeconomic status.(415) The proportion of parameters, including presence of a 
flushing toilet in the home (63/75, 84% vs 308/32, 94.8%), piped water to own home 
(40/75, 53.3 vs 256/325, 78.7%) and access to mains electricity (69/75, 92 % vs 
322/325, 99.1%) were all lower in the HIV-positive compared to the HIV-negative 
cohort. Regarding access to a flushing toilet and piped water to the participants 
homes, this was shown to be statistically significant between the two groups (p-
value=0.009, p-value=0.001). Furthermore, the level of education was lower in HIV 
participants and the level of unemployment was also higher (46/75, 61.3% vs 
164/325, 50.5%) (Figure 8-30, Figure 8-31).  This is coupled with earlier findings that 
a higher proportion of the HIV-positive participants first sought medical treatment at 
a district level hospital (38/75, 50.7% vs 60/325, 18.5%), suggesting that the 
socioeconomic status of the HIV-positive cohort is lower than the HIV-negative 
group. Although, it is noted the only parameters that resulted in a significant 
difference between HIV-positive and negative participants was the access to piped 
water and a flushing toilet and there was no formal poverty score undertaken.  
 
A summary of the socioeconomic characteristics of the study population can be seen 














































































i Total number of household members divided by the number of living rooms in 
household (kitchen or bathroom not included) 





















8.5.1.7 Blood parameters 
The majority of the participants enrolled had pre-operative (310/400, 77.5%) and 
post-operative haemoglobin (387/400, 96.8%) measured. The HIV-positive 
participants had a lower median starting pre-operative haemoglobin (11.5 [6-14.9] vs 
12.5 [5.4-17.8] g/dL) (Figure 8-32), but a lower post-operative haemoglobin drop 
(1.35 vs 2 g/dL)(Figure 8-33, Figure 8-34, Figure 8-35). There was a statistically 
significant difference in the pre and post-operative haemoglobin in the HIV-positive, 
compared to the HIV-negative participants (p vale = 0.001 and 0.005). As the age of 
the HIV-positive participants increased, the lower the level of post-operative 
haemoglobin. This is in contrast to the increase in haemoglobin in the HIV-negative 
participants (Figure 8-36). 
 
HIV-positive participants had a significant difference in albumin compared to HIV-
negative individuals (36 vs 44 g/L, p-value = 0.02). Albumin has been used as an 
indicator of nutritional status. However, it has been shown to poorly correlate with 
nutritional parameters and cannot be used independently to suggest any difference 
in the nutritional status between the HIV-negative and positive participants .(416) 
 
As with post-operative haemoglobin, the older the HIV-positive participant, the lower 
the vitamin D and albumin measurement, whereas in the HIV-negative participants 
these levels remained relatively static throughout all age groups (Figure 8-41, Figure 
8-42). 
 
Regarding the duration of surgery, the post—operative haemoglobin was similar in 
participants whose procedure lasted less than one hour (10.12 g/dL) or took between 
two to four hours (10.18 g/dL)(Figure 8-43). However, once the procedure took 
longer than four hours, there was an unusually a higher post-operative haemoglobin 
in these individuals. These results are likely to be skewed by the relatively low 







Figure 8-32. Pre-operative haemoglobin of study population 
 
Figure 8-33. Post-operative haemoglobin of study population 
 
Figure 8-34. Relationship between pre-operative and post-operative haemoglobin 







Figure 8-35. The relationship between post-operative haemoglobin stratified 
according to HIV status 
 
Figure 8-36. The relationship between post-operative haemoglobin and age, 
stratified according to HIV status 
 







Figure 8-38. Relationship between pre-operative and post-operative vitamin D level 
according to HIV status 
 














Figure 8-40. The relationship between post-operative albumin level according to HIV 
status 
 













Figure 8-42. The relationship between albumin and age, stratified according to HIV 
status 
 











8.5.1.8  Mechanism of injury  
A full breakdown of how the mechanism of injury was defined can be found in 
Appendix 13-10. The main mechanism of injury in the whole study population was 
due to road-related injuries.(Table 8-12) 62.5 % (276/442 IM nailings) of injuries were 
due to participants being hit by a car whilst a pedestrian or being in a road traffic 
collision in a vehicle. 21.5% (95/442 IM nailings) of injuries were due to GSWs, with 
the majority GSW being low velocity injuries (92/442 IM nailings). 
 
There was a higher proportion of GSWs in the HIV-negative participants (23.9% 
[85/355] vs 11.15 % [10/87]). However, there was a much higher proportion (49.4% 
(43/442) vs 32.7% (116/442)) of participants injured after being hit by a vehicle as a 
pedestrian, compared to HIV-negative participants. Additionally, more of the injuries 









Figure 8-44. Mechanism of injury of study population 
 
Figure 8-45. The mechanism of injury of study population, stratified according to 







8.5.1.9  Open fracture and additional injuries  
There were 161 open fractures (36.4%) in 442 tibia and femur fractures that required 
IM nailing across the two study sites(Table 8-13). The majority of open fractures were 
Gustilo Anderson (GA) type I injuries (113/161) (Appendix 13-11). There were 95 GSW 
fractures and the majority of these resulted in GA type I injuries (96.8%, 92/95). 
Therefore 92 out of 161 (57.1%) open fractures were due to low velocity GSWs 
fractures. 
 
More than 97% of participants had their antibiotics within 24 hours of their injury 
(97.5, 157/161) and all the participants were given antibiotics according to hospital 
guidelines prior to their surgical procedure. HIV participants waited a longer period 
of time for their antibiotics following their injury (p=value=0.02). The median length 
of time between a participant’s date and time of injury and the date and time of their 
surgery was 59.5 (27.15-106.25) / 2.51 (1.13 – 4.42) hours. 
 
A high proportion of participants underwent IM nailing as a single procedure, without 
an initial washout, or application of external fixator (88.91%, 143/161). At both study 
sites, all low velocity GSW fractures have their bullet entry and exit wounds left to 
heal by secondary intention and this reflects the high proportion of participants who 
had their open fracture wounds left open following their first surgical procedure 
(67.1%, 108/161) Across both study sites all GSW are then given a short course of 
antibiotics following their surgery. However, this information was not collected as 
part of this study protocol. 
 
Due to the nature of the energy required to fracture the tibia or femur, participants 
commonly had other injuries as well as their fractures (31.3%, 125/400). The Injury 
Severity Score (ISS) is an established medical score to assess trauma severity.(203), 
(417)  A ‘polytrauma’ was defined as the ISS being greater than 15.(417) A 





(418), (419) A full explanation of how the IIS is calculated can be found in Appendix 
13-12. Twenty percent (80/400) of the participants had an IIS greater of 16 or great 
and were therefore classed as suffering from polytrauma.  
 
There was no difference in IIS in HIV-positive compared to negative participants. (p – 
value = 0.87) When comparing the HIV-negative and positive cohorts, there was a 
higher proportion of open injuries in the negative group (39.2%, 139/355 vs 25.3%, 


































a: n=161 / 139 /22  
b: n=400 / 325 / 75) 
IQR – interquartile range 







8.5.1.10 Surgical parameters 
All 442 fractures underwent reamed locked (proximally and distally) IM nailings 
across the two study sites (Table 8-14). The procedures were undertaken 
predominantly by registrar or equivalent training level surgeons (98.4%, 435/442). 
99.1% of participants had antibiotics prior to their surgical procedures, according to 
their hospital policy. Over 50% of procedures were performed out of normal daytime 
working hours (229/442, 51.8%). 
 
In order to achieve reduction of the fracture for prior to fixation, 18.78% (83/442) of 
the fractures required the skin to be opened over fracture to gain satisfactory 
reduction. This proportion was higher in the HIV-positive (26.44%, 23/87) compared 
to the HIV-negative (18.59% 66/355) participants, but this difference was not 
statistically significant (p-value=0.828). Two hundred and seventy-seven of the 
fractures (62.67%) took between one-two hours to complete the surgery, with just 
2.05% (9/442) lasting over four hours. Furthermore, (29.64 % (131/442) of 







a:  n=215 / 171 / 44 
b: n=227 / 184 / 43 





8.5.1.11 Classification and fracture pattern 
In the study population 50.9% (225/442) of the 442 fractures were classified as a 
simple fracture pattern, according to the AO classification system (Appendix 13-8, 
Table 8-15). Femur fractures were more likely to be classified as a complex (33.5%, 
76/227 vs 20.9%, 45/215) or comminuted (16.3%, 37/227 vs 7.4%, 16/215) fracture 
pattern when compared to tibia fractures. In both tibia and femur fracture, the HIV-
positive participants had a higher proportion of simple fractures, compared to their 
HIV-negative counter parts (63.2%, 55/87 vs %, 53.8%, 191/355) (Figure 8-46). 
Therefore, overall there was a higher proportion of unstable and comminuted 
fractures in the HIV-negative participants (41.4%, 147/355 vs 31.0%, 27/87). Overall, 
although there was a proportional difference between the two groups, this was not 
statistically significant (p-value=0.300). 
 
When assessing the femur fracture classification using the Winquist classification 
(Appendix 13-9), the higher the number on the classification system the more 
unstable and comminuted the fracture. The HIV-negative participants had a higher 
percentage of comminuted type III and IV injuries (37%, 68/184 vs 25.6%, 11/43), but 
again there was no statistical difference between the groups (p-value=0.910).  
 
Comminuted and complex fractures were more likely to result in open fractures and 
in participants who suffered from polytrauma (Figure 8-48). When classifying the 
fractures according to the complexity of the injury, the GSW injuries caused a highest 
proportion of comminuted (39/53, 73.6%) and complex fractures (42/121, 34.7%) 
amongst the study population(Table 8-16). This suggests that GSW injuries result in 
more severe and complex fractures. Another important observation was that when 
hit by a car, pedestrians generally had a higher proportion of complex (31/121, 
25.6%), compared to those who sustained injuries sustained whilst in a vehicle 









Figure 8-47. Fracture pattern in closed and open fractures, according to AO 
classification system 
 














this was an intra-operative technical issue and it did not meet the definition of non-
union for this study. Therefore, it was not classified as a non-union. 
 Final study population 
The final study population included 358/400 (89.5%) participants, (Figure 9-1) who 
underwent 395/442 (89.4%) IM nailings; all participants were followed up for a 
minimum of 12 months. Of these, 71 participants (71/358, 19.8%) were HIV-positive 
(83 IM nailings (83/395. 21.0%). A full summary of the baseline characteristics of the 
final study cohort can be seen in Table 9-2. 
 








IM - intramedullary 
IQR – Interquartile range 
a – n = 400 / 42 / 358 
b – n = 442 / 47 / 395 






 Study outcomes 
Delayed union 
Overall, 17.4% (69/395) of the study population developed delayed union (Table 9-3). 
12 participants with delayed union were HIV-positive (12/395, 3.0%), whereas 57 
(57/395, 14.4%) participants with delayed union were HIV-negative. 14.5% of HIV-
positive participants developed delayed union (12/83), compared to 18.3% (57/312) 
in the HIV-negative cohort (univariate odds ratio (OR) 0.76 [95% confidence interval 
(CI) 0.37-1.44], p-value = 0.417) (Table 9-3). 
 
Non-union 
There was a non-union risk of 5.8% (23/395) in the study population with again a 
slightly higher proportion of non-unions in the HIV-negative cohort (7.1% (22/312) vs 




The number of deep surgical site infection (DSI) and superficial site infection (SSI) in 
the overall study population was 5.3% (21/395) and 1.5% (6/395) respectively. The 
proportion of DSI in the HIV-positive cohort was higher compared to those who were 
HIV-negative, but not significantly so (8.4% [7/83] vs 4.5% [14/312]), (univariate OR 
1.96 [CI 0.72-4.89], p-value=0.161); SSI proportions were very similar (HIV-positive 
1.2% [1/83] vs HIV-negative 1.6% [5/312]). A higher proportion of HIV-positive 
participants presented with late infections (6.0% [5/83] vs 0.6% [2/312]), compared 








 Determining delayed union and non-union using the RUST score – inter-
observer reliability 
Two independent reviewers (reviewer 1 and reviewer 2), blinded to the HIV status of 
the participant, reviewed all x-rays. They determined the primary outcome (delayed 
union) at six-month follow-up or before and the secondary outcome of non-union at 
nine-month follow-up or before, using the RUST score for both the femur and tibia. 
On 11 x-rays, the reviewers disagreed on the outcome. Therefore, a third reviewer 
(reviewer 3) was used to determine consensus.  The third reviewer was again blinded 
to the HIV status of the participant and also the score the two reviewers had given 
for the x-ray they were reviewing.  
 
On nine occasions the third reviewer was required in order to determine consensus 
for the primary outcome of union or delayed union at 6 months or before (9/395). 
The inter-observer agreement, between reviewer 1 and 2, of union or delayed union 
at this time point determined from the RUST score was 97.7% (Kappa = 0.92).  
 
On two occasions reviewer 3 was needed following a lack of consensus for the 
secondary outcome of non-union at nine months or before (2/69). The inter-observer 
agreement, between reviewer 1 and 2, of union or non-union at this time point 












 Primary outcome 
9.2.5.1 Delayed bone union 
The primary outcome of the HOST 1 Study was delayed bone union and was defined 
as impaired bone healing at six months on RUST score (RUST score < 9). (125), (126), 
(127), (128) 69/395 (17.4%) fractures in the overall study population exhibited 
delayed bone healing. Parameters and confounding factors included in the univariate 
and multivariable regression model included the following (selection described in the 
methods section of Chapter 8): 
1. HIV status 
2. Age 
3. Sex 
4. Smoking status 
5. Open fracture 
6. Deep surgical site infection 
7. Post-operative vitamin D 
8. Fracture site 
 
Of the 69/395 (17.5%) delayed union fractures, 3% (12/395) of them occurred among 
HIV-positive participants, compared to 14.5% (57/395) who were HIV-negative. The 
proportion of delayed unions in HIV-positive participants as a group was 14.5% 
(12/83) compared to 18.3% (57/312) in HIV-negatives. Using both univariate (OR 0.76 
[CI 0.37-1.44] p-value = 0.417) and multivariable logistic regression analysis (OR 1.06 
[CI 0.17-1.01] p -value 0.869), these differences were shown not to be statistically 
significant (Table 9-4).  
 
Female participants made up 23.7% (85/358) of the study population and were 
significantly less likely to have delayed union compared to male participants on 
univariate analysis (OR 0.38, [CI 0.16-0.78], p-value=0.014). However, on 





population, this was borderline statistically significant (OR 0.41 [CI 0.17-1.01], p-
value=0.053), although confidence intervals were wide. 
 
Fifty-seven percent (39/69) of fractures that developed delayed union occurred 
following an open fracture, with 28.5% (39/137) of all open fracture developing 
delayed bone union, compared to 11.6% (30/258) of closed injuries. Open fractures 
were associated with over three-times increased in the odds of developing delayed 
bone union compared to closed fractures. (Table 9-4)  Both univariate (OR 3.02 [CI 
1.78-5.18], p-value 0.001) and multivariable (OR 3.13 [CI 1.74-5.63] p-value = 0.001) 
logistic regression analysis confirmed that an open fractures was associated with a 
statistically significant increase in the proportion of delayed unions in the study 
population. 
 
Regarding a participant’s age, the odds of delayed union increased by 3% for every 
year increase in age at the time of fracture (univariate OR 1.02 [1.0-1.05] p-value 
0.050, multivariable OR 1.03 [CI 1.00-1.06] p-value = 0.003) in the overall study 
population. 
 
There was more than a doubling of the odds of delayed union in fractures of the tibia 
compared to the femur on both univariate and multivariable logistics regression 
analysis (OR 2.32 [1.36-4.06] p-value 0.003. OR 2.20 [1.21-3.99] p-value = 0.010). 
 
No other factors examined had any significant impact on the risk of developing 








IQR – Interquartile range 
All CI are adjusted for clustering for multiple fractures per participant 








As discussed, 12/83 (14.5%) fractures in HIV-positive participants developed delayed 
bone union following their injuries. This small number of participants makes it 
difficult to draw valid conclusions. The proportion of delayed union in ART naïve 
participants was 23.3% (7/30), compared to 12.2% (5/41) in those participants taking 
ART on enrolment. 
 
The following parameters and confounding factors were included in the univariate 
and multivariable logistic regression models to analysis delayed union in the HIV-
positive study population: 
1. Age 
2. Sex 
3. Open fracture 
4. Viral load 
5. CD4 count 
6. ART treatment 
 
Two different univariate and multivariable logistic regression models were 
constructed. One included CD4 count, viral load and ART treatment at baseline 
(Model 1, Table 9-6) and one included CD4 count, viral load and ART treatment at six-
months follow-up. (Model 2, Table 9-7)  
 
In the two models, following both univariate and multivariable logistic regression 
analysis, none of the parameters included were shown to be statistically significant 
for the development of delayed bone union within the HIV-positive population. A full 
summary of the univariate and multivariable logistic regression analysis can be seen 
in Table 9-6 and Table 9-7 
 
The median CD4 count at baseline in the delayed union participants were similar at 
460 cell/mm3 (IQR 366 -477) compared to 413 cell/mm3 (IQR 295-673, [p-value - 0.4]) 





union participants was higher (3.02 [IQR 0.98-4.76]) compared to (2.13 [IQR 1.30-









 Secondary outcome 
9.2.6.1 Non-union  
Fracture non-union was defined as one or both of the following: 
• Need for further surgery to achieve union before nine months. This decision was 
made by two orthopaedic surgeons. (125), (126), (127), (128).  
• Impaired bone healing at nine months on RUST score (RUST score < 9). (125), 
(126), (127), (128) Note all non-unions were diagnosed with this definition. 
 
There were 23/395 (5.8%) fractures that developed non-union in the study 
population.  
 
Parameters and confounding factors included in the univariate and multivariable 
regression model included the following: 
1. HIV status 
2. Age 
3. Sex 
4. Smoking status 
5. Open fracture 
6. Post-operative haemoglobin  
7. Post-operative vitamin D 
 
Deep surgical site infection was removed from this model since only one participant, 
who was HIV-negative had both deep surgical site infection and non-union. Fracture 
site was not included since a similar number of femur and tibias developed non-union 
and this did not add any improvement in fit to the models (femur 11/23 [47.8%], tibia 
12/23 [52.2%]). 
 
Of the 23/395 (5.8%) non-unions, 0.3% (1/395) were in HIV-positive participants, 





of non-union in the HIV-negative cohort (7.1% [22/312] vs 1.2 % [1/83]), compared 
to the HIV-positive participants. On both univariate logistic (OR 0.16 [CI 0.01-0.78]) 
and multivariable regression (OR 0.17 [CI 0.01-0.92]) models the associations were 
statistically significant. 
 
Sex did not have a statistically significant effect on non-union on univariate analysis, 
although odds of non-union were 70% higher in men compared to women (OR 0.30 
[CI 0.05-1.04] p-value = 0.107). On multivariable analysis estimates were less precise 
and non-significant (OR 0.51 [CI 0.07-2.01], p-value = 0.400). 
 
65% (15/23) of all the non-unions resulted following an open fracture. 10.9% 
(15/137) of all open fractures developed a non-union in the study population, 
compared to 3.1% (8/258) of closed fractures. Non-union was nearly four times more 
likely following an open fracture in univariate (OR 3.84 [CI 1.62-9.77] p-value = 0.003) 
and nearly three times as likely in multivariable analysis (2.96 [CI 1.16-8.07] p-value 
= 0.026) respectively. 
 
On multivariable logistic regression analysis, the odds of non-union increased by 3% 
for every 1 nmol/L increase in vitamin D at baseline enrolment (multivariable OR 1.03 







9.2.6.2 Deep surgical site infection 
Deep surgical site infection was defined using The Centre for Disease Control and 
Prevention definition of a wound infection involving the tissues deep to the skin that 
occurs within 30 days of injury (closed reduction of fracture) or 90 days (open 
reduction of fracture) (where day 1 = the procedure date.) (363)  
 
There were 21/395 (5.3%) fractures that developed DSI in the study population. 
Parameters and confounding factors included in the univariate and multivariable 
regression model included the following: 
1. HIV status 
2. Age 
3. Sex 
4. Smoking status 
5. Open fracture 
6. Post-operative white blood cells  
 
Of the 395 cases, 21 developed DSIs (5.3%), seven (1.8%) of which were in HIV-
positive participants. This is compared to 3.5% (14/395) who were HIV-negative. The 
proportion of DSI in HIV-positive participants was 8.4% (7/83), compared to 4.5% 
(14/312) in HIV-negative participants. HIV status was not significantly associated with 
for DSI following IM nailing in the univariate model (OR 1.96 [CI 0.72-4.89] p-value = 
0.161) or in the multivariable model (OR 2.59 [CI 0.86-7.80] p-value=0.090) (Table 
9-10). The proportion of participants taking ART was similar, with three out of the 
seven (42.9%) HIV-positive participants taking ART and four not (57.1%). Due to the 
low numbers, no univariate or multivariable analysis was undertaken. 
 
In those HIV-positive participants who developed DSI, there was no statistically 





822]) compared to participants who did not develop an infection (median CD4 417 
Cell/mm3 [306-653]) (OR 1.00 [CI 0.99-1.00] p-value = 0.394).   
 
Open fractures resulted in a higher proportion of participants experiencing DSI. Fifty-
seven percent (12/21) of DSI were in participants whose injuries were following an 
open fracture. This resulted in 8.8% (12/137) of all open fractures developing a DSI, 
compared to 3.5% (30/258) in closed injuries (univariate OR 2.66 [CI 1.10-6.67], p-
value = 0.032, multivariable (OR 3.39 [CI 1.20-9.61] p-value = 0.026). 
 
Males had nearly three times the odds of developing a DSI compared to females, 
although on univariate and multivariable logistic regression analysis this difference 
was of borderline statistical significance (univariate OR 1.70 [CI 0.63-4.23] p-value = 







9.2.6.3 Superficial surgical site infection 
Superficial surgical site infection was defined using the Centre for Disease Control 
and Prevention definition of a wound infection involving the skin and subcutaneous 
tissue that occurs within 30 days of surgery (where day 1 = the procedure date).(402)  
 
Only 6/395 (1.5%) fractures developed an SSI in the study population. Due to the low 
number of SSI, univariate and multivariable logistic regression analysis was not 
undertaken. Of the 6/395 (1.5%) SSIs, 0.3% (1/395) were in HIV-positive participants, 
compared to 1.3% (5/395) who were HIV-negative. The proportion of SSI in HIV-
positive participants was 1.2% (1/83), compared to 1.6% (5/312) in HIV-negative 
participants. As with DSI, open fractures resulted in a high proportion of the SSI 
recorded. Eighty-three percent of SSI (5/6) were in participants whose injuries were 







9.2.6.4 Late implant infection 
Late implant infection was defined as any late wound breakdown (>30 days for closed 
reduction of fractures or >90 days for openly reduced fractures) or sinus formation, 
or unexplained late pain with associated radiological changes consistent with peri-
implant sepsis.(388)  
 
There were 7/395 (1.8%) fractures that developed late implant infection in the study 
population. Due to the low number of late infections, a univariate and multivariable 
logistic regression analysis was not undertaken. Of the 7/395 (1.8%) late infections, 
1.3% (5/395) were in HIV-positive participants, compared to 0.5% (2/395) who were 
HIV-negative. The proportion of late infection in HIV-positive participants was 6.0% 
(5/83), compared to 0.6% (2/312) in HIV-negative participants (Table 9-12). All of the 







9.2.6.5 The length of time a participant diagnosed with HIV and taking anti-
retroviral therapy: How this impacted the study outcomes 
Participants had the date they first received a positive laboratory blood sample for 
HIV and the date of their IM nailing surgery recorded. Therefore, it was possible to 
determine the length of time a participant had been diagnosed with HIV. 
Furthermore, the length of time a participant was taking ART was recorded.  
 
The interquartile ranges for length of time since diagnosis of HIV and duration of ART 
were very large, and the number of participants who were HIV-positive and 
developed delayed union or DSI were low. Therefore, no further statistical analysis 
and regression modelling was undertaken. 
 
With the limited data available, participants who have had a diagnosis of HIV for 
longer were more likely to develop delayed union (union: 116.4 month [IQR 61.5-
290.8] vs delayed union: 178.2 months [IQR 44.9-324.3]). DSI was more likely in those 
participants who had been diagnosed for a shorter period of time (DSI 178.2 month 
[IQR 44.9-323.3] vs no DSI 301.8 months [IQR 163.5-347.0]). Regarding the length of 
time a participant had been taking ART, the longer the period of time on ART, the 
more likely a participant was to develop delayed union. The shorter the period of 
time on ART, the more likely a participant was to developed a DSI (DSI 138.2 months 
[IQR 57.2-290.8] vs no DSI 301.8 months [IQR 163-331.8]) (Table 9-13, Table 9-14, 
Figure 9-3). However, due to the low of participants who developed each outcome, 








Figure 9-3. A box and whisker plot of the length of time a participant had been living 








9.2.6.6 Open fractures 
There were 137/395 (34.7%) IM nailings in 358 study participants with open 
fractures. Of these 137 open fractures, 22 (16.1%) were in HIV-positive participants. 
Following an open fracture, HIV does not appear to be a statistically significant factor 
for the development of delayed union, non-union or DSI and SSI. (Table 9-15) There 
were a low number of late implants infections in the study cohort (7/395, 1.7%), three 
of which were in open fracture. Although, on univariate logistic regression analysis 
the association between HIV and late implant infection was borderline significant (OR 
11.40 [1.05-25.20] p-value = 0.051), caution should be made when interpreting this 
result due to the low numbers. 
 
The proportion of participants who developed delayed union was similar in HIV 
positive (27.3%, 6/22) and in HIV negative (28.7%, 33/115) participants. When 
reporting proportional comparisons between non-union, SSI, DSI and late implant 
infection according to HIV status in open fractures, due to the low number of 
participants who developed these outcomes overall, it is difficult to draw any valid 
conclusions from this data. However, the proportion of HIV-positive participants who 
developed nonunion (0% 0/22 vs 13.0% 15/115) were lower in HIV positive 
participants. Whereas the proportion of DSI (13.6% 3/22 vs 7.8% 9/115), SSI (4.5% 
1/22 vs 3.5% 4/115) late implant infection (9.1% 2/22 vs 0.9% 1/115) were higher in 
HIV-positive participants compared to HIV-negative. 
 
There were a high number of GA grade I open fractures, due to the high number of 
GSW fractures included in the study. After excluding all the GA grade I fractures from 
the analysis there were 44 open fractures GA grade II or above. There were 7/44 open 
fractures that were HIV-positive with a GA grade of II or above. HIV still did not appear 
to be a significant risk factor for the development of delayed union (OR 0.59 [CI 0.08-





p-value = 0.444), SSI (0 HIV+ve participants) or late implant infection (0 HIV+ve 









Figure 9-4. Summary of delayed fracture healing according to Gustilo Anderson open 
fracture grade 
 







9.2.6.7 Injury severity score 
The Injury Severity Score (ISS) is an established medical score to assess trauma 
severity(203),(417)  and has been used to define the term polytrauma. A polytrauma 
was defined as the ISS being greater than 15 in this study.(417)   
 
In the final study population, 100 (100/395, 25%) participants had an ISS ≥ 16. Out of 
83 IM nailings in HIV-positive participants, 22 (26.5%) were in participants with an ISS 
≥ 16, compared to 61 (61/312) 19.5% who were HIV-negative. 
 
An ISS ≥ 16 (polytrauma) was not a statistically significant factor for the development 
of delayed union, non-union, DSI, SSI or late infection on univariate analysis (Table 
9-18, Figure 9-6, Figure 9-7). Regarding late implant infection, although the number 
of participants who developed late implant infection were was low (7/395), 57.1% 
(4/7) of them were in participants who had sustained a polytrauma (ISS>16), although 







Figure 9-6. Summary of the number of participants who developed delayed bone 
union of a fracture stratified according to their injury severity score on admission 
 
 
Figure 9-7. Summary of the number of participants who developed non-union of a 








9.2.6.8 Disability rated index 
The median DRI in the study population at baseline, prior to injury, was 0 (IQR 0-34.3) 
and the DRI at six months was 20 (IQR – 8-33, p value = 0.001). The was no difference 
in the DRI between the HIV-positive or HIV-negative participants (baseline HIV +ve 0 
[IQR 0-33] vs HIV -ve 0 [IQR 0-28], 6 month HIV +ve 19 [IQR 10-29] vs HIV -ve 20 [IQR 
8-33]). It is expected that those participants who developed delayed union and non-
union following their injuries would have worse functional outcome, hence higher 
DRI, when compared to those participants whose fracture healed. This was confirmed 
by the study participants’ six-month DRI. There was a higher DRI in participants who 
developed delayed (median 31 [IQR 14-44] vs median 16.5 [IQR 7-30] and non-union 
(median 33 [IQR 20-47] VS median 18 [IQR 8-33]). A summary of these findings can 








9.2.6.10 Time of day of surgery: How this impacted the study outcomes. 
Over half of the surgical procedures (229/395, 51.8%) took place outside of normal 
working hours (1700-0700) across both study sites. The proportion of participants 
who developed delayed bone union following a procedure performed out of hours 
was the same as those whose fracture went onto union (34/69, 49.3% vs 169/326, 
51.8%). Similarly, in participants who developed DSI (12/69, 57.1% vs 191/374, 
51.1%). However, slightly more non-union developed after surgeries were 
undertaken out of normal operating hours (16/23, 69.6% vs 187/372, 50.2%). Overall, 
for all time points, the time of day a fracture was operated on was not statistically 
significant for the development of delayed union, non-union or DSI in this study 








9.2.6.11 Fracture site 
Of the 395 IM nailings that were undertaken in the study population, 197 (49.9%) 
were in the tibia and 198 (50.1%) were in the femur. Participants who sustained a 
fracture of the tibia were more than six times more likely to develop a DSI (univariate 
OR 6.54 [2.17-28.20] p-value=0.001) compared to the femur. However, having a 
femur or tibia fracture was shown not to significantly affect the odds of participant 
developing a non-union (OR 1.10 [CI 0.47-2.60] p-value = 0.820) SSI (OR 2.03 [CI 0.39-
14.8] p-value = 0.416) or late implant infection (7/7 infections all in the tibia). A 







9.3  Discussion – HOST 1 study 
 Principal findings 
To our knowledge this is the first large, appropriately powered, prospective study to 
investigate fracturing healing in HIV-positive individuals. HIV was shown not 
significantly associated with the development of delayed bone healing following an 
IM nailing of the tibia or femur in this study population (univariate OR 0.76, [CI 0.37-
1.44], p-value=0.417, multivariable OR 1.06 [CI 0.50-2.22], p-value=0.869). Anti-
retroviral therapy regimen, CD4 count and viral load measurement at baseline and 
six months follow-up, were shown not to be associated with a risk of developing 
delayed union in the HIV-positive study population.  
 
HIV-positive participants developed a statistically significant lower proportion of non-
unions, compared to HIV-negative (univariate OR 0.16 [CI 0.01-0.78], p-value = 0.076, 
multivariable OR 0.17 [CI 0.01-0.92], p-value = 0.100), suggesting that HIV-positive 
status reduced the risk of developing a non-union following a fracture. 
 
HIV-positive status was not associated with the development of post-operative DSI 
(univariate OR 1.96 [CI 0.72-4.89] p-value = 0.161, multivariable OR 2.59 [CI 0.86-
7.80] p-value=0.090). There was a low number of participants who developed an SSI 
in the study population, making it difficult to draw any valid conclusions. However, 
the proportion of SSIs in HIV-positive participants was slightly lower (1.2% [1/83]), 
compared to 1.6% (5/312) in HIV-negative participants. Only 1.7% (7/395) of the 
study population developed a late implant infection. A higher proportion of HIV-
positive participants developed late implant infection than HIV-negative (6.0%, 5/83 








 HIV status in study population 
The prevalence of HIV in the study population was 19.8% (71/358 participants). 41 
out of 71 HIV-positive participants (57.7%) were taking ART on enrolment to the 
study and almost all of these participants were taking the same first line therapy - 
TDF, 3TC + ERV (38/41, 92.7%).  
 
South Africa, with 0.7% of the world's population, accounts for 17% of the global 
burden of HIV infection.(52) The national prevalence of HIV is approximately 18.9%, 
but the prevalence in the Western Cape is much lower at 5.6%.(57), (58) Therefore, 
the prevalence of HIV in the study population was significantly higher at 19.8% (14.2% 
higher) compared to the Western Cape. This is potentially due to the fact that the 
majority of the study population were young adult males (273/358, 76.2%) living in 
and around the township areas of Cape Town. HIV is more prevalent in deprived areas 
of South Africa (420), such as townships. Young adult males are more likely to engage 
in high-risk behavior, potentially increasing the likelihood of HIV infection (421), (422) 
and be involved with crime (423),(424). As a result of their high-risk behaviour and 
high crime involvement, this study population represents a cohort of individuals that 
are at a high risk of suffering from trauma. In similar research from Malawi, 
researchers demonstrated a similar theme of a higher proportion of HIV in their study 
population of trauma participants when compared to the national prevalence, with 
the majority their study population being young adult males.(388), (389)  
 
Approximately, 4.4 million people are currently receiving ART treatment in South 
Africa. This equates to 61% of the people living with HIV in the country.(53) This study 
cohort had a slightly lower proportion of participants taking ART on enrolment 
(41/71, 57.7%) compared to the national average. This increase at six-month follow-
up to 69% (49/71) to be slightly higher than the national average. Current 
international targets are for 90% of those with HIV to be on ART.(425), (426) The aim 





documented that young adult males have a low uptake of HIV services in South Africa 
and this was not possible in this study population.(422) 
 
The proportion of delayed union in ART naïve participants was 23.3% (7/30) 
compared to 12.2% (5/41) in those participants taking ART on enrolment. Only one 
HIV-positive participant developed a non-union and they were on ART, making it 
difficult to draw any valid conclusions from the non-union data. However, since the 
proportion of delayed union was lower in those on ART, this might suggest that ART 
has little influence on the development of delayed union. This was further confirmed 
by the multivariable analysis which showed that ART was not a statistically significant 
factor for the development of delayed union in the HIV-positive study population. A 
much larger study would be needed to be appropriately powered to help understand 
the role of ART on fracture healing. 
 
The overall median CD4 count and viral load were similar at six-months (413 
cells/mm3, IQR 302-653/2.13 log10 cps/ml (1.3-4.62), compared to baseline (402 
cells/mm3, IQR 265-630/1.99 log10 cps/ml, 1.30-410). In this study cohort, the 
median CD4 count on enrolment was 402 cells/mm3 (IQR 265-630), which is the 
similar to published population based CD4 counts in South Africa.(427) Malaza et al 
showed the median CD4 count level in the HIV individuals on ART was 367 cells/µl 
(IQR 255–511 cells/µl) compared to 377 cells/µl (IQR 252–542 cells/µl) in ART naive 
group (p = 0.600) in a study in South Africa. (427)   
 
Historically, researchers have recommended ensuring that the CD4 count is above 
500 cells/μL prior to undertaking orthopaedic surgery, even emergency fracture 
fixation, due to high infection rates.(213) However, more recently researchers have 
suggested that the level of CD4 count makes little difference to post-operative 
complication rate following fracture surgery.(388) In those HIV-positive participants 
who developed DSI, there was no statistically significant difference in the CD4 count 





did not develop an infection (median CD4 417 Cell/mm3 [IQR 306-653]) on univariate 
analysis (OR 1.00 [CI 0.998-1.00] p-value = 0.394). Our study shows that a CD4 count 
less than 500 cells/μL appears to make no difference to the odds of developing post-
operative DSI infection following internal fixation. 
 
 Comparison with the published literature 
9.3.3.1 Whole study population  
The overall delayed union rate in the overall study population was 17.4% (69/395), 
with a higher delayed union rate in the tibia fractures (23.4%, 46/197) compared to 
the femur (11.61 %, 23/198). Prior to commencing the study, it was anticipated that 
the delayed union rate in the overall study population would be 15%. This was used 
to formulate the sample size calculation for the HOST 1 Study, and this was based on 
previous research, the majority of which was from research in a high-income setting. 
(114), (124), (126), (406), (407), (428), (429)  
 
There is little evidence currently available in the literature that accurately reports the 
risk of delayed union of tibia and femur fractures following internal fixation. This is 
likely due to the varying definitions of delayed union available in the literature and 
commonly researchers report delayed union rates that would be classified as non-
unions by definition in this study.(131) Furthermore, the majority of research to date 
has focused on fracture non-union, rather than delayed union of fractures. This may 
be due to a number of factors. Firstly, it can be difficult to measure delayed union 
without the appropriate resources and protocols. It is labour intensive, having to 
capture data at set times before a fracture heals, since the majority of delayed unions 
do go on to heal, rather than form established non-unions. This is shown in this study 
cohort, where 66.6% (46/69) of delayed unions did not progress to non-unions. 





economic status is greater than that of a delayed union, making it a higher research 
priority.(430), (431) 
 
Despite no clear and established definitions for delayed union for the tibia or femur 
in the literature, there are well-documented reports of differences in the union times 
of these two bones. (109), (114), (201), (432) The tibia takes longer than the femur 
to achieve bone union following a fracture, despite non-union rates being similar. 
(109), (114), (201), (432) A range of union times for the femur and tibia have been 
published. Approximate fracture union times of 12 weeks for the femur and 16 weeks 
for the tibia following a closed injury are commonly used.(114), (115) The higher 
proportion of delayed unions in the tibia may reflect the biological nature of the tibia 
and its normal healing process being longer to that of the femur. Therefore, due to 
the established differences in union times for both the tibia and femur, a more 
appropriate definition of delayed union for the femur should be shorter than that 
used for the tibia. This is acknowledged as a limitation of the study. 
 
The non-union rate in the tibia was very similar to the femur (12/197, 6.0% vs 11/198, 
5.5%) in the study population, with an overall a non-union rate of 5.8% (23/395) in 
the study population. This matches published data available in the literature which 
has shown non-union rates from 1.1-12.5% for femur and tibia fractures. (114), (116), 
(188), (431), (433) 
 
The rate of deep surgical site infection (DSI) and superficial site infection (SSI) in the 
overall study population was 5.3% (21/395) and 1.5% (6/395) respectively. Recent 
literature indicates that the rate of post-operative SSIs in tibia and femur fractures, 
following fracture fixation, range from 3.4–4.2% and DSI rate of between 4.1- 
6.4%.(434) although, huge variations have been reported in the literature, from 2% 
to 88% depending on the area of the bone fractured and the fixation method 
used.(433), (435), (436), (437) Therefore, the rate of DSIs and SSIs in this study, 





DSI has been reported to be more common in the tibia (6.4% [95% CI, 2.4%-9.7%]) 
compared to the femur (5.7% [95% CI, 5.4%-8.8%]). (434) The reasons for this are 
multi-factorial, including different soft tissue coverage of the bone, blood supply and 
the types of injuries sustained in the tibia and femur.(438) Similarly to the literature, 
in this study population the proportion of DSI following a tibia fracture was 10.1 % 
(18/179) compared to 1.5% (3/195) in the femur. The higher DSI in the tibia fractures 
compared those reported in the literature could also be due to the slightly higher 
number of open tibia fractures compared to femur (36.4% [72/198] vs 32.9% 
[65/197]). 
 
9.3.3.2 HIV-positive population  
To our knowledge, no published research to date has accurately reported the 
outcomes of delayed union in HIV-positive individuals following a fracture. Harrison 
et al (20) and Babruam et al (374) reported delayed union outcomes in HIV-positive 
participants but in study cohorts of less than 7 participants. Therefore, due to these 
low numbers, delayed union comparisons cannot be drawn from the literature using 
other HIV-positive cohorts.  
 
The proportion of non-unions in the study population was 5.8% (23/395), with a 
statistically significantly lower proportion of non-unions in the HIV-positive cohort 
(1.2% [1/83] vs 7.1% [22/312]), compared to the HIV-negative participants (univariate 
OR 0.161 [CI 0.01-0.78], p-value=0.076). Overall non-union rates of between 0 - 11% 
are reported in HIV-positive individuals following surgical fixation of a fracture. (213), 
(367), (382), (389), (394), (439), 
 
The rate of non-union following an open fracture in the study population was 0% 
(0/23) compared to 10-43% (371), (370), (386) (440), reported in the literature. 
Therefore, the non-union rates in this study are similar to those already reported in 





The majority of the literature groups DSI and SSI into ‘early implant infection’ 
(infection within three months of surgery) and refers to ‘late implant infection’ as any 
infection six months or more from surgery.(213) The rate of ‘early implant infection’ 
in HIV-positive individuals following fracture fixation has been reported to range from 
0-29 % in closed injuries(366), (367), (368), (369), (382) and 0-100% following an open 
fracture. (20), (213), (364), (370), (375), (393), When combining the number of DSIs 
and SSIs in the HIV-positive participants in this study to give a rate of ‘early implant 
infection’, HIV-positive participants had an infection rate of 9.6% (8/83). Therefore, 
the rates of DSI and SSI in HIV-positive participants in this study population were on 
the lower end of those reported in HIV-positive individuals in the literature. 
 
The proportion of DSIs in the HIV-positive cohort was higher compared to the HIV-
negative participants (8.4% [7/83] vs 4.5% [14/312]), (univariate OR 1.96 [CI 0.72-
4.89], p-value=0.161) although the SSI rates were very similar (1.2% [1/83] vs 1.6 
[5/312]) in the study population. As discussed in the previous section, literature 
indicates that in HIV-negative cohorts,  the rate of postoperative SSIs and DSIs in tibia 
and femur fractures, following fracture fixation, ranges from 3.4–4.2% and 4.1-6.4% 
respectively.(434) Therefore, the rate of infection in HIV-positive participants in this 
study population is higher than the reported rate in HIV-negative individuals in the 
literature, as well as the study cohort.  
 
A higher proportion of HIV-positive participants presented with late infections (6.0% 
[5/83] vs 0.6% [2/312]) compared to HIV-negative participants. The largest study to 
date reporting late implant infection, reported the outcome of late implant infection 
in 82 participants who had varying forms of fracture fixation. They reported late 
implant infection rates with a mean follow up of 25 months (12-52 months) of 
0%.(388) Other smaller cohort studies suggested late implant infection rates of up to 
18% but in smaller study cohorts. (387), (388), (439) However, in all studies to date, 
no appropriate control sample has been used. This study included a control sample 





participants. Therefore, HIV appears to be associated with an increase in the odds of 
developing a late implant infection in this study population, but more research is 
needed. 
 Confounding factors 
Age 
The median age of the study population was 33 years (18-71 years). The odds of 
delayed union increased by 3% for every year increase in age at the time of fracture 
(univariate OR 1.02 [1.0-1.05] p-value 0.050, multivariable OR 1.03 [CI 1.00-1.06] p-
value = 0.003) in the overall study population. Age was shown not to be a statistically 
significant factor for all other study outcomes of non-union, DSI, SSI or late infection. 
In vivo studies have suggested that fracture healing may be delayed in elderly 
animals,(141), (142), (143) but this has not been confirmed in clinical research and 
studies are conflicting.(144), (145), (116) This study suggests that age may influence 
the speed that a fracture heals but not the development of a non-union. 
 
Sex 
The majority of the study participants were male, 313 (78.3%) vs female: 87 (21.7%). 
This mirrors the expected cohort of individuals who are like to sustain trauma in the 
Western Cape. (73), (404), (441) Female participants were significantly less likely to 
have delayed union compared to male participants on univariate analysis (OR 0.38, 
[CI 0.16-0.78], p-value=0.014). On multivariable analysis, although delayed union was 
still less likely in the female population, this was borderline statistically significant (OR 
0.41 [CI 0.17-1.01], p-value=0.053). Sex was shown not to be a significant factor for 
the development of non-union or DSI. Due to the high rate of male participants and 
the low number of infections, all SSIs were in males and so were the majority of late 






Currently, literature suggests that females are more likely to develop non-union 
compared to males. However, the evidence from these studies is in females over 55 
years of age and following the menopause. These individuals have a lower level of 
circulating oestrogen, which plays an important role in promoting bone formation, 
stimulating anabolic and reducing catabolic processes.(59) In this study population, 
the majority of females in this study were younger than 55 years (91.8%, 78/85). 
 
Worldwide, young adult males are more likely to suffer high energy injury.(441) 
Therefore, this could increase their risk of problems with fracture healing, since high 
energy injuries are more likely to develop fracture healing problems.(116) In this 
study population, 90.1% (246/273) of the male participants had an injury as the result 
of a mechanism that could be classified as high energy (motor vehicle accident, GSW 
fracture, pedestrian hit by vehicle, high energy fall), whereas 80.0% (68/85) of 
females had a mechanism of injury with a similar mechanism. This could therefore 
have contributed to the difference seen between men and women, although 
differences were not statistically significant. 
 
Timing of surgery 
The median time between a participant’s injury and their surgery was 69.2 hours 
(33.6-121.7 hours). The time between injury and the date of surgery had no impact 
on any of the primary or secondary outcomes, including delayed union (p-
value=0.740), non-union (p-value = 0.888) or DSI on univariate analysis. (p-value = 
0.894). Just under three days (69.2 hours) is a relatively short period of time between 
injury and surgery. Long periods of time between injury and surgery have been 
associated with an increasing the risk of problems with fracture healing and infection. 
(178), (204), (442) 
 
The majority of the surgical procedures (229/395, 51.8%) took place outside of 
normal working hours (1700-0700) across both study sites. The proportion of 





out of hours was the same as those that had fractures that went onto union (34/69, 
49.3% vs 169/326, 51.8%). The same was true for participants who developed DSIs 
(12/69, 57.1% vs 191/374, 51.1 %). However, the proportion of non-unions after 
surgeries undertaken out of normal operating hours (16/23, 69.6% vs 187/372, 
50.2%) was higher than those undertaken in working hours, but this difference was 
not statistically significant (p-value=0.200). 
 
With more than half of all procedures taking place out of normal working day hours, 
this surgical practice is unique to this setting. It is due to a combination of the high 
burden of trauma and resource restrictions at the study sites and in the South African 
health care system as a whole. If an operating theatre is available, then the 
orthopaedic team will use it to undertake a procedure. As a result, orthopaedic 
trauma procedures are performed 24 hours a day. 
 
The vast majority of orthopaedic trauma practice in high income settings encourage 
minimal, if any, routine procedures to be undertaken out of hours. Health care 
systems actively encourage anything other than emergency procedures to be 
undertaken at this time of the day.(443), (444), (445), (446) There is set guidance on 
the management of pathology such as open tibia fractures out of hours in the United 
Kingdom.(447) 
 
Overall, for all time points, the time of day a fracture was operated on was not a 
statistically significant factor for the development of delayed union, non-union or DSI 
in our study population. Although, there is a suggestion that a higher proportion of 
non-unions occurred in procedures performed out of hours. This may be due to the 
low number of participants that developed non-union and a study including a large 









The post-operative vitamin D level of the HIV-positive participants was slightly lower 
(41.25 vs 45.1 nmol/L) than HIV-negative, although this difference was not 
statistically significant (p-value = 0.85). On multivariable logistic regression analysis, 
the odds of non-union increased by 3% for every 1 nmol/L increase in vitamin D at 
baseline enrolment (multivariable OR 1.03 [CI 1.01-1.05] p-value = 0.009) in the 
overall population. However, high vitamin D level was not shown to be a risk factor 
for the development of delayed union on univariate (OR 1.01 (CI 1.00-1.02), p-value 
= 0.111) and multivariable analysis (OR 1.01 (CI 1.00-1.02) p-value = 0.181). 
 
As discussed in chapter 4, HIV-positive individuals are at risk of vitamin D deficiency 
and ART also contribute to this. (274), (275), (276) Therefore, the lower level of 
vitamin D seen in the HIV positive participants compared to HIV-negative is to be 
expected. The National Institute for Health and Care Excellence define vitamin D 
deficiency as serum vitamin D levels less than 25 nmol/L.(448) Therefore, using this 
definition the median post-operative vitamin D level in both HIV-positive and 
negative groups was not within this range suggesting deficiency.  
 
The role of vitamin D in fracture healing has, to date, been poorly investigated. There 
are a limited number of conflicting experimental studies reporting either a negative 
(146), (154) or no effect (155) of vitamin D deficiency on fracture callus formation 
and mechanical callus quality. (158) In this study, it is interesting that that higher 
levels of vitamin D was one of the only parameters to statistically result in impaired 
fracture healing. Currently, there does not appear to be any other clinical data to 
support these findings, although in vivo research has demonstrated similar results in 
rat and chick models.(449), (450) Therefore, this is an area of future research that 








Bone mineral density 
A reduction in BMD is a common complication of HIV and its treatment and this has 
been established by a number of cross-sectional studies. (8), (9), (10), (11), (253), 
(254), (255), (256), (257) Additionally, ART, independently, has also been shown to 
decrease BMD and this will be discussed in more depth later on in this chapter.(253) 
 
A total of 181 participants (45.25%, n=400) had their bone mineral density BMD 
measured using a Calscan DXL Densitometer in the study population. Twenty-seven 
out of 181 participants who underwent a measurement of their BMI were HIV-
positive (15%). Confirming established research, there was a doubling of the rate of 
osteoporosis (T score > 2.5) in the HIV-positive cohort, compared to HIV-negative 
participants (2/27 [7.4%] vs 5/154 [3.2%]), but no statistical significance was found 
between the groups (p-value=0.5). The low numbers of participants meant that any 
valid conclusions are difficult draw from this data. 
 
Socioeconomic status 
A large proportion of the study population were living in the Cape Flats areas 
(250/342, 73.01%), an area of high unemployment and low socioeconomic status, 
compared to other areas of Cape Town Municipality.(451), (452) In the study 
population the unemployment rate was much higher than the regional average, at 
52.5% (210/400), compared to 29.1% across the Western Cape.(412) Therefore, 
overall the study population appeared to be from a cohort of individuals with a high 
unemployment rate, living in a socioeconomically deprived area. 
 
A higher crowding index, derived from the total household size divided by the 
number of living rooms, has been used to correlate with lower 
socioeconomic status.(415) The HIV-positive cohort had a slightly higher crowding 
index (1.5 [IQR: 0.25-4] vs 1.33 [IQR:0.25-7]), compared to the HIV-negative 
participants (p-value=(0.72).  A higher proportion of the HIV-positive participants first 





District level hospitals generally serve the Cape Flats regions.  Furthermore, the level 
of education was lower in HIV participants and the level of unemployment was also 
higher (46/75, 61.3% vs 164/325, 50.5%). 
 
HIV-positive participants had a significant difference in albumin compared to HIV-
negative individuals (36 vs 44 g/L, p-value = 0.02). Albumin has been used as an 
indicator of nutritional status. However it has been shown to poorly correlate with 
nutritional parameters and cannot be used independently to suggest any difference 
in the nutritional status between the HIV-negative and positive participants .(416)  
 
Overall, although no formal poverty score was used in the study, the socioeconomic 
status of the HIV-positive cohort could potentially be interpreted as being lower than 
the HIV-negative group but none of these factors were shown to be risk factors for 
the development of any of the primary or secondary outcomes of the study. 
 
The relationship between social deprivation and non-union is controversial. Although 
there is evidence to confirm that a lower level of socioeconomic status increases a 
individuals risk of fracture, (453) there is no reliable evidence to confirm 
socioeconomic status as clear risk factor for the development of delayed or non-
union.(454) There is, however, a clear link between social deprivation and HIV 
infection.(455) Therefore, although the level of socioeconomic status may be lower 
in the HIV-positive participants, it is unlikely that this resulted in a significant factor 
that influenced fracture healing outcomes. 
 
Mechanism of injury 
The main mechanism of injury in the whole study population was due to road-related 
injuries (276/400 66.8%) and 21.5% (95/442 IM nailings) of injuries were due to 






There was a higher proportion of GSWs in the HIV-negative participants (23.9% 
[85/442] vs 11.15% [10/442]). However, there was a much higher proportion (49.4% 
[43/442] vs 32.7% [116/442]) of HIV-positive participants injured after being hit by a 
vehicle as a pedestrian, compared to HIV-negative participants. Additionally, more of 
the injuries in the HIV participants were due to road-related injuries (70.1% [61/442] 
vs 60.6% [215/442]).  
 
If the mechanisms of injuries (high energy injuries, MVA (car and pedestrian), GSW 
fracture) that are more likely to result in a high energy fracture are grouped together, 
there was a similar proportion of these mechanisms of injury in the HIV-positive and 
negative groups (74/87 85.1% vs 317/355 89.4%).  
 
Interestingly, six participants who were enrolled following a GSW fracture, were shot 
dead within six weeks of enrolment in the study. Therefore, there was a 6.3% (6/95) 
chance of a participant, who was enrolled in the study following a GSW being dead, 
within six weeks of their injury. This highlights the high crime and dangerous 
environment a number of the study participants are living in. 
 
Open fracture 
- Study population 
There were 137/395 (34.7%) IM nailings in 358 study participants with open 
fractures. The proportion of delayed union and non-union rate in the open fracture 
study population was 28.5% (39/137) and 10.9% (15/137). The DSI rate was 8.8% 
(12/137); 3.6% (5/137) of open fractures developed an SSI and 2.1% (3/137) 
developed late implant infection. 
 
It is well established that open fractures result in higher rates of non-union and post-
operative infections when compared to closed injuries and the outcomes are 
determined by the severity of the open fracture and Gustilo Anderson grade.(210), 





nailing of open tibia fractures. Court Brown reported deep infection rates ranging 
from 1.8% to 12.5% and other research has demonstrated rates ranging from 1.9 to 
18.2%. (117), (162), (200), (407), (458), (459) Similar, SSI rates have also been 
reported.(117) Following an open tibia fracture, non-unions have been reported to 
occur in between 2.9-21.5% of study populations.(114), (117), (126), (200), (210), 
(407) The rate of infection in open femoral shaft fractures undergoing intra-
medullary nailing is slightly lower at 4.8–5.6 % and non-union rates of 4.8–
14.1%.(196), (460), (461), (462) Again, SSIs and DSIs are commonly grouped together 
and no clear definition is given. 
 
In the United Kingdom (UK) there are set standards and guidelines for the 
management of open tibia fractures, which are used for the management of all open 
fractures.(447) In South Africa, although the aim is to undertake similar management 
as those set in the United Kingdom, or similar, this is commonly not possible due to 
the high burden of trauma and resources available. An example is that the UK 
guidelines recommend debridement surgery within 12 hours for high energy injury 
or 24 hours for a low energy injury. This is simply not possible at the two study sites. 
 
A high proportion of participants underwent IM nailing as a single procedure, without 
an initial washout, or application of external fixator (88.91%, 143/161), having their 
definitive surgery at a median 59.5 hours (27.15-106.25), 2.51 (1.13 – 4.42) days. This 
is nearly 1.5 days longer than the UK guidance. 
 
GSW fractures are also managed very differently at the study sites, compared to the 
UK. These fractures in the UK would be managed like any other open fracture, with 
surgery aimed for within 12-24 hours. Whereas at both study sites, all low velocity 
GSW fractures have their bullet entry and exit wounds left to heal by secondary 
intention and the fractures are treated as a closed injury, with surgery not expedited.  
Despite this, number of participants in this study population that developed post-





fracture mirror the published literature. Few studies have reported the outcomes of 
delayed union therefore comparisons are not possible. 
 
- HIV-positive population 
Following an open fracture, HIV was not associated with the development of delayed 
union (OR 0.93 [CI 0.31-249] p-value = 0.89), non-union (0 non-unions in HIV-positive 
participants) or DSI (OR 1.86 [CI 0.39-6.91] p-value = 0.38) and SSI (OR 1.32 [CI 0.66-
9.50] p-value = 0.807). Although, on univariate logistic regression analysis the 
association between HIV and late implant infection was borderline significant (OR 
11.40 [1.05-25.20] p-value = 0.051), caution should be made when interpreting this 
result due to the low numbers.  
 
There is little evidence surrounding the risk of delayed union and non-union following 
an open fracture in HIV-positive participants in the currently literature but non-union 
rates of between 10-43% have been reported in a small number of studies. (20), 
(389), (393), (440) Whereas, the rate of non-union this study was much lower (0%). 
However only 15 participants developed a non-union following an open fracture and 
definitive conclusions cannot be drawn from these low numbers. 
 
It has been suggested that HIV is a risk factor for early and late implant sepsis in open 
fractures, with early infection rates reported to be between 0-100% and late infection 
rates of 0-8%. (20), (213), (370), (371), (386), When reporting proportional 
comparisons SSI, DSI and late implant infection according to HIV status in open 
fractures, due to the low number of participants who developed these outcomes 
overall, it is difficult to draw any valid conclusions from this data. However, the 
proportions of HIV-positive participants who developed post-operative infections 
following fracture fixation for an open fracture were higher in HIV positive 
participants (DSI - 13.6% 3/22 vs 7.8% 9/115), SSI - 4.5% 1/22 vs 3.5% 4/115) late 






 Limitations of this work  
One of the main limitations of this study is that it included fractures at two injury 
sites, the tibia and femur. Fracture site was shown to be a statistically significant risk 
factor for the development of DSI and delayed union. Therefore, ideally the study 
should have been undertaken using only one injury site. Additionally, if a participant 
had more than one fracture, both fractures were entered as two sperate injuries. 
 
Seventy-one HIV-positive participants who underwent 83 IM nailings were included 
in the final analysis. 69% (49/71) were taking ART at six-month follow-up. It has been 
suggested that ART negatively impacts the rate of fracture healing (Professor Hamish 
Simpson – personal communication of unpublished in vivo research). Ideally in order 
to determine the effect of HIV on fracture healing, the study should have only 
included those participants who were not on ART therapy. Or alternatively, only 
participants on ART could have been enrolled. However, due to ethical restrictions 
and time limitations of the study, this was not possible. Including a mix of participants 
on ART and ART naïve individuals makes it more difficult to draw any conclusions to 
from these limited in numbers. Alternatively, a large sample size of participants could 
have enabled this to be investigated. 
 
Participants had the date they first received a positive laboratory blood sample for 
HIV and the date of their IM nailing surgery recorded. Therefore, it was possible to 
determine the length of time a participant had been diagnosed with HIV. However, it 
is recognised that this is only an estimate and that it is not possible to determine the 
exact date a participant was diagnosed with HIV. This is because HIV diagnosis can be 
made from a finger prick test. Individuals are then offered a formal blood sample test 
to confirm this diagnosis (Chapter 7). The results of finger prick testing are not 
recorded anywhere on South Africa’s health care records online software. Only a 
blood sample tests recorded on the national blood sampling laboratory records were 





have been diagnosed with HIV for a longer period than that recorded in this study. 
Additionally, even if the length of time a participant has been diagnosed with HIV is 
accurate, this does not give an indication of the length of time they have been living 
with HIV, since it is rarely possible to determine when someone was actually infected 
with the virus.  
 
The length of time a participant was taking ART was recorded and again this was an 
estimate, since on occasions, participants could not fully recall the exact date they 
started their medication. This information was also reliant on the participant telling 
the truth since it is possible that they were saying that they were on ART but no 
assessment of if they were actually taking it was made. 
 
The GA grade was determined by the operating surgeon at the time of first 
debridement of the open fracture. In 88.91% (143/161) of all open fractures, this was 
done by the operating surgeon who undertook the definitive IM nailing and the first 
debridement at the same time. In 11.08% (18/161) of cases the primary debridement 
was done prior to definitive IM nailing. Therefore, the GA grade was determined 
following a discussion with the surgeon who undertook the primary debridement and 
documented by the surgeon who undertook the definitive IM nailing on the surgical 
study proforma. Ideally two surgeons, blinded to HIV status, should have made the 
assessment of the participants’ GA grade. The studies’ ethical approval meant that 
participants could not be enrolled until IM nailing had been undertaken and due to 
resource limitations, having two blinded reviewers was not possible. It is important 
to highlight that 51.8 % (229/395) of procedures were performed out of working 
hours, resulting in challenges to this potential method. Despite this, it is recognised 
that this could have introduced errors when reporting the GA grade. 
 
No formal socioeconomic scoring system was used to determine socioeconomic 
status of the participants. Therefore, it was not possible to accurately determine the 





of problems with fracture healing and infection, although there is currently no 
established evidence to confirm this. However, due to the fact this was not measured, 
potentially it could result in a confounding factor that was not taken into account 
during the analysis. 
 
The lost to follow-up rate in the study was 10.5% (42/400), which is very good in the 
study setting, since the follow-up rate of patients at GSH following an operative 
orthopaedic surgery is less than 40% in routine clinical practice.(73), (404) It is 
recognised that the systematic differences between those with and without loss to 
follow-up could have had an impact on the study outcomes but it is unlikely this low 
rate could have an impact on the results. 
 
The main study outcome was delayed bone union. In order to determine the true 
effect of HIV in fracture healing, non-union should have been used as the study’s 
primary outcome. One of the reasons it was not was that non-union was is such a 
rare outcome. In order to complete a similar study powered for the outcome of non-
union, a significantly higher number of participants would need to be enrolled. Due 
to logistical, time and financial resources this simply was not possible. In order to 
confirm this, an appropriately powered study would need to be undertaken. The 
same is true for the other outcome measures of DSI, SSI and late implant infection. 
 
The RUST score was used to determine the primary outcome of delayed union. This 
scoring system has not been validated for use in the femur. However, it is the best 
tool available to determine bone union without the need for additional 
investigations, such as computer tomography (CT) scanning.(129) GSH and TSH have 
one functioning CT scanner and a waiting list of over six months to use it. Therefore, 
logistically using this would not be possible. However, the RUST score relies on 







HIV was not shown to be associated with the risk of developing delayed bone healing 
following an IM nailing of the tibia or femur in our study population. However, the 
proportion of HIV-positive participants who developed non-union was statistically 
significantly lower than in HIV-negative equivalents. Finally, HIV-positive status was 
not shown to be a statistically significant risk factor for the development of deep 






CHAPTER 10. HIV IN ORTHOPAEDIC SKELETAL TRAUMA 2 STUDY: 
Aims, Design, Methodology and a Descriptive Analysis of the Study 
Cohort 
10.1 Aims of this chapter 
In this chapter, a description of the background, aims, methods and analysis of the of 
the HIV in Orthopaedic Skeletal Trauma (HOST) 2 study cohort will be presented. The 




There have been no previous case-control studies that have been undertaken to date 
investigating the effect of HIV on fracture healing. As discussed earlier in Chapter 5, 
it is difficult to draw any valid conclusions from the studies available in the literature 
to date regarding the true effect of HIV infection on fracture healing. These findings 
prompted this study. 
 
The hypothesis underlying this research is that HIV infection is a risk factor for the 
development of non-union following a fracture of the femur or tibia. 
 
10.3 Aims and objectives  
The aim of HOST 2 was to establish whether HIV infection is a risk factor for the 
development of non-union following a fracture of the femur or tibia.  
The main objectives of the HOST 2 Study were: 
1. To establish whether HIV infection is a risk factor for the 
development of non-union following a fracture. 
2. To investigate other risk factors associated with non-union 







 Study design 
This was a multi-centre, case-control study of participants presenting with non-union 
of fractures over a 16-month period within the Orthopaedic and Trauma Department 
at GSH and TBH, Cape Town, South Africa. Participants presenting with non-union 
following a fracture of the tibia or femur shaft were matched to a control group of 
participants with healed fractures. 
 
 Study site 
Participants were enrolled from the orthopaedic department of two tertiary referral 
trauma hospitals, GSH and TBH, in Cape Town, South Africa. 
 
 Study population 
Cases – All participants older than 18 years of age with established non-unions of the 
femur or tibia shaft, following any form of operative or non-operative management, 
were potentially eligible for inclusion in the study. 
 
Controls – All participants older than 18 years of age with closed or open tibia and 
femur fractures who underwent operative or non-operative management that went 







 Definitions and study outcomes 
The definitions used in the HOST 1 study were also applied to this study. Definitions 
to describe “union” and “non-union” of a fracture were as follows: 
 
Union: 
• Radiological union on RUST score (score of three on at least three cortices in AP, 
lateral, medial or posterior cortex – a total of nine or more) within six months of 
surgery.(125), (126), (127), (128) 
 
Non-union: 
One or both of the following: 
• Impaired bone healing at nine months on RUST score (RUST score < 9). (125), 
(126), (127), (128) 
Fracture non-unions were categorised into two main types: 
• Hypertrophic: The primary factor influencing non-union of the 
fracture is likely to be a mechanical problem with the form of 
treatment.(210) 
• Atrophic/oligotrophic: The primary factor influencing non-union of 
the fracture is likely to be a local and/or systemic biology.(210) 
The following definitions were used to determine the type of non-union on x-ray: 
Hypertrophic non-union: one or both of the non-union classification parameters 
above plus callus formation around fracture with an elephant’s foot or horse’s hoof 
appearance.(463) 
Atrophic/oligotrophic non-union: one or both of the non-union classification 
parameters above plus no callus formation around the fracture site or periosteal 





The following primary and secondary outcomes were used: 
Primary study outcome: 
• The odds ratio of femur or tibial fracture non-union, comparing HIV-positive 
to HIV-negative participants after adjustment for important confounding 
factors. 
 
Secondary study outcomes: 
• Risk factors associated with non-union in HIV-positive and -negative adults. 
• Differences in the Disability Rating between participants with and without 
fracture non-union. 
 
 Inclusion and exclusion  
The criteria used to determine if a participant was eligible for inclusion in the study 
were as follows: 
Inclusion criteria – Cases 
 
Participants were eligible for HOST 2 Study if they: 
• were older than 18 years of age 
• sustained a previous closed or open fracture of the tibia or femur (metaphysis 
or diaphysis) 
• had a single course of management for their fracture (e.g. conservative only, 
operative only) 
• developed a non-union of the tibia or femur shaft 
 
Exclusion criteria – Cases  
Participants were excluded from participation in this study in the case of: 
• major head injury 





• severe burns 
• pathological fracture 
o fractures that resulted from low energy injuries that occurred through an 
area of bone weakness with a pre-existing abnormality 
• previous non-union of a fracture that had already healed prior to enrolment in 
the study 
• intertrochanteric femur fractures  
• intra-articular fractures 
• evidence that the participant would be unable to adhere to study procedures and 
complete questionnaires 
 
Inclusion criteria – Controls 
Participants were eligible for HOST 2 study if they: 
• were older than 18 years of age 
• sustained a closed or open fracture of the tibia or femur shaft 
• fracture had healed within six months of injury 
 
Exclusion criteria – Controls 
• major head injury 
• pre- or post-surgical infection at the fracture site 
• severe burns 
• pathological fracture 
• intertrochanteric femur fractures  
• intra-articular fractures 
• fracture that had not healed within six months 








 Matching, screening and enrolment  
10.4.6.1 Matching 
Cases were matched in a 1:1 ratio with controls on the following criteria: 
a) Age: + / – 10 years 
b) Sex:  
• Male   
• Female 
c) Injury:  
• Tibia  
• Femur 
d) Management of fracture:  
• IM nailing  
• Open reduction and internal fixation with plate and screw fixation 
• Ilizarov external fixator frame 
• Taylor-spatial external fixator frame 
• Conservative management 
 
One ‘case’ was matched with a single ‘control’. Once a ‘control’ had been enrolled, 






10.4.6.2 Screening and enrolment 
Cases 
All ‘case’ participants were identified by the following four methods: 
1. Weekly limb reconstruction outpatient clinics at both base hospitals 
One senior fellowship trained surgeon (Maritz Laubscher (ML) at GSH, Nando Ferreira 
(NF) at TBH) was the sole provider of orthopaedic care for all lower limb non-union 
cases in that hospital at the time of the study. Any participant who developed a non-
union of the tibia or femur were referred to these surgeons for an opinion on ongoing 
management. ML and NF screened all their limb reconstruction clinics on a weekly 
basis and if an eligible participant was identified, they informed the research nurses 
and the participant was reviewed the same day for consideration for recruitment. If 
ML or NF was absent from clinic due to sickness or holiday, there were clear 
instructions left with their surgical fellow to do the same in their absence. ML and NF 
are co-investigators on the HOST 1 and 2 Study. 
 
2. Weekly elective orthopaedic limb reconstruction surgery admissions to both 
study site hospitals 
The two surgeons (ML and NF) were also the only surgeons at the study site hospitals 
(TBH and GSH) who provided an operative service for participants with non-unions 
to the tibia or femur at the time of the study. Thus, any participant who was missed 
by procedures described above was subsequently enrolled if they were admitted for 
surgery at GSH and TBH. The research nurses screened the weekly planned operating 
lists for ML and NF. If a participant was identified from a pre-planned elective 
operating list, the participants were considered for enrolment by the research nurse 
team on the day of admission for surgery. 
 
3. Prospective daily fracture clinics 
All orthopaedic consultants and trainees, at both GSH and TBH, screened all fracture 





If a potential participant was identified, the research nurses reviewed them and 
considered them for enrolment on the same day. 
 
4. HOST 1 Study database 
All HOST 1 Study enrolled participants were deemed eligible for recruitment into the 
HOST 2 Study. Once a HOST 1 Study participant reached their primary outcome and 
the fracture had developed a non-union, the participant was reviewed by the 
research team and considered for enrolment into the HOST 2 Study. 
 
Participants were recruited prior to treatment of their fracture non-union. When a 
‘case’ participant was deemed eligible for recruitment and a diagnosis of non-union 
was established, the research nurses were informed via mobile phone or a picture of 
the participant’s name and current location was uploaded to an encrypted 
smartphone application. Following screening by the research nurses the participants 
were either enrolled or excluded from the study. If there were any concerns 
regarding eligibility for the study, I personally reviewed the participant with the 
research nurses. 
 
All participants were recruited on the day they were identified and underwent an x-







Once a participant was enrolled as a ‘case’, the study team commenced recruitment 
to identify an appropriate ‘control’ participant using the previously mentioned 
matching criteria above. 
 
Control participants were identified by the following three methods: 
1. Daily fracture clinics 
 
All consultants and orthopaedic trainees, at both GSH and TBH, were given a weekly 
screening log sheet explaining the type of ‘control’ participant the research team 
were currently trying to identify (Figure 10-1).  
 
Figure 10-1. Example of weekly screening log used to identify ‘control’ participants 
 
The surgeons then screened all daily fracture clinics for any participant who met the 
criteria for recruitment according to the screening log (Figure 10-1). If a potential 
participant was identified who met the four criteria of a ‘control’ participant, the 
research nurses were informed using an encrypted smartphone application and the 





2. Daily orthopaedic trauma meeting 
During the daily trauma meeting Sithombo Maqungo (SMG) or ML went through the 
weekly matching screening log with all the orthopaedic trainees responsible for the 
daily care and operations for all orthopaedic in-patients. Any participants identified 
were then considered for enrolment by the research team. During weekends or 
holidays, screening commenced on the following working day and any participants 
missed were identified. 
 
3. HOST 1 Study database 
All HOST 1 Study enrolled participants were deemed eligible for matching process. 
Using the weekly screening log, once a HOST 1 Study participant reached their 
primary outcome and the fracture had united, they were screened to see if they 
matched any of the cases recruited in the HOST 2 Study. If they were matched, the 
research team recruited them to the HOST 2 Study. 
 
The sampling frame comprised of participants with confirmed fracture union. 
Participants were recruited at the following time points: 
a) First presentation following a fracture 
b) Partway through treatment for a fracture  
c) Final presentation for a healed fracture 
 
Participants who were recruited at first presentation of a fracture or partway through 
treatment were followed up until the fracture united. X-rays were performed on 
recruitment and when the participants fracture healed. 
 
Case and controls  
The case and control participants underwent a baseline questionnaire, and 
established risk factors for non-union were recorded (Table 10-1). Data collected 
included: demographic details; injury and surgery details; clinical history (including 





and history; domestic situation (including household size, number of young children 
in household, number of rooms in dwelling); and socioeconomic status. 
Socioeconomic status was defined by level of education attained, employment, asset 
ownership, access to cooking facilities, water and electricity, type of sanitation facility 
and housing type. 
 
The GA grade was determined retrospectively from the medical notes, or via 
communication with the surgeon who undertook the primary debridement following 
an open fracture. On all occasions a GA grade was able to be determined from one 
of these methods.  
 
The participants’ full blood count, renal function, vitamin D level and albumin were 
assessed. All participants underwent HIV testing; CD4 cell counts and HIV-1 viral load 
were evaluated if HIV-positive. If the participant was already known to be HIV-
positive (available laboratory confirmation), their ART regimen was recorded, if 
appropriate.  
 
Bone healing was assessed using a validated x-ray scoring system – the Radiological 









 Completion of the study 
Participants who still needed follow-up assessments as part of the clinical 
management continued to be treated by the Trauma and Orthopaedic Surgery Unit, 
until their condition had stabilised to a point where no further medical intervention 
was required, and they were discharged. 
 
 Withdrawals 
Participants who were recruited but declined to continue to take part in the study at 
any time were withdrawn without prejudice. A decision to decline consent or 
withdraw did not affect the standard of care the participant received and they 
continued standard hospital follow-up care. 
 
Participants had two options for withdrawal: 
1) Participants withdrew from completing any further questionnaires but allowed the 
study team to still view and retain, anonymously, any relevant hospital data that was 
recorded as part of normal standard of care, e.g. x-rays and further surgery 
information. 
 
2) Participants withdrew wholly from the study, but data obtained up until the point 
of withdrawal was included in the final analysis of the study; thereafter, no further 
data was collected for that censored participant. 
 
 Adverse events  
Serious adverse events (SAE) were defined as any serious untoward medical 
occurrence in a clinical study subject and which did not necessarily have a causal 
relationship with the treatment. These included any untoward and unexpected 





hospitalisation or prolongation of existing in-patient ´hospitalisation’, ‘results in 
persistent or significant disability or incapacity’, ‘is a congenital anomaly or birth 
defect’ or ‘any other important medical condition which, although not included in the 
above, may require medical or surgical intervention to prevent one of the outcomes 
listed’. These were recorded in on the electronic ‘Redcap’ database. 
 
 Sample size calculation 
Sample size calculation for the case control study used the methodology described 
by Dupont, (464) and included the Fleiss (465) correction for matched case-control 
design. Assuming that 20% of the controls would be HIV-positive (388), (368), a total 
sample size of 128 (64 cases and 64 controls) would give 80% power to detect at least 
an odds ratio of 3.0 for non-union, comparing between the case and controls 
groups (Figure 10-2). 
 









 Statistical analysis 
Distributions of baseline characteristics were summarised using means, medians, 
proportions and distributional measures (standard deviations and interquartile 
ranges), and tabulated and plotted and compared between the exposure (case) 
group and non-exposure group (control). 
1. For the primary outcome (non-union), confirmation was made that there 
were sufficient matching strata between the case and controls by cross-
tabulation.(466) A multivariable logistic regression model was then 
constructed to estimate the odds ratio and 95% confidence interval for non-
union comparing between case and control participants and adjusting for 
matching characteristics, and additional important confounders identified 
apriori through construction of putative causal diagrams. A separate model 
was constructed for HIV status of participants only to estimate the 
associations between HIV status on the outcome. 
2. For the secondary outcomes, a similarly multivariable logistic regression 
model was constructed to estimate the odds ratio and 95% confidence 
interval for non-union comparing between HIV-positive and HIV-negative 
participants and adjusting for important confounders. 
Missing data was reported in tables of baseline characteristics. In constructing 
multivariable models, we compared estimates obtained from complete case analysis 
and following multiple imputation of missing values. 
 
In order to construct the HOST 2 study univariate and multivariable logistic regression 
models, the same method was used as described in Chapter 8 for the HOST 1 study.  
 
Analysis of difference between continuous and categorical data not using logistic 






All statistical analysis was undertaken using ‘R’ statistical computing software. 
 
 Study timescale 
The study schedule for the duration of recruitment and follow-up up was as follows: 
January 2018 – April 2019 (14 months) – subject recruitment and any follow-up took 






10.5 Results: Descriptive analysis of HOST 2 study cohort 
 Recruitment 
From December 2017 until April 2019, 83 participants were identified as established 
non-unions of the tibia or femur and were screened and considered for inclusion in 
the study. cases were matched in a 1:1 ratio with controls on the following criteria: 
 
a) Age: + / – 10 years 
b) Sex:  
i. Male   
ii. Female 
c) Injury:  
i. Tibia  
ii. Femur 
d) Management of fracture:  
 
20 participants did not meet the study inclusion criteria and were not enrolled. 
(Figure 10-3) The predominant reason for participants not being enrolled was that 
the they had infected non-unions (15/20, 75%) or participant refusal to participant in 
the study (5/20, 25%). Six HIV-negative, participants were excluded since it was not 
possible to identify matched controls. (Table 10-4) The full breakdown of the 
exclusion criteria and the number of participants excluded from enrolment can be 







 Baseline characteristics 
The main study cohort of 57 cases were matched with 57 ‘control’ participants. They 
were recruited between January 2018 and April 2019. Nineteen of the 57 ‘case’ 
participants and 36/57 of the ‘control’ participants were recruited from the HOST 1 
Study. 
 
The majority of the participants were male (44/57, 77.2 % vs 13/57. 22.8%), with a 
median age of 36 years in each group. 37 tibia and 20 femoral nails were enrolled and 
the main form of treatment for the fractures was IM nailing (36/57, 63.2%). There 
were 16 circular fixators (28.1%) enrolled, three fractures managed with open 
reductions and internal fixations with plates and screws (5.3%) and three (3.5%) 
fractures treated conservatively. 
 
There was a similar proportion of smokers in the ‘control’ compared to the ‘case’ 
group (26/57, 45.6% vs 23/57, 42.1%), with no statistical significance between the 
groups (p-value=0.7).(Figure 10-4) As expected, the disability rated index (DRI) index 
was lower in the ‘control’ group, when compared to the cases (24.5 vs 45.2, p-
value=0.001).(Figure 10-5) The basic demographics and characteristics of the study 







Duration of smoking history  
(cases n=34, controls n = 31) 
< 1 year 0 0 0.912 
1-5 years 3 (8.8) 4 (12.9)  
5-10 years 7 (20.6) 11 (35.5)  
> 10 years 24 (70.6) 16 (51.6)  
Patient reported outcome measure    





DRI – disability rated index  
IM - intramedullary 
IQR – Inter quartile range 













Figure 10-5 The difference in DRI in the ‘case’ and ‘control’ groups. Note that the DRI 
is a score between 1-100. However, during the data collection process, for the 
purpose of recording the score, it was recorded in the database as a score between 



















 HIV status 
Four of the ‘case’ participants (7%) had a diagnosis of HIV.(Table 10-6) This is 
compared to nine participants (15.8%) in the ‘control’ group, and all of the 
participants knew about their diagnosis prior to enrolment in the study. Out of the 
114 study participants, there were no new diagnoses of HIV on testing at enrolment 
to the study. Only 50% (2/4) of the cases and 44.4% (4/9) of the controls who were 
HIV-positive were taking ART and all were taking the same ART regimen (TDF, 3TC + 
ERV). Although there were only small numbers, the ‘control’ group of participants 
had been taking ART for a slightly longer period of time, compared to the cases (1376 
days vs 1172 days). The viral load (0.65 vs 2.56 log10 cps/ml) was higher (p-value = 
0.3) and the CD4 count (569 vs 393 cell.mm3) was lower (p-value = 0.2) in the ‘control’ 
group, (Figure 10-6) suggesting the participants with HIV in the ‘case’ group had 
better control of their HIV virus. However, it is acknowledged that due to the small 















 Household and socioeconomic characteristics 
The crowding index was higher in the ‘control’ group, compared to the cases (1.5 vs 
1.25, p-value=0.7). (Table 10-8, Figure 10-7) The crowding index is derived from the 
total household size divided by the number of living rooms. Higher crowding index 
has been shown to correlate with socioeconomic status.(415) The ‘control’ group 
had a lower number of participants with flushing toilets (51, 89.5% vs 54/57. 94.7%) 
and piped water (41/57. 71.9% vs 47, 82.5%) to their homes. Furthermore, the 
‘control’ participants had a lower level of completed education. (Table 10-8), overall 
suggesting that the ‘control’ participants may originate from a population of lower 
socioeconomic status. However, the ‘case’ participants had a higher unemployment 
rate (31/57, 54.4% vs 24/57, 42.1%) and fewer participants had electricity to their 
homes (54/57, 94.7 vs 57/57, 100%). Despite these differences in the two groups, 

























IQR – Inter quartile range 
a Total number of household members divided by the number of living rooms in household (kitchen or bathroom 
not included). 
 










Figure 10-8 The haemoglobin level of the ‘case’ and ‘control’ groups 
 
































 Open fracture and additional injuries  
There was a higher proportion of open fractures in the ‘control’ group compared to 
the cases (28/57, 49.1% vs 22/57, 38.6%, p-value=0.300).(Figure 10-12) Additionally, 
more participants in the ‘control’ group had additional injuries as well as their 
fracture at the time of injury (1/57, 26.3 vs 11/57, 19.3%, p-value=0.500) and had a 
higher injury severity score (IIS) (15/57, 26.3% vs 13/57, 22.8%, p-value=0.800). 
 
The higher the GA grade were more likely to be managed with a circular fixator. 
Therefore, there were more circular fixators used in the ‘control’ group when 
compared to the cases. (Table 10-12) 
 
A summary of the number of open fractures, additional injuries, summary of fixation 
















 Classification and fracture pattern 
It has been established that fractures that are unstable and comminuted are 
associated with problems of fracture healing. (193), (198), (404) However, it was the 
‘control’ study group that had a higher proportion of fractures that were classified as 
unstable or highly unstable compared to the ‘case’ study group using the AO 
classification system (Appendix 13-8) (28/57, 49.1% vs 24/57, 42.1%, p-value=0.6). 
Although these differences were not statistically different. (Figure 10-13) A summary 
of the number of fracture classification and x-ray parameters for the two study 















 Type of non-union 
Non-unions were categorised into two main types: hypertrophic, (the primary factors 
influencing non-union is mechanical) and atrophic/oligotrophic, (the primary factor 
influencing non-union is local fracture and/or systemic biology).(210) 
 
There were 32/57 (56.1%) atrophic and 25/57 (43.9%) hypertrophic non-unions in 
the ‘case’ study cohort. Of the four participants who were HIV-positive three (3/4, 
75%) had atrophic non-unions. The majority of non-unions that developed were 
following IM nailing (36/57, 63.2%), with 71.9% (23/36) of IM nailings non-unions 
resulting in atrophic non-unions in this study populations (p-value=0.08).(Figure 
10-14)  
 
A higher crowding index higher (1.4 vs 1, p-value=0.500) was seen in the in atrophic 
non-union subgroup, as was a lower albumin level (40.5 vs 46 g/L, p-value=0.800). 
(Figure 10-15, Figure 10-16) However, although both suggest nutritional and 
socioeconomic status may have an association with atrophic non-unions in this study 
cohort, with such small numbers and no formal validated assessment of 
socioeconomic status made, it is difficult to draw any valid conclusion and none were 
statistically significant.  
 
Open fractures (14/32, 43.7% vs 8/25, 32%, p-value=0.500), pedestrians hit by motor 
vehicle (15/32, 46.9% vs 10/25, 40.0%) and GSW fractures (6/32, 18.8% vs 3/25, 12%) 
resulted in a higher proportion of atrophic than hypertrophic non-unions. As 
discussed in previous chapters, open fractures and high energy mechanism of injury 
are associated with periosteal stripping and potential local vascular problems at the 
fracture site. To add further to this, atrophic non-unions were more unstable (17/32, 







A summary of the number of the non-union types and baseline parameters for the 







Classification    
Simple 
Complex - unstable 












IQR – Inter quartile range 
 
 


















Figure 10-15 The crowding index of the ‘case’ participants according to non-union 
type 
 





















CHAPTER 11. HIV IN ORTHOPAEDIC SKELTAL TRAUMA 2 STUDY 2: 
Analysis of the Primary and Secondary Outcomes and Discussion 
 
11.1 Aims of this chapter 
This chapter details the analysis of the primary and secondary outcomes of the HOST 
2 Study and ends with a discussion regarding the study. 
 
11.2 Results  
 Final study population 
The main study cohort of 57 non-union cases were matched with 57 union ‘control’ 
participants.  The primary outcome of fracture non-union was defined as one or both 
of the following: 
• Impaired bone healing at nine months on RUST score (RUST score < 9). (125), 
(126), (127), (128) 
 
Parameters and confounding factors included in the univariate and multivariable 
logistic regression model were: 
1. HIV status 
2. Age 
3. Sex 
4. Fracture management 
5. Fracture site 
6. Smoking status 
7. Open fracture 
8. Haemoglobin at baseline  






Of the 57 non-unions cases, 7.0% (4/57) occurred among HIV-positive participants, 
compared to 15.7% (9/57) in the controls. On univariate and multivariable logistic 
regression analysis, HIV was not statistically associated with the development of a 
non-union in the study population (univariate OR 0.40 [CI 0.10-1.32] p-value = 0.151, 
multivariable OR 0.85 [0.18-3.73] p -value = 0.831). 
 
The haemoglobin level was lower in the ‘control’ group (median 9.8 per 1 g/dL [8.02-
11.6]) participants than in the cases (median 13.2 per 1 g/dL [11.6-14.3]). The 
univariate (OR 1.55 [CI 1.31-1.89], p-value = 0.001) and multivariable analysis (OR 
1.64 [CI 1.33-2.09] p-value = 0.001) confirmed that the higher the level of 
haemoglobin, the more likely a participant was to have a non-union, both of which 
were statistically significant.  
 
Vitamin D level was lower in controls (median 50.4 per 1 nmol/L (39.5-60.0)) 
participants than in the cases  (median 59.65 per 1 nmol/L (44.8-73.6)) The univariate 
analysis, (1.03 [1.01-1.05] p-value = 0.005) showed that the higher the level of vitamin 
D in the study population, the more likely a participant was to have a non-union, but 
on multivariable analysis although this increase in risk of non-union was shown, it 
was not statistically significant (1.02 [1.00-1.05], p-value = 0.069). 
 
Age, sex or smoking were not shown to be associated with the development of non-
union on both univariate and multivariable analysis (Table 11-1). A summary of the 





























Vitamin D (IQR, 








0.005 1.02 (1.00-1.05) 0.069 
CI – Confidence intervals 







 Determining union and non-union using the RUST score – inter-observer 
reliability. 
Two independent reviewers (reviewer 1 and 2), blinded to the HIV status of the 
participant, reviewed all x-rays and determined union (controls) and non-union 
(cases) using the RUST score for the femur or tibia fracture. On four x-rays (4/114), in 
four participants, there was a lack of consensus between the two reviewers on the 
outcome. Therefore, a third reviewer was used to determine the outcome.  The third 
reviewer (reviewer 3) was again blinded to the HIV status of the participant and also 
the score the two reviewers had given for the x-ray they were reviewing. Out of the 
four disagreements, two were in cases participants and two were in a ‘control’.  
 
The inter-observer agreement, between reviewers 1 and 2, of the outcome of union 
or non-union using the final RUST score was 96.5% (Kappa = 0.93).  
 
The reviewers also determined the type of non-union a participant had developed 
(hypertrophic or atrophic/oligotrophic). The inter-observer agreement between the 








 Non-union in the HOST 1 and HOST 2 studies 
When combining the HIV-positive participants from the HOST 1 and HOST 2 studies 
there was a total of 96 fractures in 84 HIV-positive participants. Overall there were 
five non-unions that were HIV-positive all together (5.2%, 5/96), four of which were 
taking ART therapy (80%, 4/5). 
 
Note that as part of the HOST 2 study methodology a number of the non-unions and 
unions from HOST 1 were included in the HOST 2 study as cases. The HIV-positive 
participant from the HOST 1 study developed a non-union after recruitment for the 
HOST 2 study had closed. Therefore, this participant was not included in the final 
HOST 2 study population. Seven HIV-positive participants from the HOST 1 were 
included in the HOST 2 study as controls. When combining the data, these seven 
participants were removed. Therefore, there were 89 fractures in 77 HIV-positive 
participants included in this analysis.  
 
When analysing the CD4 count of the participants, the HIV-positive participants 
whose fractures had united had a mean CD4 count that was higher than that of the 
participants who developed non-union, in both ART naïve and participants taking 
ART. (Table 11-2, Figure 11-1. The CD4 count at baseline in the two studies combined 







11.3  Discussion – HOST 2 study 
 Principal findings 
The HIV in Orthopaedic Skeletal Trauma Study 2 showed that HIV status was not 
associated with the development of non-union following the management of tibia 
and femur fractures, on both univariate (OR 0.40 [0.10-1.32], p-value = 0.151) or 
multivariable (OR 0.86 [0.18-3.73], p-value = 0.831) logistic regression analysis. 
Higher levels of post-operative vitamin D and haemoglobin were shown to increase 
the odds of non-union on univariate analysis. However, on multivariable analysis of 
vitamin D level, this difference was found not to be statistically significant (OR 1.02 
[1.00-1.05] p-value = 0.069). However, the haemoglobin finding remained statistically 
significant on multivariable analysis (OR 1.64 [CI 1.33-2.09] p-value = 0.001). No other 
confounding factors was not shown to have any statistically significant impact on the 
odds of developing non-union in this study cohort, including open fracture and 
smoking. 
 
 HIV status in study population 
The prevalence of HIV in the case was 7% (4/57) and 15.8% (9/57) in the controls. 
There was an overall prevalence of 11.4% (13/114) in the study population. The 
prevalence of HIV in the HOST 1 study population was 19.8% (71/358 participants) 
and the national prevalence of HIV in South Africa is approximately 18.9%.(57), (58) 
As discussed previously, the prevalence in the Western Cape is much lower at 
5.6%.(57), (58) The overall prevalence in the HOST 2 study was therefore over double 
the region rate and although the prevalence appears to be low when compared to 
the HOST 1 study, this study population does in fact represent a cohort of the 
population with a higher prevalence of HIV compared to the regional average. 77.2 





that this study population are more likely to suffer a traumatic injury and have higher 
rates of HIV than the national average. 
 
Seventy-five percent (3/4) of the cases and 44.4% (4/9) of the controls who were HIV-
positive were taking ART. This is slightly higher than those in the HOST 1 study (69 % 
[49/71]) and the national average (61%). (53) The low number of participants make 
firm conclusions difficult, but this suggests that a higher proportion of participants 
on ART develop a non-union.  
 
The study sample size calculation anticipated a prevalence of 20% of HIV in the 
‘control’ group. Overall, the rates of HIV in both study ‘case’ and ‘control’ groups 
were lower than anticipated, as a result any conclusions need to be interpreted with 
caution. 
 
 Comparison with the published literature 
There have been no previously published case-control studies in the literature 
investigating HIV and fracture healing. As previously discussed in the HOST 1 study 
discussion, the literature to date has reported overall non-union rate of between 0-
11% (213), (367), (382), (389), (394), (439) in HIV-positive individuals following 
numerous different methods of fracture fixation. These reports cannot be compared 






 Parameters that influence the study outcome 
Socioeconomic factors 
The relationship between social deprivation and fracture healing was discussed in the 
HOST 1 study. In summary, there is no reliable evidence to confirm socioeconomic 
status as clear risk factor for the development of delayed or non-union or infection 
following fracture fixation.(454)  
 
The crowding index was slightly higher in the ‘control’ group compared to the cases 
(1.5 vs 1.25, p-value=0.7). The ‘control’ group had a lower number of participants 
with flushing toilets (51, 89.5% vs 54/57, 94.7%) and piped water (41/57, 71.9% vs 
47, 82.5%) to their homes. Furthermore, the ‘control’ participants had a lower level 
of completed education. Therefore, although no parameter was shown to be 
statistically different between the two groups, the ‘control’ participants may 
originate from a population of lower socioeconomic status compared to the ‘case’ 
group, but this is unlikely to have influenced the study outcomes. 
 
Smoking status 
There is strong evidence demonstrating the link between smoking, particularly 
nicotine, to problems with fracture healing.(163) However, in this study population, 
smoking was not found to be associated with the development of non-union on 
multivariable analysis (OR 1.24 [CI 0.47-3.30) p-value = 0.662) There were similar 
proportions of smokers in both the ‘case’ (23/57 40.4%) and ‘control’ (26/57, 45.6%) 
groups. This mirrored the findings from the HOST 1 study, were delayed union 
(multivariable OR 0.414 [CI 0.17-1.01] p-value = 0.113) and non-union (multivariable 
OR 1.67 [CI 0.68-4.67] p-value = 0.303) was not higher in those participants that 






The current prevalence of smoking South Africa is approximately 17.6%. It has been 
reported that males (29.2%) have a prevalence four times higher than that of females 
(7.3%) (OR 5.20 [CI 4.39 - 6.16] p-value = 0.001).(467) The prevalence in this study 
population is 43.0% (49/114), more than double the population average. This again 
highlights the potential high-risk taking behaviour of the study population group. The 
high smoking proportion in each group does not explain why, unlike in the 
established literature smoking was not shown to be a factor associated with the 
development of non-union in both studies. 
 
Blood parameters 
The haemoglobin (9.8 vs 13.2 g/dl, p-value=0.2), vitamin D (50.35 vs 59.65 nmol/L, p-
value=0.4) and albumin (35 vs 44.5 g/L, p-value=0.07) levels were all lower in the 
‘control’ compared to the cases, although none of the differences between the 
groups were statistically significant. All three of these blood parameters have been 
linked to problems of fracture healing and non-union in in vivo animal research.(146), 
(83), (147), (148), (174), (175), (158) Therefore, these findings are contrary to what 
would have been expected, with lower levels of haemoglobin, vitamin D and albumin 
anticipated in the cases. 
 
Univariate (OR 1.55 (CI 1.31-1.89), p-value = 0.001) and multivariable (OR 1.64 [CI 
1.33-2.09] p-value = 0.001) logistic regression analysis of the study cohort confirmed 
that the higher the level of haemoglobin a participant had, the more likely they were 
to have a non-union. This may be explained by the difference in the time between 
the date of injury and enrolment into the study for the cases compared to the 
controls (320 days [276-523] vs 180 [122-241] p-value = 0.001). cases had longer to 
recover from their injury and any surgery, potentially leading higher haemoglobin 
levels. 
 
Any effect on fracture healings that may result from lower levels of vitamin D, 





values for each blood parameter. For example, as discussed in chapter 9, vitamin D 
level in the cases and controls was within the ‘normal’ range and not < 25 nmol/L 
which is used by the National Institute for Health and Care Excellence as a definition 
of vitamin D deficiency. (448) Therefore, essentially, the values of vitamin D were 
very similar between each group and of limited clinical significance. 
  
Open fractures 
There was a higher proportion of open fractures in the ‘control’ group compared to 
the cases (28/57, 49.1% vs 22/57, 38.6%, p-value=0.3). It would be expected that the 
number of open fractures would be higher in the ‘case’ group, rather than the 
‘control’, since there is established evidence that open fractures have a higher rate 
of non-union. (210), (456), (457) Contrary to the HOST 1 study and published 
literature, open fractures were not shown to be a statistically significant risk factor 
for the development of non-union in the study population. 
 
This cannot be explained by the high number of GSWs in this study population as 
there was a similar proportion of GSWs in each of the two groups. Nine of the 22 
(40.9%) and eleven of 28 (39.3%) open fractures were GSW fractures in the ‘case’ and 
‘control’ group respectively. GSWs are open fractures by definition but the 
pathogenesis of how the fractures heal and outcomes are different from a GA grader 
II and above open fracture.(404), (468) 
 
The proportion of fractures that progressed to union following an open fracture in 
the HOST 1 study population was 32.8% (122/372). This is lower than the number in 
the ‘control’ group in this study (49.1%, 28/57). The proportion of non-unions that 
resulted from open fractures in the HOST 1 study was 65% (15/23), compared to 
38.6% (22/57) in this study. 
 
It may, therefore, be a combination of the number of open fractures in the ‘case’ 





‘control’ group being slightly higher than expected, due to the inclusion of GSWs as 
open fractures, that resulted in open fractures not being found to be a risk factor for 
non-union in this study populations.  
 
Conversely in the HOST 1 study, 54.7% (75/137, 54.7%) of open fractures were GSW 
and having an open fracture was shown to have a higher proportion of non-unions. 
In conclusion, it is not clear why open fractures were not shown to be a risk factor for 
the development of non-union in this study population, but it is likely to be the result 
of a small number of study participants. 
 
 Limitations of this work 
One of the main limitations of this study is the selection of ‘control’ participants. Once 
a participant was enrolled as a ‘case’, the study team commenced recruitment to 
identify an appropriate ‘control’ participant using a number of methods previously 
discussed in the methodology part of this thesis. During this process, no formal 
blinding to HIV status was undertaken and therefore this has the potential to 
introduce bias into the selection process. Furthermore, the participants were only 
matched for age, sex, management and fracture site. They were not matched for 
parameters such as day of the week admitted, day operated on or the operating 
surgeon. This was logistically not possible; however, it is acknowledged as limitation 
of the study. 
 
The initial sample size calculation, assumed that 20% of the controls would be HIV-
positive (368), (388), and therefore a total sample size of 128 (64 cases and 64 
controls) would give 80% power to detect at least an odds ratio of 3.0 for non-union, 
comparing between the case and controls groups. The prevalence of HIV was much 
lower (11.4% [13/114]) than 20% in the study population and therefore the study was 






The study included all participants who had developed a non-union, irrespective of 
the type of non-union that developed or the method of management for the fracture. 
Ideally, all cases should have been managed with one method of fixation and only 
one type of non-union included to limit the introduction of confounding factors.(116) 
 
The presence of established infection at the fracture site was an exclusion criterion. 
However, in a high proportion of non-unions, up to 40% have undiagnosed underlying 
infection.(210) If the fractured limb appeared infection-free on inspection, no 
microbiology assessment was included in the diagnosis of non-union. No intra-
operative microbiology samples following non-union surgery were assessed. 
Therefore, some of the cases included could have been undiagnosed infected non-
unions. 
 
Six participants were not matched with cases and therefore were excluded from the 
study and not included in the analysis. None of these participants were HIV-positive, 
but it is recognised that this could have introduced bias in the selection process, and 
ideally, matches should have been found. 
 
 Summary 
This is the first case-control study ever performed investigating non-union of a 
fracture in HIV-positive individuals. HIV was shown not to be associated with the 







CHAPTER 12. OVERALL DISCUSSION 
 Aims of chapters 
In this chapter a summary of the findings of this thesis will be discussed, and further 
details of the strengths and weaknesses of the work performed. Any health policy 
implications will be explored and suggestions for future work will be considered. 
 
 Principal findings of the research 
The primary hypothesis of this research was that HIV causes delayed bone union and 
is a risk factor for the development of non-union following a fracture. 
 
12.1.2.1 Delayed union 
This research demonstrates that HIV is not associated with the development of 
delayed union following an IM nailing for a fracture to the tibia or femur. (univariate 




The proportion of non-unions was statistically significantly lower in HIV-positive 
participants in the HOST 1 study, compared to HIV-negative participants. (univariate 
OR 0.16 [CI 0.01-0.78], p-value = 0.076, multivariable OR 0.17 [CI 0.01-0.92], p-value 
= 0.100) The HOST 2 further demonstrated no evidence of association between HIV 
status and the development of non-union, between cases and controls. (univariate 
OR 0.40 [CI 0.10-1.32] p-value = 0.151, multivariable OR 0.85 [0.18-3.73] p -value = 
0.831). In summary, HIV is not a risk factor for the development of non-union in either 
the HOST 1 or HOST 2 studies and fracture healing may be improved in HIV-positive 





 Secondary findings of research 
12.1.3.1 Delayed union 
In HIV-positive participants, there was no association between delayed union and the 
level of CD4 count (multivariable OR 1.00 [CI 0.97-1.00] p-value = 0.181) or viral load 
(multivariable OR 1.03 [CI 0.66-1.58] p-value = 0.897). 57.7% (41/71) of participants 
in the HOST 1 study were taking ART on enrolment. This increased to 69.0% (49/71) 
at six-month follow-up. The proportion of delayed union in ART naïve participants 
was higher at 23.3% (7/30), compared to 12.2% (5/41) in those participants taking 
ART on enrolment. However, the true effect of ART on delayed fracture union cannot 




The number of participants who developed non-union and were HIV-positive in both 
studies was low, making it difficult to draw any valid conclusions from this data. On 
combining non-union data from the HOST 1 and HOST 2 study, 80% (4/5) of the HIV-
positive participants who developed non-union were taking ART on enrolment. This 
is in comparison with 56% of HIV-positive participants who were taking ART and went 
on to fracture union when combining the HOST 1 and 2 studies data (HOST 1: 40/70, 
HOST 2: 5/9, combined: 45/79). Therefore, although ART was not shown to be a risk 
factor for delayed union or non-union on both univariate and multivariable analysis 
in the studies, a higher proportion of participants taking ART developed non-union, 
compared to ART naïve participants. This suggests that ART could be associated with 
an increase in the risk of non-union in HIV-positive participants, but more research is 
indicated 
 
When analysing the CD4 count of the participants on combining the studies, HIV-





higher than that of the participants who developed non-union (CD4 262 cell/mm3 
[IQR 201-365] vs CD4 451 cell/mm3 [IQR 264-640]).  
 
12.1.3.3 Infection 
There was a low number of SSIs in the HOST 1 study (6%, 6/395), making conclusions 
difficult be drawn from this data. However, the proportion of SSIs in HIV-positive 
participants was lower than in the HIV-negative cohort (1.2%, 1/83 vs 1.6% 5/312).  
 
The rate of DSIs was higher in the HIV-positive participants (8.4% [7/83]) vs 4.5% 
[14/298]), however this difference was not significant on multivariable analysis (OR 
2.59 [CI0.86-7.80] p-value- = 0.090). When combining the number of DSI and SSI in 
the HIV-positive participants in this study to give a rate of ‘early implant infection’, 
HIV-positive participants had an infection rate of 9.6% (8/83) compared to 6.1% 
(19/312) in the HIV-negative population. The infection rate was therefore still higher 
in the HIV-positive participants, compared to controls. Furthermore, rates of DSI in 
HIV-positive participants was slightly higher in this study population than that 
published in the literature for HIV-negative individuals.(434) 
 
Only 1.7% (7/395) of the study population developed late implant infection. A higher 
proportion of HIV-positive participants developed late implant infection than HIV-
negative (6.0%, 5/83 vs 0.6%, 2/310), but this was not statistically significant on 
univariate analysis.  
 
In summary, the proportion of DSIs and late infections in HIV-positive participants 
appears to be higher than HIV-negative equivalents, but this did not reach statistical 







 Comparisons with literature and interpretation of results 
A full comparison with the literature for each of the HOST 1 and 2 studies has already 
been discussed in Chapters 9 and 11. In summary, the overall outcomes in the study 
population of non-union and post-operative infection, irrespective of HIV status, are 
similar to published literature.(114), (116), (188), (431), (433), (435), (436), (437) 
There has been no previously published research investigating delayed bone union 
and HIV. However, proportion of non-unions in HIV-positive participants was similar 
to previously published literature. (366), (367), (368), (369), (382) The outcome of DSI 
and SSI infection was on the lower end of published reports to date in HIV-positive 
participants, but higher than the literature reports in HIV-negative individuals. This 
study reported late implant infection rates higher in the HIV-positive participants, 
contrary to the most recently published literature. (213), (388)  
 
12.1.4.1 Delayed union and non-union 
HIV affects a number of chemical mediators and cytokines which have been shown 
to play a role in the fracture repair process.(5), (6), (7) HIV and ART have both been 
shown to reduce bone mineral density (BMD), bone mineralisation and bone 
turnover.(8), (9), (10), (11) In the general population, it has been postulated that a 
reduced BMD is associated with a reduced speed of fracture healing. A major factor 
known to affect fracture healing is local blood flow to the site of the injury. It is now 
well established that HIV infection is associated with osteonecrosis – due to 
interruption in osseous blood supply.(12) Conditions that jeopardise arterial flow to 
the site of primary bone healing are associated with higher rates of delayed fracture 
healing and non-union.(15), (16), (17) Finally, a small number of studies have 
investigated the role of HIV in the fracture healing process. These have suggested 
that HIV and/or ART may be associated with delayed fracture healing and result in 
non-union.(18), (19) Other researchers have suggested that HIV may impair fracture 





Despite all the published literature, this study demonstrated the HIV status does not 
appear to affect the fracture healing process and may potentially lower the risk of 
non-union. The reason for this possible improvement cannot be fully determined 
from this research but potential reasons can be discussed but are speculative.  
 
The initiation of fracture healing is stimulated by local release of pro-inflammatory 
cytokines, such as TNF-α, IL-1 and IL-6, activate cytokine cascades which trigger the 
recruitment and differentiation of cells involved in the formation of callus and 
fracture healing. Despite HIV resulting in immunosuppression, TNF-α is raised and 
individuals are in a consistently ‘hyperinflammatory state’.(19) (224), (226) ,(227), 
(228), (229) The effect of this on fracture healing is not known. Chronically raised 
TNF-α could theoretically lead to desensitisation, preventing or decelerating the 
fracture healing process to the detriment HIV-positive individuals following a 
fracture.(19) (224), (226) ,(227), (228), (229) Alternatively, the continuous 
‘hyperinflammatory state’ could prime the body for an inflammatory response to a 
fracture. This could result in a highly efficient up regulation of cytokines, ultimately 
improving fracture healing and this alternative explanation could assist in explaining 
the findings in this study. 
 
Bone formation is inhibited by CD8 T cells and this has been demonstrated in a 
number of in vivo studies.(244), (245) In a mouse model, Reinke et al, demonstrated 
that depletion of CD8 T cells improved fracture callus formation and bone mineral 
density. Additionally, increasing the CD8 T cell population resulted in delayed fracture 
callus formation and decreased bone mineral density.(245) HIV is able to decrease 
the circulating pool of CD8 T-cells that are able to combat viral infection. This is 
carried out by disturbing the function of CD4 T-cells and antigen presenting cells that 
are needed for appropriate CD8 T-cell maturation.(244) This results in a decrease in 
of CD8 T-cell function. This downregulation in CD8 T cells in HIV-positive individuals 
could theoretically result in a subsequent improvement in fracture healing, not seen 





The overall effect of T cells on bone depends on their activation state. As well as CD8 
T cells, activated CD4 T cells promote bone loss in inflammatory diseases such as 
rheumatoid arthritis(233) and periodontitis.(242) Conversely, resting CD4 T cells may 
contribute to dampening of bone resorption in vivo.(238) T cell-deficient mice have 
significantly increased bone resorption and reduced bone density, as compared to 
controls.(243) HIV results in an inflammatory process, although it is not by definition 
an inflammatory disease. CD4 T cells could behave in a similar way as in rheumatoid 
arthritis and resulting bone loss. However, depending on the stage of the HIV 
infection and if an individual is on ART, the activation of the CD4 T cells could change 
and as a result so could how they affect bone and ultimately fracture healing. A full 
understanding of the role of CD4 T cells have in fracture healing is not fully 
understood. However, they could have an impact on the results seen in this study, 
but more research is needed surrounding the mechanism of T cell action on the 
fracture repair process. 
 
The overall study population represent a socially and economically deprived group of 
the population in the Western Cape, with 73% (250/342) of participants living in a 
township. The low rates of nonunion and delayed union in the HIV-positive 
participants, may reflect the poorer overall health status of the HIV-negative cohort. 
HIV-positive participants who are aware of their diagnosis, may be more likely to be 
engage with their own health and well-being compared to HIV-negative participants 
in this study population. This is due to the likelihood that, because of their diagnosis, 
they will have contact with health care and health care providers. 57.7% (41/71) of 
HIV-positive participants were on ART on enrolment and therefore were receiving 
their therapy from some form of health provider. People living with HIV who survive 
the first year of ART treatment are likely to live as long as people without HIV and 
have overall similar health outcomes. (469) Therefore, having a diagnosis of HIV could 
in theory result in participants engaging with their own health and an overall 





suggested difference is hypothetical and there was no clear evidence of this in the 
study population.  
 
HIV-positive participants in the HOST 1 study had a lower proportion of smokers 
(44.6% [37/83] vs 55.5 [174/312] p-value = 0.090) and open fractures (26.5% [22/83] 
vs 36.9% [115/312] p-value = 0.100) in their study population compared to HIV-
negative equivalents. These are established parameters that increase the risk of non-
union.(163), (437) Therefore, collectively differences seen in the HIV-positive and 
negative populations and the ‘case’ and controls cannot completely explain the 
results seen in this study population, but they could have contributed. 
 
In summary, an explanation for the findings in this study cannot be fully determined 
but there are a number of potential immunological factors to consider and others 
that may not be known yet. Additionally, the findings could also be the result of 
population difference in enrolled study cohorts.  
 
12.1.4.2 Anti-retroviral therapy and CD4 count 
A number of ART drugs have been implicated in the emerging evidence that the 
therapy plays a role in HIV-associated bone disease. Evidence to date appears to 
implicate TDF as having the clearest detrimental effect on bone. (306), (307), (308), 
(309) The HIV-positive participants were all taking TDF in combination with other 
therapies. In this study, ART appeared not to influence the outcome of delayed union 
but potentially resulted in a higher risk of non-union. No definitive conclusions can 
be made from the study data due to the low numbers of HIV-positive participants 
taking ART on enrollment (69%, 49/71). More research is needed to address this still 
unanswered question. 
 
Any effect ART has on bone usually occurs in the first 12 months following 





was the most relevant time point to use, since although more participants were 
taking ART at six months, any effect on bone may not have fully occurred at this time 
point.  
 
12.1.4.3 CD 4 count 
As discussed earlier, the role of CD4 T cell on bone formation and fracture healing is 
poorly understood. The median and mean CD4 cell count in the delayed union 
participants were similar (median CD4 460 cell/mm3 [IQR 366 -477] / mean CD4 449 
cell/mm3 [263-641]) to healed participants (median CD4 413 cell/mm3  [IQR 295-673] 
/ mean CD4 454 cell/mm3 [IQR 328-621]) [p-value = 0.400]). However, the HIV-
positive participants whose fractures had united had a mean CD4 count that was 
higher than that of the participants who developed non-union (CD4 262 cell/mm3 
[IQR 201-365] vs CD4 451 cell/mm3 [IQR 264-640]). Although the number of 
participants who developed non-union was small, CD4 count appears to be lower in 
these participants. Future research is needed to clarify these differences, since when 
combining the HOST 1 and 2 studies, there were only five non-unions. As a result, it 
is not possible to draw any statistically significant conclusions from this data. The 
reason for displaying the mean rather than the median is due to the low number of 
participants who developed, while non-union and for lower numbers reporting the 
mean is more appropriate.(470) 
 
12.1.4.4 Infection 
HIV principally affects a patient’s immunological status by reducing the host CD4 T 
cell count, resulting in an increase in the risk of a patient developing opportunistic 
infections. Therefore, it would be anticipated that there could be higher post-






The proportions of participants with DSI and late implant infection in the HOST 1 
study were higher the in HIV-positive population, although no statistical significance 
was found compared the HIV-negative cohort. This could be due to the low numbers 
of participants enrolled to detect a difference. 
 
The proportions of DSI and SSI in HIV-positive participants in this study population 
were on the lower end of those reported in HIV-positive individuals in the literature. 
However, they were higher than the reported rates in HIV-negative individuals, as 
well as in the study cohort. A higher proportion of HIV-positive participants presented 
with late infections in the study population, compared to HIV-negative participants 
and this is again higher than the published literature.(388)  
 
Over half of all DSIs (57.1% 12/9) and 42.9% (3/7) of late infections were following 
open fractures. Over one third of the final study population were enrolled following 
an open fracture (34.7% [137/395]). Open fracture are an established risk factor for 
the development of post-operative infection following fracture surgery.(471) 
Therefore, this is likely to substantially impact the outcomes of infection in the study 
population, and provide an explanation for the slightly higher proportions of infection 
in the HIV-positive cohort. More research is needed to enable definitive conclusions 







 Limitations of the research  
In both the HOST 1 and HOST2 studies, a varying number of participants were taking 
ART. Determining the true effect of ART on fracture healing and also HIV independent 
of ART would require a much larger sample size of HIV participants, taking a 
considerably longer period of time. This would not have been possible in the study 
timeline. This does, however, represent a potential confounding fact when 
interpreting the results. 
 
GSWs were included in both studies and classified as open fractures according to the 
GA grading system. The majority of GSW fractures were from low velocity guns 
(96.8% [96.8]) and classified as GA type I open fractures. At both study sites, GSW 
fractures are treated as closed injuries. This is very different to the approach in a high-
income setting, were they are managed as open fractures. The outcomes of low 
velocity GSW, which represent most GSWs injuries were in the study, are different to 
that of the GA grade II and above fractures.(468) In fact, the outcomes of all GA I 
fractures are different to GA grade II and above. Therefore, the inclusion of GSW 
fractures and other GA I in the analysis of open fractures, has the potential to 
introduce errors in the interpretation of the outcomes in the open fracture study 
population. 
 
In both the HOST 1 and 2 studies, there was a higher proportion of males compared 
to females, due to the nature of trauma in this study population. Males are more 
likely to smoke, have lower overall CD4 counts (472) given in HIV-negative individuals, 
and present a significant confounding factor when interpreting the results.  
 
Further limitation of the HOST 1 and 2 studies have been discussed independently in 






 Future studies 
The HOST 1 and HOST 2 studies suggest that that fracture healing is the same 
irrespective of HIV status and could even be better in HIV-positive participants. 
However, there are a number of areas would benefit from future research to address 
some unanswered questions. 
 
The following list of potential future research studies are suggested following the 
completion of this research; 
 
a) Non-union: A mirrored study to the HOST 1 study with a larger sample size to 
assess if fracture healing is improved by HIV, focusing on non-union as the 
primary outcome. This would ultimately mean a larger number of participants 
would need to be recruited but it would confirm if fracture healing is improved in 
HIV positive individuals. To address the need for a larger sample size, the study 
could be expanded across multiple sites to reach the necessary size study sample 
in an appropriate period of time. This study should aim to further explore the 
reasons surrounding why this potential difference exists. The inclusion of 
accurate measurement of CD4 count to determine how it influences fracture 
healing outcome would be useful. 
 
Primary research question: Does HIV-positive status result in improved bone healing 
following fracture? 
Hypothesis: HIV-positive status results in improved bone healing following a fracture. 
Study design: A multi-centre prospective case-cohort study of participants 
undergoing fracture surgery. All adult participants with fresh tibia and femur 
fractures who undergo IM nailing for fracture fixation will be eligible for inclusion.  







b) ART: In order to determine the effect of ART on fracture healing, an appropriately 
designed study with an adequate sample size is required. Ideally, it would 
investigate the effect of ART on fracture healing on participants who are HIV-
negative. That way, any effect of HIV on fracture healing would be negated. 
However, the only reason for a participant being on ART without having HIV 
would be for Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexual 
transmission of HIV. This is being trialed in the UK but only 1600 people were 
taking it as of April 2018.(473) With such low the numbers of people taking PrEP, 
any study in this cohort is simply not feasible. (474)  
 
An alternative would be to undertake a study enrolling two different, 
appropriately sized cohorts of HIV-positive ART naive and those taking ART and 
subsequently assessing fracture union in the two study groups. This would also 
enable the true effect of HIV on fracture healing in ART naïve participants to be 
assessed. ART does not appear to be a risk factor for the development of delayed 
bone union in this study. Therefore, it is recommended that any future studies 
focus on non-union, rather than delayed union. Again, in order to achieve an 
appropriate sample size, the study will need to be undertaken across multiple 
sites and potentially different countries. 
 
Primary research question: Does taking ART result in non-union following fracture? 
Hypothesis: ART is a risk factor for the development of non-union following a 
fracture. 
Study design: A multi-centre prospective matched case-control study of participants 
presenting with non-unions following a fracture. HIV positive adult who develop a 
non-union of the tibia and femur following a fracture (cases) will be matched with 
HIV positive individuals whose fractures have healed following a tibia or femur 
fracture (controls). An assessment of the proportion of participants taking ART in 
both cases and controls will be made to determine if a higher proportion of cases are 





Primary outcome Non-union at 9 months post injury (RUST score < 9 on three 
cortices). 
 
c) Infection: The proportion of participants with open and closed fractures who 
were HIV-positive who developed DSI and late implant infection was higher than 
those who were HIV-negative. Overall, the number of participants who developed 
infections was not sufficient to fully determine the effect of HIV on post-operative 
infection following fracture fixation. However, from these preliminary findings, 
further studies investigating the outcome of infection in HIV-positive participants 
in both open and closed fractures would be beneficial. If the rate of infection was 
higher in HIV-positive participants, it would be important to established why and 
to look at possible interventions to reduce this potential outcome. One of the 
main challenges likely to be faced in this study would be the large sample sizes 
needed and again in order to achieve an appropriate sample size the study will 
need to be undertaken across a number of sites and countries. 
 
Primary research question: Does HIV-positive status result in an increased risk of 
infection following fracture? 
Hypothesis: HIV-positive status is a risk factor for the development of infection 
following a fracture. 
Study design: A multi-centre prospective case-cohort study of participants 
undergoing fracture surgery. All adult participants with fresh tibia and femur 
fractures who undergo IM nailing for fracture fixation will be eligible for inclusion.  
Primary outcome: Deep surgical site infection within 30 days of injury (closed 







d) HIV infection: In the HOST 1 study there was some suggestion that the longer a 
participant had had a diagnosis of HIV the more likely they were to develop 
delayed union. Furthermore, DSI was more likely in those participants who had 
been diagnosed for a shorter period of time. In addition, the longer the period of 
time on ART the more likely a participant was to develop delayed union. The 
shorter the period of time on ART, the more likely a participant was to develop a 
DSI. However, due to the low of participants who developed each outcome, no 
definitive conclusion can be drawn from these results. Therefore, a study to 
assess if the length of time an individual has been living with HIV and if the length 
of time, they have been taking ART influences the risk of the development of 
delayed union and post-operative infection following a fracture would be 
beneficial. If any of these findings were shown to be significant, alternative ART 
could be recommended and approaches to limit any effect union be explored. 
 
Primary research question: Does the length of time an individual has been living with 
HIV and/or taking ART increase their risk of the development delayed union following 
fracture? 
Hypothesis: The longer period of time an individual has been living with HIV and/or 
taking ART is a risk factor for the development of delayed bone healing following a 
fracture. 
Study design: A multi-centre prospective case-cohort study of participants 
undergoing fracture surgery. All adult participants with fresh tibia and femur 
fractures who undergo IM nailing for fracture fixation will be eligible for inclusion.  










Primary research question: Does the length of time an individual has been living with 
HIV and/or taking ART increase their risk of the development infection following 
fracture? 
Hypothesis: The shorter period of time an individual has been living with HIV and/or 
taking ART is a risk factor for the development of infection following a fracture. 
Study design: A multi-centre prospective case-cohort study of participants 
undergoing fracture surgery. All adult participants with fresh tibia and femur 
fractures who undergo IM nailing for fracture fixation will be eligible for inclusion.  
Primary outcome: Deep surgical site infection within 30 days of injury (closed 
reduction of fracture) or 90 days (open reduction of fracture).(363) (Appendix 13-5) 
 
 Health policy implications 
As discussed, previous basic science research studies have suggested that HIV 
infection may be associated with delayed and non-union of fractures.(19) A number 
of clinical research studies highlight that caution is to be used when considering the 
use of internal fixation in managing HIV-positive individuals following a fracture and 
the removal of all such implants in HIV-positive individuals should be considered. This 
feeling was echoed by numerous other study groups. (364), (366), (387), (397), (475) 
This has meant in many countries in sub-Saharan Africa and across the world, health 
care providers manage HIV-positive trauma patients differently to those without HIV. 
This study demonstrates that internal fixation is safe and as effective in HIV-positive 
participants as HIV-negative. 
 
The vast majority of people living with HIV are located in low-and middle-income 
countries, with an estimated 68% living in sub-Sharan Africa. (30) Among this group, 
20.6 million are living in East and Southern Africa which saw 800,000 new HIV 






Ninety-one percent of the people living with HIV are from a low- or middle-income 
country.(476) Musculoskeletal disease represents a large proportion of the burden 
of disease in low-and middle-income countries, but is often a neglected issue that 
goes untreated.(477) It is estimated that more than 90% of injury-related deaths 
worldwide occur in these countries,(64) accounting for approximately the same 
number of deaths as malaria, tuberculosis and HIV/acquired immunodeficiency 
syndrome (AIDS) combined.(478) By 2020, it is expected that seven out of ten deaths 
in LMICs will be as a result of non-communicable disease, with road traffic accidents 
rising to the third leading cause of death.(479) 
 
With increases in the number of people globally having access to ART, the number of 
people dying from HIV is decreasing. Therefore, although infection rates have been 
shown to be decreasing in some countries,(30) the number of people living with HIV 
is not, and the prevalence is even increasing in areas of South Africa.(480) Therefore, 
the number of people presenting with fractures who are infected with HIV is likely to 
increase. Therefore, low- and middle-income countries have a high burden of trauma 
and a high burden of HIV. 
 
Despite this, currently, other than scientific publications, there is no national or 
international public health policy promoting or educating health care providers about 
the most up to date evidence for the management of fractures or trauma in HIV-
positive individuals. Therefore, engagement from international health policy with this 
important public health problem to promote the most up-to-date evidence and 








This research disproves the primary hypothesis set at the beginning of this thesis. The 
HOST 1 and 2 studies demonstrate that HIV is not associated with the development 
of delayed union following fracture of the tibia or femur. Additionally, HIV-positive 
status appears to be associated with lower risk of developing a non-union. 
 
In conclusion, the evidence from this study suggests that fractures sustained in HIV-
positive participants can be managed in the same way as those who are HIV-negative, 
with no increased risk of delayed or non-union.  
 
Future areas of research are indicated to assess the role of ART and CD4 count on 
fracture healing and post-operative infections outcomes following fracture surgery 
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Appendix 13-2. HOST Study consent form 
 
3rd January 2019 Version 8 
INFORMED CONSENT FORM 1 
Institution: Groote Schuur Hospital 
Investigators: DR Graham, SM. DR. Held, MS. Dr Maqungo S.  
 
THE INFORMATION BELOW WILL BE SUPPLIED TO ALL PARTICIPANTS TAKING PART IN THIS STUDY. 
What is this study about? 
HIV and its treatment, known as antiretroviral therapy (ART), have been shown to affect how bone 
cells work and the risk of infection. Researchers have suggested that they may result in a bone taking 
longer to heal, or not healing at all following a break in the bone and increase the risk of infection. 
However, the effects of HIV and ART on bone healing and infection are poorly understood. 
This research study is being carried out to determine the effect of HIV and ART on infection and bone 
healing. We would like to ask you to be part of this study. With this data, we will hopefully improve 
future care for HIV infected patients around the world and provide them with the best possible 
treatment following a traumatic injury. 
We would like to offer you an HIV test if you do not know your status.  This testing is offered to all of 
our patients, regardless of your participation in this study.  You can therefore test for HIV without 
taking part in our study. Please be reassured that your HIV test result and any subsequent treatment 
will be kept confidential. 
As well as the HIV test, we would like to measure certain parameters in your blood to look at the way 
your body reacts to your injury. This will be a single test at the start of the study, if you decide to take 
part. We may also ask to undertake an additional blood sample during your follow-up. The samples 
may also be stored for future research. 
As well as measuring the reaction of the cells in your blood, depending on why you have been recruited 
to the research study we may also like to measure how the cells are working in your bone. This will 
involve taking a small sample from the inside of your bone during the operation. It is normal to remove 
some of your bone in order to perform your operation. Normally these samples are discarded. We 
would like to use these samples, that are normally discarded, to analyse your bone, assess certain 
parameter in your bone and see how your bone cells work. We would also potentially store these 
samples for future research into this area. The reason for taking these measurements are because it 
is thought if a person has HIV the body’s cells react and work differently to a patient without HIV. 





Throughout your treatment, as well as assessing how your bone is healing, we will assess your overall 
physical, emotional and mental health to fully understand the impact your injury has had on you. This 
will be in the form of questionnaires and patient recorded outcome measures. If we determine that 
you need any further assessment, support or treatment by any other medical speciality, unrelated to 
your orthopaedic injury, this will be organised by the research team. If your injury is the result of 
interpersonal violence we will also enquire about the nature of this injury, how it was sustained and if 
this is the first injury you have sustained as a result of interpersonal violence. 
You will also be asked to undergo a measurement of your bone mineral density as part of the study. 
This involves a simple bedside test, measuring the density of bone in your heel during your time in 
hospital. The test is non-invasive, painless and uses special X-rays in very small doses. This puts no risk 
to your health. The reason for doing this investigation is because it is thought that if a person has HIV, 
their bone density is lower than someone with out HIV. Therefore, in theory this may affect how well 
bones heal. However, no one knows if this is true and our study will help provide an answer. 
Why have I been selected to be in the study? 
You have been selected due to the type of broken bone you have sustained and the type of operation 
you have had. Patients who have had a break to the tibia or femur bone and have a nail used to fix the 
broken bone or patients who present with a tibia or femur bone that has not healed are being asked 
to be in the study. You may also be asked to be involved in the research as if you have undergone non-
operative (plaster cast) or operative management for a break to the tibia or femur bone and your bone 
is in the process of healing or it has healed.  
What will it involve for me?  
You will be treated no differently to anyone who does not take part in this study and undergo the 
same number and type of investigations, including x-rays. We may follow you up at regular intervals 
over the next 2 weeks – 12 months, depending how quickly your bones heal. This normally involves 5 
clinic visits at 2 weeks, 6 weeks, 3 months, 6 months, and 9 months. At one year you will receive a 
telephone consultation. If you need a clinical appointment at one year for ongoing clinical care then 
you will be seen in the outpatient clinic. At the end of this study, if you are still needing treatment, 
you will continued to be managed by the orthopaedic team for your injuries.  
Depending on the reason why you were recruited to the research study, you may not be required to 
return for follow up as part of the research study and if this is the case you will continue to be managed 
by the orthopaedic team for your injuries if this is required. 
You will be provided with pre and post HIV testing counselling by our trained staff, offered treatment 
and referred on to the appropriate care services if appropriate. 
Are there any risks or disadvantages for me taking part? 






Are there any benefits for me? 
There are no additional medical benefits for you but your travel to clinic follow up at 6 weeks and 6 
months will be reimbursed. You will also receive a payment on enrolment. This reimbursement on 
enrolment and at 6 weeks and 6 months will be 150 rand. No further reimbursements will be given. 
What happens if I refuse to participate? 
All participation in research is voluntary. You are completely free to decide if you want to take part or 
not and can make that decision up until  you are due to be discharged. If you do agree  to take part 
can change your mind at any time and withdraw from the research. This will not affect your care now 
or in the future. 
Who will have access to information about me in this research? 
All data will be registered to a study identification code.  Only the local investigators have access to 
the key of the coding, so identifiable data will not leave the participating centres. Any additional staff 
involved (Research assistants, statisticians) with the research project will only see your data WITHOUT 
your personal details.  The data will be stored indefinitely.  
Who has allowed this research to take place? 
Our departmental research committee and the local ethics committee have looked carefully at this 
work and agreed, that the research will be conducted properly and participants’ safety and rights have 
been respected. 
What if I have any questions? 
You may ask any of our staff questions at any time.  Your contact person for this study is: 
Prof. S Maqunga. Division of Orthopaedic Surgery 
Secretaries: University of Cape Town, Mrs. Priest, tel.  021 404 5108. Bernadette.priest@uct.ac.za 
If you want to ask someone independent anything about this research: 
If you have any questions, concerns or complaints about this research study, its procedures, risks and 
benefits, or alternative courses of treatment, you should ask the Chairperson of the Human Research 








Appendix 13-3. HOST Study patient information leaflet 
 
PATIENT INFORMATION 
Version 8. 3.1.2019 
Institution: Groote Schuur Hospital 
Investigators: DR Graham, SM. DR. Held, MS. Dr Maqungo S.  
 
THE INFORMATION BELOW WILL BE SUPPLIED TO ALL PARTICIPANTS TAKING PART IN THIS STUDY. 
What is this study about? 
HIV and its treatment, known as antiretroviral therapy (ART), have been shown to affect how bone 
cells work. Researchers have suggested that they may result in a bone taking longer to heal, or not 
healing at all following a break in the bone and increase the risk of infection. However, the effects of 
HIV and ART on bone healing and influences infection are poorly understood. 
This research study is being carried out to determine the effect of HIV and ART on bone healing and 
the risk of infection. We would like to ask you to be part of this study. With this data, we will hopefully 
improve future care for HIV infected patients around the world and provide them with the best 
possible treatment following a traumatic injury. 
We would like to offer you an HIV test if you do not know your status.  This testing is offered to all of 
our patients, regardless of your participation in this study.  You can therefore test for HIV without 
taking part in our study. Please be reassured that your HIV test result and any subsequent treatment 
will be kept confidential. Additionally, the result of the test does not influence your involvement in the 
study. Both HIV-positive and HIV negatibe patients are included in the research. 
As well as the HIV test, we would like to measure certain parameters in your blood to look at the way 
your body reacts to your injury. This will be a single test at the start of the study, if you decide to take 
part. The samples may also be stored for future research. We may also ask to undertake an additional 
blood sample during your follow-up. 
As well as measuring the reaction of the cells in your blood we would also like to measure how the 
cells are working in your bone. This will involve taking a small sample from the inside of your bone 
during the operation. It is normal to remove some of your bone in order to perform your operation. 
Normally these samples are discarded. We would like to use these samples, that are normally 
discarded, to analyse your bone, assess certain parameters in your bone and see how your bone cells 
work. We would also potentially store these samples for future research into this area. The reason for 
taking these measurements are because it is thought if a person has HIV the body’s cells react and 
work differently to a patient without HIV. Therefore, by measuring them we hopefully can see if this 





You will also be asked to undergo a measurement of your bone mineral density as part of the study. 
This involves a simple bedside test, measuring the density of bone in your heel during your time in 
hospital. The test is non-invasive, painless and uses special X-rays in very small doses. This puts no risk 
to your health. The reason for doing this investigation is because it is thought that if a person has HIV, 
their bone density is lower than someone with out HIV. Therefore, in theory this may affect how well 
bones heal. However, no one knows if this is true and our study will help provide an answer. 
Why have I been selected to be in the study? 
You have been selected due to the type of broken bone you have sustained and the type of operation 
you have had. Patients who have had a break to the tibia or femur bone and have a nail used to fix the 
broken bone or patients who present with a tibia or femur bone that has not healed are being asked 
to be in the study. You may also be asked to be involved in the research as if you have undergone non-
operative (plaster cast) or operative management for a break to the tibia or femur bone and your bone 
is in the process of healing or it has healed.  
What will it involve for me?  
You will be treated no differently to anyone who does not take part in this study and undergo the 
same number and type of investigations, including x-rays. We may follow you up at regular intervals 
over the next 2 weeks – 12 months, depending how quickly your bones heal. This normally involves 5 
clinic visits at 2 weeks, 6 weeks, 3 months, 6 months, and 9 months. At one year you will receive a 
telephone consultation. If you need a clinical appointment at one year for ongoing clinical care then 
you will be seen in the outpatient clinic. At the end of this study, if you are still needing treatment, 
you will continued to be managed by the orthopaedic team for your injuries.  
Depending on the reason why you were recruited to the research study, you may not be required to 
return for follow up as part of the research study and if this is the case you will continue to be managed 
by the orthopaedic team for your injuries if this is required. 
You will be provided with pre and post HIV testing counselling by our trained staff, offered treatment 
and referred on to the appropriate care services if appropriate. 
Are there any risks or disadvantages for me taking part? 
You will have exactly the same risks as someone with your injury not taking part in this study. 
Are there any benefits for me? 
There are no additional medical benefits for you but your travel to clinic follow up at 6 weeks and 6 
months will be reimbursed. You will also receive a payment on enrolment. This reimbursement on 
enrolment and at 6 weeks and 6 months will be 150 rand via a Standard Bank Voucher to collect from 
any Standard Bank ATM. You may need to attend your normal clinic follow up other than the above 
times but these will not be reimbursed. No further reimbursements will be given. 





All participation in research is voluntary. You are completely free to decide if you want to take part or 
not and can make that decision up until you are due to be discharged. If you do agree to take part can 
change your mind at any time and withdraw from the research. This will not affect your care now or 
in the future. 
Who will have access to information about me in this research? 
All data will be registered to a study identification code.  Only the local investigators have access to 
the key of the coding, so identifiable data will not leave the participating centres. Any additional staff 
involved (Research assistants, statisticians) with the research project will only see your data WITHOUT 
your personal details.  The data will be stored indefinitely.  
Who has allowed this research to take place? 
Our departmental research committee and the local ethics committee have looked carefully at this 
work and agreed, that the research will be conducted properly and participants’ safety and rights have 
been respected. 
What if I have any questions? 
You may ask any of our staff questions at any time.  Your contact person for this study is: 
Prof. S Maqunga. Division of Orthopaedic Surgery 
Secretaries: University of Cape Town, Mrs. Priest, tel.  021 404 5108. Bernadette.priest@uct.ac.za 
If you want to ask someone independent anything about this research:If you have any questions, 
concerns or complaints about this research study, its procedures, risks and benefits, or alternative 
courses of treatment, you should ask the Chairperson of the Human Research Ethics Committee, Prof 







Appendix 13-4. Superficial surgical site infection  
Criterion Must meet the following criteria: Superficial incisional Surgical Site Infection (SSI)  
 Date of event for infection occurs within 30 days after any NHSN operative 
procedure (where day 1 = the procedure date)  
AND  
involves only skin and subcutaneous tissue of the incision  
AND  
patient has at least one of the following:  
 
a. purulent drainage from the superficial incision.  
b. organisms identified from an aseptically-obtained specimen  
from the superficial incision or subcutaneous tissue by a culture or non-culture 
based microbiologic testing method which is performed for purposes of clinical 
diagnosis or treatment (e.g., not Active Surveillance Culture/Testing (ASC/AST).  
c. superficial incision that is deliberately opened by a surgeon, attending physician 
or other designee and culture or non-culture based testing is not performed.  
 
AND  
patient has at least one of the following signs or symptoms: pain or tenderness; 
localized swelling; erythema; or heat.  
d. diagnosis of a superficial incisional SSI by the surgeon or attending physician or 









The following do not qualify as criteria for meeting the NHSN definition of 
superficial SSI:  
· _Diagnosis/treatment of cellulitis (redness/warmth/swelling), by itself, does not 
meet criterion “d” for superficial incisional SSI. Conversely, an incision that is 
draining or that has organisms identified by culture or non-culture based testing 
is not considered a cellulitis.  
· _A stitch abscess alone (minimal inflammation and discharge confined to the 





· _A localized stab wound or pin site infection- Such an infection might be 
considered either a skin (SKIN) or soft tissue (ST) infection, depending on its depth, 
but not an SSI  
 
Note: A laparoscopic trocar site for an NHSN operative procedure is not 
considered a stab wound.  
· _Circumcision is not an NHSN operative procedure. An infected circumcision site 
in newborns is classified as CIRC and is not an SSI  








Appendix 13-5. Deep Incisional Surgical Site Infection  
Criterion Deep Incisional Surgical Site Infection (SSI)  
Must meet the following criteria:  
 The date of event for infection occurs within 30 or 90 days after the NHSN 
operative procedure (where day 1 = the procedure date) according to the list in 
Table 2  
AND  
involves deep soft tissues of the incision (e.g., fascial and muscle layers)  
AND  
patient has at least one of the following:  
a. purulent drainage from the deep incision.  
b. a deep incision that spontaneously dehisces, or is deliberately opened or 
aspirated by a surgeon, attending physician or other designee and organism is 
identified by a culture or non-culture based microbiologic testing method which is 
performed for purposes of clinical diagnosis or treatment (e.g., not Active 
Surveillance Culture/Testing (ASC/AST) or culture or non-culture based 
microbiologic testing method is not performed  
 
AND  
patient has at least one of the following signs or symptoms: fever  
(>38°C); localized pain or tenderness. A culture or non-culture based test that has 
a negative finding does not meet this criterion.  
c. an abscess or other evidence of infection involving the deep incision that is 






















Appendix 13-7. Zone of fracture comminution 
The zone of fracture comminution was measured by a single orthopaedic surgeon 
(Maritz Laubscher) on the first post-operative x-ray with uncalibrated computer x-ray 
software, using a previously established method.(404) The reviewer was blinded to 
the HIV status of the patient.  
  
Participants who developed both delayed (70mm (IQR 23-104) vs 44mm (IQR 4.25-
80)) and non-union (67mm (IQR 7.9-105) vs 45mm (IQR 9.75-85.5)) had a wider zone 
of fracture comminution than those fractures that healed. For delayed healing, for 
every 1 mm increase in the zone of comminution resulted in a 1% increase in the rate 
of delayed union (OR1.01 (CI 1.00-1.01), p-value = 0.005). However, the OR suggests 
that any difference was not statistically significant.  Furthermore, the increase in the 
zone of comminution in the non-union fractures did not results in a statistically 
significant (OR 1.00 (CI 1.00-1.01) p-value = 0.294) increase in the non-union rate. 
 
The width of the zone of comminution was not shown to be a risk factor for the 
development of DSI (OR 1.01 (CI 1 -1.01) p-value = 0.115) SSI  (OR 1.00 (CI 0.98 -1.02) 
p-value = 0.665) or late implant infection (OR 0.984 (CI 0.96-11.00) p-value = 0.143). 











Appendix 13-9. Winquist femur classification system (482) 
 
0 = No comminution 
I = Significant amount of comminution 
II – Greater than 50% cortical contact 
III= Less 50% cortical contact 
















Appendix 13-12. Injury severity score (483) 





• abdominal and pelvic contents 
• spine 
• upper extremity 
• lower extremity 
• external 
Calculation; 
Abbreviated Injury Scale (AIS) grades  
• 0 - no injury 
• 1 - minor 
• 2 - moderate 
• 3 - severe (not life-threatening) 
• 4 - severe (life-threatening, survival probable) 
• 5 - severe (critical, survival uncertain) 
• 6 - maximal, possibly fatal 
ISS = sum of squares for the highest AIS grades in the three most severely injured 
body regions (1-9) 
ISS = A2 + B2 + C2 
• where A, B, C are the AIS scores of the three most severely injured ISS 
body regions 
• scores range from 1 to 75 
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